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Idiopathic pulmonary fibrosis (IPF) is a late-onset disease characterized by 
inflammation and scarring of the lung parenchyma. 10-15% of IPF is attributed to genetic 
causes. The prevalence of familial pulmonary fibrosis (FPF) is up to I Ox higher in 
Newfoundland & Labrador (NL) in comparison to other populations of European origin 
such as the United Kingdom (UK) and Finland. The five genes (TERT, TERC, ABCA3, 
SFTPC and SFTPA2) known to carry variants causing FPF have been screened in our NL 
cohort with no pathogenic variants found. This suggested there is/are novel variant(s) to 
be identified. Previous work done in this cohort utilized microsatellite genome-wide 
scans, fine-mapping/haplotyping and SNP genotyping to find loci associated with FPF. 
From these loci on chromosome 16 and 6, ten positional and functional candidate genes 
were previously sequenced with no pathogenic variants identified. 
In this thesis, selection and sequencing of candidate genes from previously 
mapped loci is performed. Nine candidate genes were sequenced by Sanger sequencing in 
FPF Family R0942; however, no pathogenic variant was discovered out of28 variants 
found. Also, genotyping was carried out on a common MUC5B rs35795950 promoter 
polymorphism that has been recently implicated with both sporadic and familial forms of 
pulmonary fibrosis (PF). A case-control analysis was carried out using I I 0 affected 
individuals and 277 healthy controls from the Newfoundland population. Results showed 
a significant association between rs35705950 genotypes and IPF. The odds ratio for 
individuals affected with IPF who were heterozygous and homozygous for the variant 
allele of this SNP were 5.4 (95% confidence interval, 3.3 to 9.6, P < .001) and 12.2 (95% 
confidence interval, 3.3 to 44.7, P < .00 1), respectively. Furthermore, two of our FPF 
fami lies (R0942 and R11 36) showed familial segregation of the variant allele with the 
phenotype. In these families, all affected individuals were carriers of the variant T allele. 
Furthermore, a Simplified rapid Segregation Analys is (S ISA) analysis demonstrated that 
the probabil ity by chance that co-segregation of the vari ant T allele with PF in fan1ily 
R0942 was 1.56%. 
This thesis supports the suggestion that the minor T allele ofrs35705950 is li kely 
a contributor to the pathogenes is of IPF in the NL cohort. The MUC5B gene encodes for a 
major gel -forming mucin macromolecule in respiratory secretions and is upregulated in 
other lung diseases. Further evidence of assoc iation is provided by tissue expression 
studies done through previous research. 
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1. Introduction 
I .1 Interstitial lung disease 
Interstitial lung disease (ILD), also known as diffuse parenchymal lung disease 
(DPLO), describes a variety of lung diseases affecting the alveoli, airways and pulmonary 
interstitium. Estimates state that there are over 50 million people worldwide affected with 
one of the many ILDs (Maher, 2008). 
I LOs can be broken down into seven major categories: I) Idiopathic interstitial 
pneumonias; 2) Granulomatous ILDs (i.e. sarcoidosis); 3) ILDs caused by inhalational 
agents (i.e. asbestosis, silicosis); 4) Connective tissue disease-associated ILDs (i.e. 
scleroderma); 5) ILDs induced by drugs (i .e. bleomycin, amiodarone); 6) Other disease-
related I LOs (i.e. some reno-pulmonary syndromes); 7) Other rare I LOs (i.e. 
lymphangioleiomyomatosis, alveolar proteinosis, langerhans' cell histiocytosis). 
Furthennore, the idiopathic interstitial pneumonias ( liP) category can be segmented into 
two groups: idiopathic pulmonary fibrosis (IPF) and non-IPF idiopathic pulmonary 
pneumonia. Non-IPF idiopathic pulmonary pneumonias are further divided into six 
groups: I) non-specific interstitial pneumonia; 2) acute interstitial pneumonia; 3) 
respiratory bronchiol itis; 4) desquamative interstitial pneumonia; 5) lymphocytic 
interstitial pneumonia; 6) cryptogenic organizing pneumonia (Figure 1.1 ). 
The different disease states can vary from being benign and running a very limited 
course to being progressively debilitating and lethal. The most common symptom of ILDs 
is shortness of breath- this is usually progressive (Peros-Golubicic and Sharma, 2006). 
Many of the disease states overlap in tenns of clinical features, physiology 
Figure 1.1: The Subtypes oflnterstitial Lung Disease 
measures, radiological and histological patterns (Alder et al., 2008). Therefore to make a 
diagnosis for one of the many I LOs, a multi-disciplinary approach involving clinicians, 
pathologists, and radiologists is required. This multi-disciplinary approach is now 
considered the "gold standard" for diagnosis of lLDs (Bradley et al. , 2008). The specific 
ILD this thesis will concentrate on is IPF and the underlying genetic etiology. 
1.2 Idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis is the most common type of all liPs. IPF is a late-
onset disease which is more frequent in males and generally occurs in the 51h to 7rn 
decades of life (King eta\., 20ll ). IPF has a debilitating prognosis - it presents as 
progressive dyspnea and fibrosis limited to the lung. Respiratory failure is common 3 - 5 
years after diagnosis (ATS 2000). It is always associated with a histopathological 
appearance of usual interstitial pneumonia (UIP) when surgical lung biopsy is perfonned. 
The prevalence of IPF can vary depending on the population in question but typical 
estimates are between I - 24 cases per 100,000 (Raghu et al., 2006). Corticosteriods such 
as prednisone have been used as a therapy but there is linle evidence of benefits to 
patients/clinical outcomes. A number of clinical trails using novel drugs (N-
acetylcysteine, etanercept, bostentan) have resulted in some patients with mi ld-stage IPF 
showing positive change in pulmonary function tests (PFTs) after one year of treatment 
(King et al., 2011). However, all of these trials exclude patients with severe IPF so results 
are not generalizable to all IPF patients. Currently the only effective treatment that 
increases survival time for any individual with TPF is lung transplant. 
To diagnose IPF, a systemic approach involving clinical evaluations, PFTs and 
high resolution computed tomography (HRCT) scans should be implemented (2000). If 
there is diagnostic confusion, lung biopsy is performed to provide a definitive diagnosis 
of TPF. The pathological changes are usually found in the subpleural parenchyma of the 
lung. As shown in Figure 1.2, honeycombing and fibroblastic foci are the hallmarks of 
typical UIP (Gross and Hunninghake, 2001). Diagnosis involves a multi-disciplinary team 
consisting of various clinicians, including respirologists, pathologists and radiologists. 
Figure 1.2: Histopathologic features of IPF. Reproduced with permission from and 
Hunninghakc, 200 1. Copyright Massachusetts Medical Society. The asterisk represents a 
fibroblast focus; the arrow points to alveo lar septa with litt le abnormality. 
IPF has been associated with exposure to a variety of agents/factors including 
metal, wood, texti le dusts, stone and sand, wood fire, cigarette smoking, certain li vestock, 
agri cultural offending agents, certain drugs (i.e. bleomycin) and other di seases (Peros-
Golubicic and Sharma, 2006; King et a!. , 20 II ). Although these factors have been 
associated with IPF, there is a lack of consistency in these findings . Also, IPF cases in the 
absence of these fac tors are commonplace. Thus, the complete pathogenesis of lPF is still 
not completely understood. Previously, it was thought that fi brosis of the lung 
parenchyma was directl y caused by chronic inflammation (Gross and Hunninghake, 
200 I). This school of thought stated that an initial stimulus led to chronic inflammation of 
the lung which in tum caused injury to the lung. Due to this, an aberrant infl ammatory 
repair process ultimately caused fib rosis. However, thi s theory was not entirely correct fo r 
a number of reasons: anti-inflammatory drugs did not improve the outcome of IPF, 
inflammation is not always present histopathologically, and epitheli al injury alone 
without inflammation can result in aberrant wound healing, ext race llu lar matrix (ECM) 
remodeling and fibroblast foc i formation (Selman et a!. , 200 1). 
The current prevalent theory for pathogenesis of iPF involves the combination of 
genetic/environmental factors and alveolar epithelial cell (AEC) injury as a primary step. 
Briefly, the susceptible lung, by virtue of genetic factors, shortened telomeres or reduced 
ability to regenerate, is affected by repetitive injuries (smoking, offending agents etc). 
This ultimately results in the death of many alveolar type I and II epithelial cells (King et 
al., 2011 ). In tum, wound clots and other AECs are aberrantly activated, producing a 
number of growth factors and chemokines which migrate to the site(s) of lung injury. All 
of these factors are involved in the differentiation of fibroblasts to myofibroblasts. This is 
indicative of the breakdown of nonnallung repair processes (King et al., 20 I I). 
Myofibroblasts, which are ditTerentiated cells with potent profibrotic ability, leads to 
increased and irreversible fibrosis by depositing ECM as well as further AEC death 
(Waghray et al., 2005). These theories and observations illustrate that multiple molecular 
mechanisms may be implicated in pathogenesis in that the inflammatory pathway and/or 
the aberrant epithelial pathway can lead to PF (King et al., 20 II ). 
From these previous theories and observations, IPF is believed to be a complex 
disease with more than one environmental and/or genetic factor involving a variety of 
physiological pathways to produce the phenotype, the primary focus of this thesis will be 
determining the genetic susceptibility of IPF in the NL population. 
1.3 The genetics of idiopathic pulmonary fibrosis 
1.3.1 Familial pulmonary fibrosis 
Famil ial pulmonary fibrosis (FPF) is defined as the occurrence of IPF within two 
or more members of a family- these individuals must be ls1 or znd degree relatives with a 
common ancestor. The clinical presentation of FPF (symptoms, medical examination, 
PFT levels, radiological and pathological findings) generally matches that of IPF- the 
only difference is that FPF has an earlier age of onset than IPF by approximately 8-12 
years (Tsakiri eta\., 2007). Although FPF is primarily a late-onset disease, there have 
been recent rare findings ofFPF in three siblings diagnosed very early in adulthood as 
well as rapid progressive ILD in young children not more than 2 years of age (Vece eta\., 
2012). 
Anywhere between 2-19% of patients with IPF report having a I st degree relative 
with similar symptoms (van Moorsel et al., 20 10). In affected families, FPF typically 
displays an autosomal dominant inheritance panem (Figure 1.3) with reduced penetrance. 
An autosomal dominant inheritance pattern implies that if an affected mutation carrier has 
offspring, an average of 50% of the offspring of the mutation-carrier will carry the 
disease-causing variant. Penetrance refers to the correlation between disease genotype 
and phenotype. I fa disease is fully penetrant, every individual with the disease-causing 
genetic variant will present with the disease phenotype. In a disease that has reduced 
penetrance, such as FPF, there are individuals who may carry the disease-causing genetic 
variant but will not present with the disease phenotype during their lifetime. Furthermore, 
phenocopies can also be present in families with FPF. Phenocopies are defined as the 
san1e phenotype being displayed by different individuals due to differing genetic and/or 
environmental causes. These genetic factors complicate the ability to identify a haplotype 
and pathogenic variants that segregate with the FPF phenotype (Strachan and Read, 
1999). 
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Figure 1.3: Pedigree showing a typical autosomal dominant inheritance pattern 
1.3.2 Documented FPF-causing genes 
To date, causal variants in the genes TERT, TERC, SFTPC, SFTPA2 andABCA3 
account for 2-20% ofFPF depending on the population studied (Armanios eta!., 2007; 
Nogee et al., 200 I ; Wang et al. , 2009) . Out of these known FPF -causing genes, genetic 
variants in TERT and TERC are the most common. 
1.3 .2. 1 TERTand TERC 
TERT is a gene located on chromosome Spl5.33 at position I ,253 ,287- 1,295,162 
(hgl9) . TERT codes for the telomerase enzyme. Telomerase has both a reverse 
transcriptase catalytic component (also known as hTERT) and a functional RNA 
component (TERC) (Diaz de Leon et al. , 20 I 0). As shown in Figure 1.4, telomerase is 
involved in many pathways and thus has a variety of important physiological functions in 
the body. Telomerase functions as a transcriptional regulator of the Wnt-P-catenin 
pathway, addition oftelomeric repeats to stabilize chromosomes, a regulator for apoptosis 
in the mitochondria, production of small interfering RNAs that can inhibit gene 
expression, and a determinant of oxidative stress in the cell (Martinez and Blasco, 20 II ). 
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Figure 1.4: T he various functions of telomerase. Reprinted with permission from 
Martinez and Blasco, 2011 (Appendix .J). 
The main function of telomerase is the addition oftelomeric repeats to the end of 
chromosomes. This stabilizes and slows down the progressive shortening of 
chromosomes that occurs with each cell division {Armanios et al., 2007). Once the 
telomeres reach a critical size, the cell stops its normal cell cycle and/or apoptosis 
(programmed cell death) is initiated. Thus, the length oftelomeres is a limiting factor tOr 
the capacity of tissues to replicate. If chromosomes have short telomeres, each cell 
division will lead to the telomere reaching the critical size in a shorter time period and 
thus apoptosis/ inhibition of the cell cycle will occur earlier than average. This is one of 
the main reasons abnormal telomere length is associated with age-related disease and 
disease involving tissues with a high rate of turnover, such as the lung (Armanios eta!., 
2007). 
Due to its various functional roles in the body, defective telomerase has been 
shown to result in a variety of disorders such as dyskeratosis congenita, aplastic anemia, 
coronary artery disease, liver cirrhosis and/or PF. One of the disorders, dyskeratosis 
congenital, is a multi-system disorder that can have a variety of clinical features such as 
abnormal skin pigment, bone marrow failure, lung and liver fibros is, premature graying 
of the hair, osteoporosis and mental retardation, among other varying features (Bessler et 
al., 2010). 
FPF is more common in the 51h decade of life and beyond. As well, the epithelial 
tissue in the lung displays a relatively high turnover rate in comparison to other tissues. 
We also know that abnormal telomere length is associated with later onset disease and 
disease involving tissues \Vith a high rate of turnover, and a number of studies have found 
genetic variations in TERTand TERC to be the most common molecular cause ofFPF 
(Armanios eta!., 2007; Tsakiri eta!., 2007; Alder et a!., 2008; Diaz de Leon et a!., 2010). 
Considering the various funct ions that telomerase has in the cell, it is surprising that 
heterozygous mutations in TERT and TERC commonly cause a specific pulmonary 
fibrosis phenotype instead of a multi-systemic phenotype. 
In a study using the Vanderbilt Familial Pulmonary Fibrosis Registry for 
recruitment, 6/73 FPF pro bands has heterozygous mutations in TERT or TERC (Armanios 
eta\., 2007). These mutations also segregated with FPF in all six families and were not 
present in 623 unaffected subj ects. Furthermore, telomere length in lymphocytes was 
significantly lower in pro bands and asymptomatic mutation-carriers than relatives without 
the mutation {Annanios et al., 2007). From this study, it was evident that mutant 
telomerase is associated with FPF. Further studies have also shown that heterozygous 
mutations in TERT or TERC cause FPF and over time confer a large increase in 
susceptibility to adult-onset FPF with the phenotype presenting earlier in successive 
generations (Tsakiri et al., 2007). 
1.3.2.2 SFTPC and SFTPA2 
Two surfactant protein genes, SFTPC and SFTPA2, have also been associated 
with IPF. Surfactant is a pulmonary-specific viscous fluid consisting of various proteins 
and phospholipids. Surfactant is produced by Type 11 alveolar epithelial cells and its main 
function is to reduce surface tension by lining the epithelial air space. This is essential in 
allowing lungs to expand and contract with ease by stabilizing alveoli as well as to 
prevent the collapse of the lung due to abnormal pressure changes. Surfactant proteins 
such as SFTPA2 and SFTPC are integrally involved in these processes. These surfactant 
protein components are also part of a homologous family of inunune~defense proteins 
called collect ins. Mouse models have shown that without subunits of surfactant such as 
SFTPA./A2, mice are susceptible to pulmonary infections and disease (Wang et a!., 2009). 
Due to lung surfactant being made up of a variety of phospholipids, surfactant proteins 
and cholesterol, any hann/change in either one these components can have disruptive 
effects in normal lung function. Certain surfactant proteins were first documented in 
association with IPF in 1991 when a study showed that there were elevated levels of 
surfactant protein A in IPF patient bronchoalveolar lavage in comparison to healthy 
\0 
controls (McConnack et a!., 1991 ). Other studies have focused on using surfactant 
proteins as biomarkers and/or prognostic factors in IPF with variable results (Takahashi et 
al., 2000; Greene et al., 2002). 
Subsequently, there have been recent studies that have found SFTPC mutations as 
a cause for both familial and sporadic fom1s of iPF. One study found genetic variations in 
SFTPC in 11/34 patients with ILD (Nogee eta\., 2001). The main variant found was a 
spl icing mutation (c.460+ I G>A) that resulted in skipping of ex on 4 and reduced 
expression of SFTPC. Also, this variation was absent from I 00 control chromosomes 
(Nogee eta\., 2001). Another study found an SFTPC exon 5 mutation in two FPF famil ies 
and seven sporadic IPF cases which results in a missense amino acid change that can 
affect peptide processing (Chibbar et a\., 2004). Furthermore, variants in SFTPA2 have 
also been associated with IPF. Wang et al. found two rare variants in SFTPA2 (c.692G>T, 
p.G231 V; c.593T>C, p.FI98S) which caused FPF in two separate families (2009). Both 
mutations disrupt tertiary structure of a carbohydrate recognition domain in the protein 
(Figure 1.5). Site-directed mutagenesis and human lung epithelial cell lines were used to 
see if the mutations effected synthesis and secretion of the protein. In comparison to wild-
type protein, the SFTPA2 p.G23 1 V and p.Fl 98S variants were expressed in cell lines very 
poorly and tested negative for SFTPA2 protein in cell lines (Wang et a\., 2009). Thus, this 
study demonstrated that these SFTPA2 germline variants disrupt protein 
trafficking/function and result in FPF. 
II 
Figure 1.5: The crystal structure of the carbohydrate recognition domain, neck 
domain of rat surfactant protein A, and positions corresponding to codons 198 and 
231 of the human sequence. Reprinted with permission from Wang et at., 2009 
(Appendix J). 
Since there have been separate genetic variations identified in SFTPC and SFTPA2 genes 
that account fo r a small proportion of FPF in various populations around the world, these 
surfactant protein genes have become well-documented FPF-causing genes (Nogee eta!., 
2001 ; Wanget a!. . 2009; Onoet a!.. 20 11 ). 
1.3 .2.3 ABCAJ 
The ABCA3 gene, ATP-Binding Cassette sub-fami ly A member 3, is another gene 
that can harbor FPF-causing variants as demonstrated by previous research (Young eta!., 
2008). The protein encoded by the ABCA3 gene is a membrane protein part of the ATP-
binding cassette transporter fami ly. ATP-binding transporter proteins function by utilizing 
the energy of ATP to actively transport various substrates across a membrane. ABCA3 is 
expressed exclusively in lung tissue and functions as part of a transmembrane transporter 
of the phospholipid components of surfactant (Yamano eta!. , 2001). Since ABCA3 is 
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needed to maintain pulmonary surfactant phospholipid balance, genetic variants 
modifying the activity of this gene can have serious consequence in lung-related disorders 
(Young et al. , 2008). Interestingly, the processing and secretion of surfactant protein C is 
dependent on ABCAJ, highlighting its involvement in a biological pathway known to be 
involved in some cases of IPF. 
Genetic variants in ABCAJ have been shown to cause IPF in adolescents as well 
as increase the severity of FPF in patients with SFTPC variants (Young et al. , 2008; van 
Moorsel eta!., 2010). The first docwnented case of ABCAJ variants causing PF was 
reported in 2008. A 15 year-old Caucasian boy of European descent presented with 
symptoms of lung disease and was diagnosed with IPF based on usual interstitial 
pneumonia histology (Young et a!. , 2008). Genetic analysis did not find variations in any 
known FPF genes but novel heterozygous ABL.AJ variants were discovered (c.-28A>G; 
c.3765C>G). Furthermore, there have been other ABCAJ variants found in unrelated 
children with mild lung disease, implying that ABCAJ could also be predictive of other 
lung-disease phenotypes (Bullard et al., 2005, Crossno eta!., 2010). Due to ABCAJ ' s role 
in processing surfactant protein C, one study tested the hypothesis that potential ABCAJ 
variants could modify the severity ofTPF in patients with SFTPC variants (van Moorsel., 
2010). This study showed that sisters carrying an ABCAJ variant (c.3784A>G; p.S1262G) 
presented with FPF 15 years earlier than affected patients without this variant but the 
effects of this variant on FPF are still not yet fully understood (van Moorsel. , 2010). 
1.3.3 Association of a MUCSB promoter polymorphism 
Recently, a variant (rs35705950: dbSNP; http://www.ncbi.nlm.nih.gov/ 
projects/SNP/) located in a promoter region Jkb upstream of a major gel-forming mucin 
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gene, Mucin Sb (MUC5B), that is associated with IPF in sporadic and familial forms in 
populations in the USA was identified (Seibold et al., 2011). Specifically, the minor T 
allele was present in 38% of IPF subjects and 34% of Familial Interstitial Pneumonia 
(FIP) subjects in comparison to 9% of controls (Seibold et al., 2011 ). All documented 
FPF-causing genetic variants are in coding sequences that result in a measurable 
pathogenic change in the protein. The rs35705950 variant is an intergenic variant with no 
direct effect on protein and thus is harder to prove as causative. 
However, it was demonstrated that unaffected individuals with at least one copy of the 
minor T allele expressed MUC5B protein in lung tissue 3 7.4 times more than unaffected 
individuals with the wild-type G allele (Seibold et al., 2011). This analysis was done 
using biopsied lung tissue samples from unaffected individuals with at least one copy of 
the T allele and unaffected individuals with the wild-type G allele. The results suggest 
that gene expression is primarily altered by having one copy of the variant T allele and 
not due to presence of the phenotype. MUC5B expression in the lung for affected 
individuals was also 14.1 times higher than in unaffected individuals (Seibold et al., 
2011). To see if smoking modified the effect of MUC5B expression, lung tissue from 
smokers and non-smokers was also examined to test for differences in MUC5B protein 
expression. Smoking did not modify the expression of MUC5B in the lung in healthy 
controls or affected individuals (Figure 1.6). Furthermore, the variant is in a known 5' 
promoter region of MUC5B and is conserved across primate species. Aberrant MUC5B 
expression has profound effects in the lung and has been previously shown to be involved 
in other lung disease, being upregulated in chronic pulmonary disease progression 
(Kirkhan1 eta!., 2008) and downregulated in cystic fibrosis airway secretions (Henke et 
14 
a!., 2004). The association of this single nucleotide polymorphism (SNP) with IPF has 
since been confirmed by one other group in the same issue of the original paper (Zhang et 
al. , 2011) and hence seems to play a role in the development of IPF. This MUC5B 
promoter SNP has also recent ly been associated with IFF-specific pathways rather than 
di seases that can exhibit pulmonary fibrosis such as systemic sclerosis and sarcoidosis 
(Stock et al. , 2013). These findings suggest that there is a distinct genetic susceptibility 
that specifically contributes to IPF and is less likely to involve the inununological and/or 
inflammatory mechanism than pathogenesis via a mucus-related mechanism (Stock et a!. , 
20 13). Furthermore, the AfUC5B promoter variant was associated with a less severe 
decline in patients ' pulmonary function tests and slower disease progression with 
compared to patients with systemic sclerosis and sarcoidosis. Another study conducted 
using a Caucasian American cohort shO\ved similar findings in that the MUC5B promoter 
variant was associated with signi ficantl y improved survival in IPF (Peljto et al. , 2013). 
Both of these recent findings suggest IPF and the A1UC5B promoter SNP may be 
linked with a distinct disease pathogenesis. It is possible that the IPF phenotype is 
heterogeneous and that the MUC5B promoter polymorphism may be responsible for this 
(Pelj to et a!., 20 13). 
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Figure 1.6: MUCSB Expression in 33 Subjects with IPF and 47 Healthy Controls, 
Stratified According to MUCSB Promoter Single-Nucleotide Polymorphism (SNP) 
(rs35705950) Genotype and Smoking Status. Reproduced with permission from 
Seibold et al (2011). Copyright Massachusetts Medical Society. 
Panel A: the distribution of MUC58 expression among subjects with wild-type or heterozygous 
rs35705950 genotypes of MUC5B according to the presence or absence ofiPF. Panel B: MUC5B 
ex pression among all controls, controls who smoked. and controls who did not smoke, according 
to rs35705950 genotype . Panel C: comparison ofMUC5B expression in all subjects with IPF, 
those who smoked, and those who did not smoke, according to rs35705950 genotype. In all the 
panels, the horizontal lines indicate group medians, and the expression of MUC58 is shown in 
re lation to the expression of the glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH). 
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1.4 The Newfoundland population 
1.4.1 Population structure and genetic isolation 
The province of Newfoundland and Labrador (NL) consists of both an island 
(Newfoundland) as well as a continental landmass (Labrador) and is located on the east 
coast of Canada (Figure I. 7). According to Statistics Canada 2012, NL has a population 
of approximately 515,000. Since immigration started in the 1600s and was at its highest 
point in the mid-1700s, Newfoundland is a very young population (only - 20 generations 
old). This population is unique since it remains spread out in geographically isolated 
communities- approximately 60% of the current population live in communities with a 
total population of 2500 or less (Ralunan et a!., 2003) and there is only one urban centre 
with a population greater than 50,000. These communities, almost all of which were 
originally settled by the Engl ish and Irish, are long-standing, established settlements with 
very little or no migration at this time (Bear et al., 1987). Furthermore, most marriages 
occurred between individuals with similar religious practices and there was little to no 
admixture between individuals of differing religions. The chief means for the increase in 
the population ofNL after 1800 is natural increase and 98% of the NL population in 2003 
has English or Irish ancestry, illustrating its homogenous nature (Rahman et al., 2003). 
Due to the geographical and religious isolation, minimal inwards migration and 
small population size that arose from a limited founder population, Newfoundland is 
considered a series of small genetic isolates. In these genetic isolates with a small number 
of founders, there is less genetic variation and some rare disease alleles may be present at 
a higher frequency, resulting in an enrichment of certain diseases. It can be easier to 
detect certain rare disease alleles in isolated populations since fewer haplotypes are 
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segregating through an isolated population. This is an overrepresented amount of 
Mendelian disorders in Newfoundland compared to other Canadian provinces after 
accounting for population size, highlighting its importance for studying genetic disease 
(Rahman et a!., 2003). 
A 
Figu re 1.7: Canadian provincia l geography. A) Area shaded in grey highlights Canada. 
White areas to the bottom and left highlights USA. White areas to the top highlights 
Greenland. B) The province of Newfoundland and Labrador. Newfoundland is the island 
portion with St. John' s as the capital city; Labrador is the continental region bordering 
Quebec (yellow). 
In the Newfoundland population, a founder effect has been documented in a 
number of disorders such as Lynch Syndrome (Stuckless et al., 2007), hemophilia A (Xie 
et al., 2002), Bardet-Biedel Syndrome (Young et al., 1999) and Arrhythmogenic right 
ventricular cardiomyopathy type 5 (Memer eta\., 2008). A founder effect is seen when a 
limited genetic diversity forms in a population due to a small group of individuals (i.e. 
founders) that become isolated for a number of reasons. Due to isolation, the gene pool of 
these " founders" is disproportionately more common in the resulting population and 
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genetic diversity is reduced. For instance in Newfoundland, many Europeans (primari ly 
of English and Irish descent) who migrated into an out port stayed in the same 
geographical region with little to no migration, creating clusters of small founder 
populations distributed across the entire island. Since FPF is a rare disease with a strong 
genetic component that has a high prevalence in the Newfoundland population compared 
to others, the possibility of a founder mutation cannot be ruled out as being a cause. 
Alternatively, there may be heterogeneous genetic causes that contribute to the high 
prevalence of FPF in Newfound land. 
1.4.2 Familia l Pulmonary Fibrosis in Newfoundland 
The prevalence of FPF in the Newfoundland population is over 12 cases per 100, 
000. This is considerably high when compared to most population groups around the 
world. For instance, populations in the USA and the United Kingdom (UK) had genetic 
transmission ofPF in only 1·3 cases per 100 000 (Gribbin eta\. , 2006; Raghu eta\. , 
2006). In Finland, a country with a well·known founder population which also contains 
many rare di sease phenotypes, the prevalence ofFPF is less than one per 100 000 (du 
Bois, 2006). Since the Newfoundland population is enriched for FPF, it is an excellent 
population to study to determine the genetic variations that cause thi s disease. 
To date, over 80 patients from more than 30 Newfoundland families have been 
d iagnosed with FPF (Woods, unpublished data). The number ofaffecteds per family 
ranges from only two affected individuals in a fami ly to a large, six·generation family 
with ten affected individuals. The proband in each of these fami lies as well as all sporadic 
IPF probands were previous ly screened for genetic variants in the following genes: TERT, 
TERC, SFTPC, SFTPA2, andABCA3. Variants in TERTwere identified in eight affected 
19 
individuals. Seven of these individuals were from two unrelated fami lies with FPF and 
one individual with sporadic IPF. These variations (c.2594G>A; p.Arg865 His and 
c.2648T>G; p.Phe883Cys) were IPF-causing based on previous linkage findings by 
another research group (Tsakiri eta!., 2007) and bioinformatics analysis. No other 
disease-causing variants were found in the remainder of FPF cases. 
1.5 Previous statistical work done 
The I 000 Genomes Project shows that each individual carries - 250 to 300 loss-of-
function variants in annotated genes (Altshuler eta!., 2010). Thus, it is extremely 
important to be able to correctly exclude non-causative genetic variations and narrow 
dov.rn the regions of interest in order to find a disease-causing variant. Linkage analysis is 
used in order to identi fy genetic regions that are linked with a disease in a particular 
family or famil ies when a mode of inheritance is known (Greenberg et a!. , 1998). 
Genetic linkage analysis is based on the assumption that genes physically close 
together on a chromosome tend to be inherited together, or linked, when passed on 
through generations from parents to offspring. A genome-wide scan using SNPs or 
microsate ll ite markers is carried out in affected and unaffected family members. Since 
recombination occurs in germ cells that are passed on to offspring, the parental origin of 
different alle les is easil y traced. When genetic markers are closer together, they are more 
likely to be inherited together than markers much further apart. This probability for a 
recombination benveen two genes is knov.rn as the recombination fraction, theta (9) . 
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Linkage analysis measures the expected versus observed recombination events 
given the parameters for genetic inheritance modes, penetrance of disease and frequency 
of genetic variations to determine region(s) linked with disease (Lathrop et al., 1984). 
Generally, genes with a pathogenic variant have a marker or multiple markers close by 
that are in linkage disequilibrium (LD) with this variant. The pathogenic variant that is in 
LD with one or more markers segregates in affected individuals. In linkage analysis, all 
regions, including regions ofLD in a single family or multi-family analysis are shown by 
a specific log of odds (LOD) score for each marker. 
LOD scores indicate the likelihood of whether loci are linked or not. LOD scores 
are quantified based on logarithms (10 times) and can be positive or negative values. 
There is one assumption used for the calculation of LOD scores: two genes are tightly 
linked with no recombination events occurring between them, indicated by 9 = 0. LOD 
scores can also be calculated for different theta values. For instance, a LOD score of3.0 
(9 = 0) indicates that the marker(s) in question has a 1000: I likelihood of being linked 
with a pathogenic variant or another marker- this is considered significantly linked. A 
LOD score of -1.0 (8 = 0) indicates that the marker(s) in question has a I 00: I likelihood 
of not being in LD with a pathogenic variant or another marker. LOD scores are used in 
both two-point and multipoint linkage analyses. In two-point linkage analyses, there is 
usually one marker plus the disease being compared in order to calculate the LOD score; 
whereas, multipoint linkage analysis compares a number of markers to calculate the LOD 
score. Horne et al (2003) suggested multipoint linkage analysis is less sensitive to 
incorrect allele frequencies but can be prone to statistical loss of power. Nevertheless, 
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reasonable concordance is found between the different analysis methods (Horne eta!. , 
2003). SNP genome-wide scans and both two-point and multi -point linkage analyses were 
previously carried out on infom1ative Newfoundland FPF families including Fami ly 
R0942. 
1.6 Previous work done 
1.6.1 Participant Recruitment 
Affected individuals were diagnosed us ing the American Thoracic Society 
diagnostic criteria (2000) for probable lPF (Table 1.1 ). These individuals were asked to 
participate in this study by the respiro logist initially examining the patients. Interested 
individuals were contacted by the research nurse coordinator for the study, Mrs. Barbara 
Noble, and wrinen consent was obtained fo r the use of fami ly/medical histories and 
biological samples for research (HIC #2.26). After the proband was enrolled in the study, 
all 1st and 2"d degree relatives were contacted by Mrs. Noble and asked to participate in 
the study also. Dr. Bridget Fernandez, the principal investigator, and Mrs. Barbara Noble, 
then used this information to construct famil y pedigrees. For all study participants, 
venous blood was drawn from affected and unaffected participants and whole genomic 
DNA was extracted by Mrs. Amanda Dohey or Ms. Krista Mahoney (Memorial 
Univers ity). 
1.6.2 Clinical Assessment 
A methodical procedure was used to diagnose all affected individuals enrolled in this 
study. Definitive diagnosis of IPF is only possible via surgical lung biopsy. However, thi s 
is an invasive procedure with a mortality rate of 4.3% after 30 days (Park et a\. , 2007). 
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Thus, lung biopsy to definitively confirm diagnosis was only available in a minority of 
patients. Due to the invasive nature of lung biopsy, the A TS/ERS criteria for diagnosis of 
I PF in absence of surgical lung biopsy was used for all diagnoses (Table 1.1 ). 
Table 1.1: Criteria for diagnosis of lPF in absence of surgical lung biopsy. Adapted 
from ATS/ERS. 
Major Criteria 
Exclusion of other known causes of ILD such as certain drug toxicities, 
environme ntal exposures, and connective t issue d iseases 
Abnormal pulmonary function studies that include evidence of restriction 
(reduced VC, often with an increased FEVdFVC rat io) and impaired gas 
exchange [increased P(A-a)02, decreased Pa02 with rest or exercise or 
decreased Dlc0 ] 
Bibasilar reticu lar abnormalities with minimal ground glass opacities o n HRCT scans 
Transbronchial lung biopsy or BAL showing no fea tures to support an 
alternative diagnosis 
Minor Criteria 
Age > 50 yr 
Insidious onset of otherwise unexplained dyspnea on exertion 
Duration of illness > 3 mo 
Bibasilar, inspiratory crackles (dry or "Velcro" -type in quality) 
Definition of abbreviations: SAL = bronchoalveolar lavage; DLco = d iffusing capacity of 
the lung for CO; HRCT = high-resolution computerized tomography; ILD = interstitial 
lung disease; P(A-a)02 = alveolar-arterial pressure difference for 0 2; VC = vital capacity. 
• Reprinted by permission from Reference 60. 
1 In the immunocompetent adult, the presence of all of the major diagnostic criteria 
as well as at least three of the four minor criteria increases the likelihood of a correct 
clinical diagnosis of IPF. 
Each participant in the study completed a medical history form, a family history 
questionnaire and an occupational exposure questionnaire. All participants were offered 
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clinical assessment which initially included a physical examination, PFTs and HRCT of 
the chest. PFTs include testing for forced vital capacity (FVC), forced expired volume/sec 
(FEY 1) and diffusing capacity of t he lung for carbon monoxide (DLCO). These PFTs 
were examined by Dr. George Fox, a respirologist (Memorial University). 
HRCTs of the chest were also performed on patients who consented and the 
results were interpreted blindly by two radiologists, Dr. Rick Batia and Dr. Eric Sal a 
(Memorial University). Scoring was based on the Royal Brompton Hospital scoring 
system (Wells eta!., 2003). Concisely, each radiologist scored the images at five levels. 
Each level was given a score based on the proportions of ground-glass attenuation, 
reticular abnormalities and the coarseness of these reticular abnonnalities (Wells eta!., 
2003). This scoring method allowed the radiologists to label each case as definite lPF, 
probable IPF, possible lPF or unaffected. 
In the event that a lung biopsy was performed, a diagnosis of UIP is the only 
indicator that a patient that was definitely affected- this was performed via a single blind 
procedure with respect to the pathologist. Overall, with the combination of family 
pedigrees, medical history, PFTs, HRCTs and tissue biopsies, a panel of physicians/ 
researchers reviewed the infonnation to make a final diagnosis and classify each 
individual as definitely affected, probably affected, possibly affected or unaffected. 
The clinical classifications differed from the classifications used in this thesis in a 
number of ways. For an individual to be classified definitely affected, the individual must 
present with UIP on lung biopsy. For an individual to be classified probably aHected, the 
individual must satisfy the A TS/ERS criteria (Table 1.1 ). Nonetheless, for the purpose of 
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statistical analysis in this study, all individuals that were clinically classified as definitely 
or probably affected were assigned a classification of definitely affected. 
1.6.3 Genome-wide scan - microsatellite markers 
A genome-wide scan was previously done (Ms. Laura Edwards, Memorial 
University) on two families, ROSSI and R0942, using a I OcM resolution human mapping 
set consisting of 382 microsatellite markers (Edwards, 2006). Microsatellite markers for 
the genome-wide scan covered the 22 autosomal chromosomes and excluded the X 
chromosome since the majority of FPF exhibits an autosomal dominant inheritance 
pattern (Steele and Brown, 2007). 
In family R0942, 87% of the microsatellite markers were successfully genotyped. 
Using this data, two-point linkage analysis was done. Two-paired linkage analysis 
resulted in none of the markers with a LOD score of?: 3.00, indicating that no markers 
showed statistically significant linkage to a disease locus. There were 11 markers that had 
a LOD score ranging from ?: 1.00 to :S 3.00, indicating that II markers showed suggestive 
linkage to a disease locus (Table 1.2a). The experimental maximum LOD score for family 
R0942 was 2.19 for marker D16S423, located at 16p13.3. Since simulation analysis 
revealed that the theoretical maximum LOD score for these families is 2.10 at 8=0 (due to 
the size and structure of the family), which is slightly lower than the LOD score obtained 
for marker D \6S423 , fine-mapping was done (section 1.6.4) to further analyze this region 
on chromosome 16 (Kamel, 20 I 0). 
In family ROSSI , 84% of the microsatellite markers were successfully genotyped. 
Using this data, two-point linkage analysis was done. None of the markers had a LOD 
score of?: 3.00, indicating that no markers showed statistically significant linkage to a 
25 
disease locus. There were 4 markers that had a LOD score ranging from 2: 1.00 to S 3.00, 
indicating that 4 markers showed suggestive linkage to a di sease locus (Table 1.2b). This 
region on chromosome 16p 13 was analyzed further after a SNP genome-wide scan was 
perfonned using 5 families. 
Table 1.2: Microsatellite marker genome-wide scan results suggestive of linkage for 
A) Family R0942 and B) Family R0851. Adapted from Edwards, 2006. 
A Marker LOD Score B Marker LOD Score 
0 25347 1.83* Dl S2890 1.09 
025338 1.33 DI S207 1.26 
045412 1.11 D4S405 1.20 
065309 1.11 D4S I592 1.32 
065470 1.41 
065289 1.11 
0 75531 1.11 
075517 1.11 
095287 1.17 
0165423 2. 19* 
0205195 1.17 
TOTAL: 11 - TOTAL:4 
I .6.4 Fine mapping - microsatellite markers 
Using the results from the init ial I OcM microsatellite marker genome-wide scan 
on family R0942, fine-mapping was carried out by Ms. Laura Edwards and Mr. Fady 
Kamel (Memori al University) using add itional microsate llite markers between D 16S3084 
and D 16S3046 (Kamel, 20 I 0). This was done using up to 10 microsatellite markers on 
chromosome 16p for each of these six families: ROSS I, R0892, R0896, R0942, Rl1 36 
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and Rl487. After the successful genotyping of microsatellite markers, haplotypes were 
determined assuming least number of recombinations for each family. Focusing on family 
R0942, there was a haplotype that was determined to be segregating with FPF. This 
observed haplotype is on chromosome 16p- specifically, from the telomeric end (top) of 
16p to marker DI 6S3 103. This is a 17.38Mb region that contains 386 genes in total, 
including known and hypothetical genes (Kamel, 2010). 
1.6.5 Genome-wide scan - SNP markers 
In addition to the microsatellite marker genome-wide scan performed by Ms. 
Laura Edwards on families R0942 and R085 I, a SNP marker genome-wide scan was 
performed using five families: R0851, R0892, R0896, R0942 and R 11 36. The SNP 
marker genome-wide scan was done using a 610 Quad Illumina array (I llumina, Inc., 
Califonia, USA) which genotypes over 550,000 SNP markers distributed across the 
genome. Affected and unaffected individuals from each family were genotyped using the 
610 Quad II lumina array. This SNP marker genome-wide scan was done by the Genome 
Quebec hmovation Centre (Quebec, Canada). 
To detennine if any of the genotyped SNP marker(s) were linked to a causal 
variant, two-point and multipoint linkage analysis was performed (Kamel, 20 I 0). All of 
these statistical analyses and tests were performed by Dr. Marie Pierre-Dube (Universite 
de Montreal, Montreal Heart Institute, www.statgen.org/) and her group. Additionally, the 
results of the statistical analyses were analyzed by Dr. Michael Woods, Mr. Fady Kamel 
and me (Manhattan plot shown in Figure 1.8). 
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Figure 1.8: 2-point parametric linkage LOD scores on SOOk SNPs for R0942, 
dominant model. This is a Manhattan plot received by Mr. Fady Kamel, 20 10. This data 
and the accompanying SNP genome-wide analysis fo r R0942 were re-visited by me in 
order to confi nn and fine-map the ROis. 
Using the data from the five families, there were only two markers that produced 
HLOD (heterogeneity LOD) scores over 3.00 using two-point parametric linkage 
analysis . HLOD scores are calculated by a fonnu la that combines LOD scores fo r all of 
the fami lies used in the analysis. This method is usefu l if there is a suspected rare variant 
or fo under variant accounting for the phenotype in all fami lies. The two markers that 
produced HLOD scores over 3.00 using two-point parametric linkage analysis were 
markerrs94263 1 (HLOD ~ 3.22) and marker rs3130922 (HLOD ~ 3. 15), located on 
chromosomal regions 6p24.3 and 6p21.3 respectively (Kamel, 201 0). Due to these HLOD 
scores being above 3.00, indicating statisticall y significant linkage to a di sease locus, 
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these chromosomal regions were analyzed further and two genes from this region, 
snoRNA66 and PIN/ L, were selected for full gene sequencing (section 1.6.6). 
Multipoint parametric linkage analysis only produced one region of interest (ROI) 
with HLOD scores over 3.00. This was observed on chromosome 18, from marker 
rs3747899 to marker rs930027 (spanning - 0.5Mb). This region was not previously 
identified by the microsatellite marker genome-wide scan. Upon further analysis, no 
individual family produced LOD scores greater than 1.00 and genes in this region were 
not associated with possible fibrosis/aberrant repair/functionally related pathways 
involving the lung. Thus it is unlikely that a causal variant in this region is responsible for 
FPF in all five unrelated families used for this analysis (Kamel, 201 0). Due to these 
factors, this region was not looked at in any further detail. 
Finally, the SNP marker genome-wide scan analysis identified markers with LOD 
scores greater than 1.00 on chromosome I p in family ROSS I. This was interesting since 
the microsatellite marker genome-wide scan also showed suggestive linkage (LOD score 
ranging from 1.0 I to 1.36) in this 1 p region. When these findings were combined, 
chromosome I p22 was deemed as a good candidate locus (Kamel, 2010) and two 
candidate genes from this region were picked for sequencing. 
1.6.6 Genes sequenced 
From the regions of interested identified by microsatellite marker genome-wide 
scan, microsatellite marker fine mapping and SNP marker genome-wide scan, there were 
three positive candidate loci containing genes that could potentially have an FPF-causing 
variant. From these regions of interest, 13 genes were picked as possible candidates based 
on gene function and lung tissue expression (Kamel, 20 I 0). The largest transcript was 
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picked for each gene according to Ensembl Assembly GRCh37 and all exons of the gene 
were fu ll y sequenced. 
From the region of interest on chromosome I, snoRN A66 and PIN lL were fully 
sequenced in at least two FPF patients from all six fami lies (ROSS I, R0892 , R0896, 
R0942, Rll36 and Rl487) used for the initial microsatellite marker genome·wide scan. 
From the ROI on chromosome 6, TFAP2a, TFAP2fi, WRNIPI and SERPINBI were fully 
sequenced in at least two FPF patients from all six fami lies used fo r the initial 
microsatellite marker genome·wide scan. From the region of interests on chromosome 16, 
DEXI, EMP2, VASN, GLIS2, TID/ , ABCA3, and PPL were fully sequenced in at least two 
FPF patients from all six fami lies used for the initial microsatellite marker genome· wide 
scan. All variants found were investigated further and excluded as being FPF-causing by 
Mr. Fady Kamel (20 10). 
1.6.7 Telomere assays 
The lengths of telomeres fo r selected FPF patients from ROSSI , R0892 , R0896, 
R0942 and R 1136 who were still alive were determined by Repeat Diagnostics (British 
Columbia, Canada). Briefly, white blood cell s were isolated from venous blood samples . 
Repeat Diagnostics measured the lengths oftelomeres from lymphocytes and 
granulocytes by in situ hybridization and fl ow cytometry. The telomere lengths were 
compared by using a percentile ranking system to average values of telomere lengths seen 
in a control Caucasian population (Kamel, 20 I 0). In Family R0942, te lomere assay 
analysis on lymphocytes and granulocytes in two affected individuals showed these 
individuals did not have significantly shortened telomeres (Figure 1.9). From this analysis 
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it was concluded that the FPF-causing variant is probably not residing in a gene involved 
in a telomere maintenance pathway, such as TER T. 
1. 7 Hypotheses 
The hypotheses of this project are as follows: 
1. There is a novel genetic variant that causes FPF in Family R0942. 
2. Newfoundland is an island with a series of founder populations. Thus, there are 
likely multiple novel genetic variants that cause IPF in the Newfoundland 
population. Of these, the rs35705950 MUC5B promoter variant may be 
responsible for conferring risk of IPF in the population. 
1.8 Objectives 
The purpose of this study is two-fold. The first objective is to utilize previous 
work done to continue the candidate gene sequencing analysis in order to determine the 
genetic variant(s) that causes FPF in Family R0942. The second objective is to test the 
significance of a recently discovered MUC5B promoter variant and its association with 
risk of developing lPF. 
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Figure 1.9: Average telomere lengths for lymphocyte and granulocyte cells in two 
affected individuals from family R0942 (partial pedigree). Adapted with permission 
from Kamel, 2010 (Appendix J). N umbers on the graphs correspond to the same 
numbers on the pedigree. The legend shows the mean values for a control population. 
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2. Materials and methods 
2.1 Study Population 
For the purpose of this thesis, a family is described as FPF i f there are two or more 
family members with IPF that are I sl or 2nd degree relatives (Annanios et al., 2007). 
Using this criteria, there are 31 families in Newfoundland that have been ascertained for 
this study. From these 31 families, six families were previously chosen to be investigated 
further using a candidate gene approach since these families exhibited the greatest 
potential to find an FPF-causing variant (Kamel, 2010). One (R0942 originating from 
South Cove, Newfoundland) of these six fami lies was chosen to be investigated for an 
FPF-causing variant by using a candidate gene approach in this thesis. This family was 
selected since this family appeared to have the strongest genetic predisposition of all the 
unsolved families since there are seven affected family members in just two generations, 
DNA samples were available for all seven affected individuals and ten unaffected family 
members. Finally, the family pedigree displayed a clear autosomal dominant inheritance 
pattern (Figure 2.1 ). 
For MUC5B rs35705950 SNP genotyping, sporadic IPF cases (n=61) and all 
fami lial cases (n=291) with DNA were used. The 291 familial samples consisted of 49 
affected and 242 unaffected individuals that were successfully used for genotyping the 
rs35705950 SNP in MUC5B. An additional 277 healthy individuals, previously recruited 
for a colorectal cancer study by random-digit-dialing (Wang et al., 2009), served as a 
control cohort for rs35705950 genotyping. All control samples tested were anonymous 
and could not be linked back to the individual person (Woods et al., 20 I 0). All 
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participants consented to the use of their DNA fOr this study. These procedures and the 
use of the samples were approved by the Health Research Ethics Authority, St. John's, 
NL, Canada (Study Reference #12.033). 
2.2 Candidate Gene Selection 
Since one of the focuses of this thesis is on family R0942, the microsatellite 
marker genome-wide scan, fine mapping, and SNP marker genome-wide scan data was 
reanalyzed. In total, there were five affected individuals nine unaffected individuals who 
were genotyped using 550,000 SNPs distributed across the entire genome (Figure 2.1 ). 
Since the highest LOD scores in the SNP genome-wide analysis on family R0942 were 
located on chromosome 6p24.3-6p23 and 16pl3.3 (Manhattan plot in Appendix A), the 
genes in these regions (386 genes, chromosome 16pl3.3; 134 genes, chromosome 
6p24.3-6p23) were regarded as positional candidates. After determining the regions of 
interest on chromosomes 6 and 16, a candidate gene table was constructed (Appendix B). 
All genes in the region of interests, known and hypothetical, were included in the table. 
The function of the genes was determined by using the websites Online Mendelian 
Inheritance in Man (OMIM - http://www.ncbi.nlm .nih.gov/omim) and UCSC Genome 
Browser (http://genome.ucsc.edu; Kent et al. , 2002). Gene expression in different tissues 
of the human body was determined by the BioGPS website (http://\\ww.biogps.org/), a 
free online gene annotation portal (Wu et al. , 2009). Furthermore, protein interaction data 
was also gathered using the STRING database of known and predicted protein 
interactions (http://string-db.org/). 
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' ' ' ' ' '''' Figure 2.1: Pedigree of family R0942 with individuals genotyped for SNP-genome 
wide scan analysis: 5 affected individua ls genotyped (red), 9 unaffected individuals 
genotypcd (blue). 
Gene functions, expression in adult tissues, interesting protein interactions for 
each gene and any previously known associations with lung disease were all put into the 
candidate gene table. Using this combined infonnation, a somewhat arbitrary scale for 
prioritizing which genes to sequence first was determined. The likelihood of each gene 
harbouring a potential FPF-causing variant in family R0942 was ranked using the 
following scale from most likely candidate to most unlikely candidate : possible > 
possible but unlikely > unlikely > very unlikely. All of the 'possible' candidate genes 
were numerically ranked to detennine priority for analysis by DNA sequencing. 
2.3 Oligonucleotide Primer Design 
Primers (both forward and reverse directions) were designed using the Primer3 
v.0.4.0 webtool (http://frodo.wi.mit.edu/primer3/). Primer3 is a useful tool since 
35 
important parameters such as primer length, melting temperature, GC content, binding 
location and likelihood ofprimer-dimer formation can be noted (Rozen and Skaletsky, 
2000). Primer pairs designed ideally were between 18-22bp in length, had melting points 
within I °C of each other and were no greater than 65% GC content. Also, primers were 
designed to be at least 20bp away from the start/end of the target sequence. Once the ideal 
primers were determined, primer sequences were imported into the BLAT Genome 
Search tool (http://genome.ucsc.edu/cgi-binlhgBiat?command=start) to confirm each 
primer was specific for that particular region only. Primer sequences were labe led and 
ordered from Eurofins (Alabama, USA). See Appendix C for primer sequences and 
labe ls. Once arrived, primers were centri fuged for a few seconds and diluted to I J.lg/).11 by 
adding the appropriate amount of UltraPure DNAse and RNAse free disti lled water from 
Life Technologies (Ontario, Canada). Furthermore, a 1: 10 dilution was made using I 0}11 
of the initial primer dilution and 90~ll of distilled water (dH20). The I :10 dilutions of 
primers [1 OOng/).tl] were then ready for usc in the PCR reaction. 
The reference sequence used in comparison to the experimental sequence was 
obtained from Ensembl (http://useast.ensembl.org/Homo_sapiens/ lnfo/ lndcx). The 
reference sequence used was the longest protein-coding transcript of the gene in question-
thi s provided the most encompassing coverage for analysis of genetics variations. 
2.4 Polymerase Chain Reaction I DNA Sequencing 
Polymerase Chain Reaction (PCR) is a widely-used method for the 
synthesis/amplification of specific DNA sequences. It utilizes two oligonucleotide 
primers to hybridize to a region of interest on opposite sides of the double-stranded DNA 
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(Erlich, 1989). After hybridization of a primer with complementary sequence, a DNA 
polymerase and free deoxyribonucleotide triphosphates (dNTPs) are utilized to copy the 
template strand. The product can be used as a template for the next cycle, thus the DNA 
region of interest can theoretically double every cycle- this is done by repeating cycles of 
denaturation, primer annealing and extension (Erlich, 1989). Specitically, the following 
steps were fo llowed to perfonn a standard PCR reaction: 
A mastermix consisting of 1.5).ll of lOX PCR Reaction Buffer, 0.75!.11 of 50mM 
MgCl, 0.375~tl of dNTPs, 0.15!.11 of Platinum Taq Polymerase, 0.50)..11 of forward primer, 
0.50!.11 of reverse primer and 9.475!.11 ofdH20 was made up.ln some instances, 0.75!.11 of 
Dimethyl sulfoxide (DMSO) was also added. The amounts of each material used was 
multiplied by the nwnber of reactions carried out x 1.1 (i.e. if20 DNA samples were 
being tested : each of the amounts ofPCR Reaction Buffer, 50mM MgCI, dNTPs, 
Platinwn Taq Polymerase, forward primer, reverse primer, dH20 and in some cases 
DMSO would be multiplied by 22) and this would be added to the mastennix. All 
materials except primers were obtained from Life Tedmologies (Ontario, Canada). 13!.11 
of the mastennix was aliquoted to each reaction well in a 96-well 0.2ml PCR plate. To 
each well, except the "negative control(s)", gDNA from affected or unaffected members 
of fami ly R0942, either lOOng/).ll or 50ng/).ll , was added. Genomic DNA from four 
affected individuals and three unaffected individuals in R0942 were used (Figure 2.2). No 
genomic DNA was added to the negative control well(s). The PCR plate was capped, 
vortexed and centrifuged up to IOOOrpm. The PCR plate was placed in either a Biometra 
or Eppendorf thennocycler and a specific thermocycler program was run (Appendix D). 
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Figure 2.2: Family R0942 with DNA samples used for Sanger sequencing (in red). 
In order to test the success of PCR amplification for the region of interest, a gel 
electrophoresis technique was used. Briefly, one gram of Ultrapure Agarose and SOml of 
I X TBE Buffer was mixed and heated by microwave to dissolve the agarose in solution. 
3.75j.d of SYBR Safe DNA Stain Gel (Life Technologies, Ontario, Canada) was added 
and the mixture was allowed to set in a gel electrophoresis tray. Once solidified, a 
mixture containing 3Ml each of dye and PCR product was pipened into each well. In one 
well, a mixture containing IMl of IOObp DNA ladder (Life Technologies, Ontario, 
Canada) and 3J.Ii of dye was added. A PowerPac 300 from Bio-Rad (Ontario, Canada) 
was used to supply 120V for 35 minutes for gel electrophoresis. An image of the gel was 
taken using a Kodak UV imager. PCR was considered successful if a band(s) of 
appropriate length in base pairs was visible under UV light when compared to the DNA 
ladder with no negative control band(s). 
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From each PCR product, 8fll was pipetted into individual wells in another 96-well 
0.2ml PCR plate. Into each well, 0.5~1 of Shrimp Alkaline Phosphatase ( I U/~1), 0 . 5~1 of 
Exonuclease I ( I OU/fl l) and 7 .Sfll of dH20 were added. The PCR plate was capped, 
vortexed and cenlrifuged up to I OOOrpm. The PCR plate was placed in either a Biometra 
or Eppendorf thermocycler and the "Exosap" program was run (Appendix D). 
From this "exosap" product, 4.0).11 was pi petted into a Microamp Optical 96-well 
reaction plate. To each well, the following was added: O.Sfll ofBigDye Terminator v3.1 
Cycle Sequencing Mix, 2.0fll BigDye Terminator v3.1 Sx Sequencing Buffer (Applied 
Biosystems, Ontario, Canada), l 3.83fll of dH20 and 0.67fll of primer (forward). The 
same reagents were added to different wells for a second time with the only change being 
0.67fll of reverse primer used during the second time. The Microamp reaction plate was 
capped, vortexed and centrifuged. The Microamp reaction plate was placed in either a 
Biometra or Eppendorf thennocycler and the "Abiseq" program was run (Appendix D). 
To precipitate the desired product for sequencing, Sfll of 125mM 
Ethylenediaminetetraacetic acid (EDT A) and 65).11 of I 00% ethanol (EtOH) was added to 
every reaction well. The reaction plate was re-capped, vortexed and stored in a drawer (in 
the dark) for a minimum of2 hours to a maximum of 24 hours in order to precipitate the 
desired product for sequencing. 
To continue EtOH precipitation of cycle sequencing reactions, the plate was 
centrifuged for 30 minutes at 3000g. The caps were then removed and the plate was 
inverted onto clean, folded paper towels to remove the EtOH. The inverted plate and 
paper towel were placed in the centrifuge for a quick spin at 200rpm. ISOfll of 70% EtOH 
was added to every well. The caps were placed back on the plate and the plate was 
39 
centrifuged for I 5 minutes at 3000g. After this period, the caps were removed and the 
plates were inverted again onto clean, folded paper towels. The inverted plate and folded 
paper towels were placed in the centrifuge for a quick spin at 200rpm. 15~1 ofHiDi 
formamide was added to every sample in the plate. The plate was capped, vortexed and 
centrifuged for a quick spin at 600rpm. The plate was placed onto a thermocycler and the 
program "denature" was run (Appendix D). After the denaturing thermocycler process, 
caps were removed and a Septa sequencing mat was tined onto the Microamp reaction 
plate. The plate was placed in a reaction cover and put in the ABI prism 3130 Automated 
Genetic Analyzer for automated sequencing to proceed. 
Raw sequencing data was extracted from the ABI prism 3130 and quality of 
sequence was assessed automatically by the Sequencing Analysis 5.2 program and 
manually (Kamel, 2010) as well. Sequence of acceptable quality (bi-directional coverage 
of all exonic bases) was assessed manually using the Sequencher 4.9 or 5.0 programs. 
2.5 Genomic Regions Analyzed I Characterizing Variants 
Complete bi-directional sequencing was done for all exons (coding and non-
coding) in all candidate genes analyzed. The sequences were independently verified for 
quality control. Furthennore, 25bp of each intron-exon boundary was analyzed. This is 
because the intronic regions were not always covered at distances greater than SObp from 
the cxon start locations. Also, since - 50bp away from the exon is typically where the 
primers were designed to bind, immediate sequence next to the primer binding site was of 
poor quality. Due to this 25bp cutoff, variants found outside of these cutoffs were 
reported but not analyzed further fo r any possible effects. 
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All variants found within exons and within 25bp of intron·exon boundaries were 
further analyzed by a systematic method. First, a search was conducted using the dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNPf) and Ensembl (hnp;//useast.ensembl.orgl 
index.html) websites to determine if the variant was previously reported in the literature. 
Based on this search, a variant was labeled as ' previously reported' or ' novel' If the 
variant was ' previously reported', the Caucasian population frequency was noted since all 
of the Newfoundland families in this study were Caucasian. Variants were investigated 
further if the Caucasian population frequency was <1% and/or if variants segregated with 
the disease (since FPF is a rare autosomal disease, the expected population frequency is 
expected to be very low). Reported effects of the protein were noted and further 
bioinfonnatic testing was done to determine the potential importance of the variant allele. 
For all variants that were 'novel' and/or did not have Caucasian frequencies listed, 
segregation of the variant in affected and unaffected individuals in family R0942 was 
determined. If the variant did not segregate with the disease, it was ruled out as being 
causative (shown in results Tables 3.2 and 3.3). The SNPs found in these candidate genes 
were not phased. 
The bioinformatics tools/software utilized included: PolyPhen (Polymorphism 
Phenotyping, http://genetics.bwh. harvard.edu/pphl), a tool "which predicts possible 
impact of an amino acid substitution on the structure and function of a human protein 
using straightforward physical and comparative considerations" (Ramensky et at., 2002); 
Panther (Protein Analysis Through Evolutionary Relationships, http://wwv .. '.pantherdb 
.org!), a tool designed by expert biologists that classifies genes by their functions using 
evolutionary relationships and experimental evidence; and SIFT (Sorting Intolerant from 
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Tolerant, http://sift.jcvi.org/), a too l that predicts if an amino acid substitution affects 
prote in function and what impact this change may have. 
2.6 MUCSB rs35705950 SNP genotyping 
2.6.1 TaqMan genotyping procedure 
To analyze the frequency and segregation of the MUC58 rs35705950 SNP in our 
study population, a 40X TaqMan SNP Genotyping assay mix (Assay ID: C-1 582254-20, 
part number4351379) was ordered (Applied Biosystems, California, USA). This kit 
contained specific probes and reagents required for genotyping the rs35705950 SNP. The 
kit was stored at -20°C. To prepare the reaction, a mastennix consisting of 525).11 2X 
TaqMan Universal PCR Master mix, 13.125).11 of 40X TaqMan SNP Genotyping assay 
mix, 13.125).11 of TE buffer (consisting of tris-hydroxymethyl-aminomethane and EDTA) 
and 393.75).11 of dH 20 was made. 9).11 of the mastennix was ali quoted into each well of a 
0.1 ml MicroAmp Fast Opt ical 96 reaction well PCR plate. I ).11 of [50ng/J.tl] genomic 
DNA was also added into each reaction we ll, bringing the total volume to 10).11 per 
reaction well. A MicroAmp Optical Adhesive Film was applied to the PCR plate and the 
plate was then centrifuged at lOOOrpm for approx imately 5 seconds. 
To perfonn SNP genotype analysis, the experimental PCR plate was placed in an 
Applied Biosystems 7900HT Real-time PCR analyzer. Sequence Detection Systems 
(SDS) v2.4 software was used to construct Allelic Discrimination (AD) and Alle lic 
Quantification (AQ) curves (Appendix E). The 79001-IT perfonned a pre-read in the AD 
file , an AQ run, and a post-read in the AD fi le (Appendix E). The data from these reads 
were automatically called by SDS and a genotype plot was obtained (Figure 2.3). 
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Figure 2.3: SDS Allelic Discrimination genotype plot for MUC5B rs35705950 
Sample of a 96 reaction plate. All individual coloured dots and X' s represent individual 
genotype calls. Red and blue dots are homozygous for GIG and Tff respectively. Green 
dots are heterozygous. X' s consist of3 control reactions with no DNA and undetermined 
DNA samples. 
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Some samples failed to genotype probably due to degradation of DNA, quantity and/or 
quality of DNA, or contamination of the PCR we ll . All experimental samples (6.0%) that 
failed to be genotyped by the TaqMan assay were repeated again. If a sample fai led to be 
genotyped twice, it was excluded from further analysis. The genotype plot was saved and 
genotype data for all samples was exported and analyzed. 
To confirm that genotype calls made by the 7900HT Real-time PCR analyzer 
were correct, a subset of samples that were successfully genotyped (n=20) was randoml y 
selected . These 20 samples consisted of eight GIG genotype samples, eight Off genotype 
samples and four TIT genotype samples. Primers were designed to cover the MUC5B 
promoter SNP (Primer sequences in Appendix C). PCR and Sanger sequencing were 
performed to validate if the call s were correctl y made. All 20 calls made by the 7900HT 
Real-time PCR analyzer in this subset were validated, confirming the accuracy of calls 
made by this system. 
2.6.2 Description of clinical variable paramete rs 
Clinical variables were also gathered for all of the cases, (n= l l 0) and controls 
(n=277) used in genotyping. Cases consisted of sporadic IPF individuals (n=68) and 
familial PF individuals (n=48) from 12 affected fami lies. Variables such as age, gender, 
smoking status, smoking duration, pulmonary function tests and method of diagnosis 
were all gathered from electronic clinical records by Mrs. Barbara Noble (Table 3.4). For 
the controls, clinical variables are based on n=270 since questionnaires were not returned 
by seven participants. These controls were from a colorectal cancer study in 
Newfoundland (Woods eta\., 20 10) and no pulmonary functi on information was 
gathered. 
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Age and smoking status were variables that had sub-classifications. For all cases, 
age of diagnosis was recorded. For all controls, age of sample collection was recorded. 
Smoking status data was divided into four categories: smokers, ex-smokers, occasional 
smokers and never smoked. Smokers were individuals who were actively smoking at the 
time of diagnosis and/or sample collection. Ex-smokers were individuals who had 
stopped smoking at the time of diagnosis and/or sample collection. Out of all cases, there 
were 73 ex-smokers. 71.2% of these individuals had smoked for over 20 years. Out of all 
control individuals, 128 were ex-smokers. 53. 1% of these individuals had smoked for 
over 20 years. Occasional smokers were classified as individuals who do not smoke 
habitually and only smoke in certain social settings. Out of the five total occasional 
smokers in the study, only one had smoked occasionally for over 20 years. 
2.6.3 MUCSB case-control statistics 
In order to assess the association of the rs35705950 MUC58 promoter 
polymorphism with IPF in the Newfoundland population, a case-control study was carried 
out utilizing various statistical methods. To determine Hardy-Weinberg equilibrium 
(HWE) of genotype frequencies for cases and controls, a Chi-squared Hardy-Weinberg 
equilibrium test calculation for biallelic markers was used (Rodriguez et al., 2009). Chi-
square values (x2) represent the difference between observed and expected genotype 
frequencies. If the P value > .05 then genotype frequencies are consistent with HWE and 
what is expected and ifP < .05, the genotype frequencies are significantly different than 
what is expected. 
To detem1ine if there is a significant difference between cases and controls for 
rs35705950, a logistic regression was carried out. Logistic regression was used because it 
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is a generali zed linear model that can predict the probability of an outcome (i.e. di sease) 
based on one or more predictor values (i.e. genotype) by yielding odds ratio and 
confidence interval values. If the odds ratio is greater than one, the outcome is more 
likely to occur than not. In our case, the outcome was the disease phenotype. Therefore, if 
the odds ratio was greater than one, ri sk of PF was more likely than not. Conversely, if 
the odds ratio was less than one, thi s would indicate a preventative effect rather than a 
risk effect. The confidence interval (CI) associated with the odds ratio demonstrates the 
reliability of the odds ratio number and show the upper and lower boundary of possible 
effect sizes (Davies, 1998). If a 95% CI includes the odds ratio value that shows an effect, 
this finding is non-significant at the 5% level. Furthermore, the Cl upper and lower limits 
show how big or small the effect could be (Davies, 1998) but this also depends on the 
sample size of the study. 
The logistic regression type used in this study was multinomial to demonstrate if 
there was additional predicted risk based on the number of variant alle les possessed. This 
produced odds ratio/CI for each variant genotype in comparison to the wild-type 
genotype. Multinomial logistic regression analysis was carried out comparing probands to 
controls . Furthermore, in order to compare all cases to contro ls, multinomial logistic 
regression anal ysis using familial clusters was done since 27.2% of all cases were related 
and had to be corrected for. Individuals from a related family were put in the same cluster 
and all unrelated individuals were placed in different clusters. Statistical correction for 
related individuals was implemented by using thi s method. 
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3. Results 
3.1 Clinical description and findings- Family R0942 
Famil y R0942 is from a small community in Trinity Bay, Newfoundland, Canada. 
According to the Statistics Canada Census of2006, the population of thi s community is 
slightly over 300. There are other families with FPF in other small communities across 
the island of Newfoundland, suggesting a series of founder effects leading to the higher-
than-average prevalence of FPF. 
Figure 3.1: Location of Trinity Bay on a map of Newfoundland. Location of Trinity 
Bay is denoted by the red arrowhead. 
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The clinical histories of individuals in this family have been well -documented by 
the Provincial Medical Genetics Program (PMGP). The proband of this family is a male 
(R0942.0000, Figure 3.2) who was diagnosed at 39 years of age. He presented with 
shortness of breath and pneumonia. Review of the questionnaire he provided showed that 
he did have some exposure to asbestos and wood. Furthermore, he was a smoker for over 
20 years. PFTs, HRCT scan and a lung biopsy were performed. A diagnosis ofiPF was 
given. The proband also stated that his father (R0942. 1000) had died ofPF and there 
were others in his nuclear family that had simi lar symptoms to his, leading to screening of 
other family members. 
After careful screening, IPF was diagnosed in one brother (R0942.0002) and one 
sister (R0942.0005) of the proband. The brother presented with a chronic cough, 
shortness of breath and chest pain for many years. He was also a smoker for over 25 
years. He was diagnosed by PFTs and HRCT scan at age 46. The sister of the proband 
presented with shortness of breath and chest pain. She had recently given up smoking but 
had smoked for 3 1 years. A diagnosis of IPF was given after PFTs, HRCT scan and a 
lung biopsy. The proband has three other siblings (two brothers, one sister) who have 
been screened clinically but have not presented with any symptoms. 
The father of the proband (R0942. 1 000) who had died of IPF also had siblings 
who were affected. From his six siblings (three brothers, three sisters), two brothers 
(R0942.1001. R0942.1002) and one sister (R0942.1 005) were diagnosed by IPF from 
screening of the family (Figure 3.2). All three of these siblings had smoked for over 40 
years. The other unaffected sib lings were also clinically screened but there have been no 
presenting symptoms yet. 
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Figure 3.2: Family R0942 with identifying numbers for affected individuals only. 
3.2 Candidate genes analyzed 
Previous microsatellite genome-wide scans, SNP genome-wide scans and 
microsatellite fine-mapping yielded regions of LD on chromosome 16p and 6, these 
regions were the focus of candidate gene analysis (Edwards, unpublished data; Kamel, 
2010). Mr. Fady Kamel fully sequenced all exons in four genes on chromosome 6 
(TFAP2a, TFAPlfJ, WRNIPI and SERPINBI) and six genes on chromosome 16 (DEJ(f, 
EMP2, VASN, GL!Sl, TID/, and PPL) in two affected individuals in R0942. Sequencing 
of these 10 genes was unsuccessful in determining a FPF-causing genetic variant(s). 
Therefore, additional candidate genes from these two ROI were methodically 
selected for sequencing. In total , four additional genes from chromosome 6 (EDNJ. 
CD83, DTNBPI, VEGFA) and five additional genes from chromosome 16 (SOCS/ , 
TEL02. SNRNP25. MSLN, IL/7C) were fully sequenced (Table 3. 1 and Figure 3.3). 
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Table 3.1: All genes fully sequenced in the regions of interest on chromosome 6 and 
16 from this project 
Sequenced in 5 affected and 2 unaffected individuals 
in Family R0942 
Chromosome 6 16 
EDNJ SOCSI 
CD8J TEL02 Genes sequenced DTNBPI SNRNP25 
VEGFA MSLN IL/ 7C 
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Figure 3.3 : Physical location of genes sequenced within regions of interest on 
chromosomes 6 and 16. 
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These genes were fully sequenced in four affected and three unaffected 
individuals from family R0942 (F igure 2.2). The unaffected individuals were sequenced 
to perform a preliminary segregation analysis in case a potential causative variant was 
found. Two of the unaffected individuals are 78 and 81 years of age and have smoked for 
29 and 45 years respective ly. It is therefore Jess likely that they wi ll deve lop PF based on 
genetic causes at such an advanced age. The third unaffected individual was used to see if 
a potential variant segregated with PF in the sibship. All variants found within these 
seven individuals are reported in Table 3.2 and Table 3.3. 
3.2.1 Results from candidate gene sequencing- Chromosome 16 
3.2. 1.1 SOCSI 
SOCSI is a gene located on chromosome 16: 11 348274-11350039 (UCSC 
Genome Browser, GRCh37/hg19 assembly; Kent et al. , 2002). There is only one 
transcript for SOCS/ which is made up of two exons consisting of a total of 1225 base 
pairs and codes for a 211 amino acid protein. SOCS/ is a member of the suppressor of 
cytokine signaling fami ly of genes. Cytokine and cytokine signaling proteins have 
previous ly been demonstrated to be involved in molecular pathways leading to PF and are 
thus of interest. A study also indicates SOCS/ is a suppressor for pulmonary fibrosis since 
there was a significantly downregulated expression of SOCS/ in the lungs of IPF patients 
(Nakashima et al. , 2008). Furthermore in this study, viral gene therapy with SOCS/ in 
mice reduced inflammation and PF, suggesting its importance in the pathogenesis of PF 
(Nakashima eta!., 2008). Even though SOCS/ gene expression results were uninteresting 
(Figure 3.8), the functional significance of SOCSI in relation to PF made thi s an ideal 
candidate gene for thi s study. 
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Both exons of SOCSJ were fu ll y sequenced in the seven selected individuals from 
R0942. Two variants were found, both of which were previous ly reported variants (Table 
3.2). One variant was a substitution located in intron I (c.-50-18T>G). This was labeled 
non-pathogenic since the frequency in the Hap Map Caucasian population was 0.992 and 
it did not segregate with FPF in this fami ly. The other variant found was a deletion in the 
3' UTR (c .*426delT). This variant was also excluded as FPF-causing because it did not 
segregate with FPF in this family (Figure 3.4). Furthermore, it was previously reported in 
other control populations. 
1) SOCSl c.-50-18T>G 
2) SOCSl c.*426de!T 
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Figure 3.4: Segrega tion a nalysis of both variants found in SOCSI. Segregat ion 
of SOCSJ c.-50-1 8T>G is shown in the first line and segregation of SOCSJ c.*426delT is 
shown in the second line. Red arrowheads indicate individuals with DNA sequenced. 
These variants did not segregate with the disease in this fam il y. 
3.2.1.2 MSLN 
The MSLN gene is located on chromosome 16: 810765-818865 (UCSC Genome 
Browser, GRCh3 7/hg 19 assembly; Kent et al., 2002). There are ten protein-coding 
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transcripts for MSLN with the longest one containing 17 exons and coding for a 630 
amino acid protein. According to the BioGPS gene expression profile, MSLN is 
significantly expressed in the lung in comparison to all other tissues in humans. The 
precursor protein encoded by this gene is cleaved into two products: mesothelin and 
megakaryocyte potentiating factor (UCSC Genome Browser; Kent et al , 2002). These 
products are involved in developing the mesothelium, a layer of cells that provides a 
protective covering for some human organs. Normally, the site of normal developing 
mesothelium is the lung- specifically its internal chest wall. However, if the mesothelial 
cells are differentiated abnormally, malignant mesothelioma (MM) can occur. Just like 
pulmonary fibrosis caused by inhalational agents, MM is most commonly caused by 
asbestos exposure (Tan et al., 201 0). Therefore it is possible there are some overlapping 
molecular mechanisms in both diseases' pathogenesis. Along with a significantly higher 
expression in the lung, these observations led to MSLN being selected as a candidate 
gene. 
All 17 exons of t he longest transcript of MSLN were fully sequenced in the seven 
selected individuals from R0942. Three variants were found in this gene of which two 
were intronic. One of the intronic variants was found in introns 8 (c.795+11 A>G). This 
previously reported SNP was present in all seven affected and unaffected individuals 
sequenced in R0942 and thus did not segregate with FPF (Figure 3.5). Also, the allele 
frequency was 0.967 based on a pilot-! CEU population, indicating it is present at a high 
frequency in the Caucasian population. The other intronic variant (c.1 230+16G>T) was 
located in intron II and had a 1000 Genomes minor allele frequency of 0.0 18. However, 
this SNP was previously reported in the literature, did not segregate with affected 
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individuals in R0942 and had no predicted impact on splicing or protein function. Hence 
this variant was excluded as a potential FPF-causing variant. The only SNP found in an 
ex on of MSLN was located in ex on I I (c.l204A>G). This substitution caused a protein 
change, p.Asn402Asp. Since this SNP was only present in one affected individual in 
R0942, it was also excluded as a potential FPF-causing variant in this family (Figure 3.5). 
Furthermore, the 1000 Genomes minor allele frequency was 0.095. 
1) MSLN c. 79 5+ llA>G 
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Figure 3.5: Segregation a na lysis of th ree variants found in MSLN. Segregation 
ofMSLN c.795+11A>G is shown in the first line and segregation of MSLN c. l204A>G is 
shown in the second line. Red arrowheads indicate individuals with DNA sequenced. 
These variants did not segregate with the disease in this family. 
3.2.1.3 TEL02 
TEL02 is a gene located on chromosome 16: 1543352-1560460 (UCSC Genome 
Browser, GRCh37/hg l9 assembly; Kent eta!. , 2002). There are three protein coding 
transcripts for this gene. The longest transcript contains 21 exons and codes for an 837 
amino acid protein. The functions of TEL02 are largely unknown in mammals but it is 
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suggested to be involved in the regulation of telomere length. This is of importance since 
variants in TERT, a gene involved in preventing the shortening oftelomeres, are the most 
conunon documented genetic cause of FPF (Tsakiri et al., 2007; Alder et al., 2008; 
Annanios et al., 2007; de Leon eta!., 2010). Furthermore, it is possible that TEL02 has 
additional funct ions besides that of telomere maintenance since it is highly conserved in 
Drosophila. Drosophila and other insects of the same order lack the canonical 
telomerase-based telomere system thus the conservation of TEL02 sequence in this order 
is interesting (Takai ct a!., 2007). TEL02 also has median expression in the lung and 
interacts with other proteins involved in DNA repair pathways (Figure 3.9). Due to its 
involvement in telomere maintenance and other possible functional involvements, TEL02 
was selected as a candidate gene. 
All 2 1 exons of TEL02 were fully sequenced in the seven selected individuals 
from R0942. Eight variants were found in this gene, all of which were previously reported 
(Table 3.2). Three of the eight variants were intronic substitutions (c.682+ 11 5C>T; 
c.2226+38A>G; c.2227-39C>T) and were excluded as FPF-causing because they were 
located more than 30 bases into the introns, were all present at an allele frequency of 
greater than I%, had no predicted impact on protein or gene expression and did not 
segregate with pulmonary fibrosis in this family. There were two variants found in exon 
21: one variant in exon 21 (c. *174C>T) was found and labeled non-pathogenic since it 
was located in the non-coding part of the ex on and had a HapMap CEU allele frequency 
of0.367. Another substitution variant (c.2415T>C) was labeled non-pathogenic since the 
substitution resulted in a synonymous amino acid change and the allele frequency in the 
HapMap CEU population was 0.429. Three variants (exon 2: c. l9G>C, c.20A>G; exon 3: 
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c.437A>G; exon 16: c.202 1 A>G) resulted in a change in amino acid. However, these 
variants d id not segregate with FPF in this family and thus were labeled as non·disease 
causing (Figure 3.6). 
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Figure 3.6: Segregation ana lys is of three missense variants in TEL02 . . 
Segregation of TEL02 variants c. l9G>C, c.20A>G, c.43 7 A>G and c.202 1 A>G 
are shown in the fi rst, second, third and fourth lines respect ive ly. Red arrowheads 
ind icate individuals with DNA sequenced. These variants did not segregate with 
the di sease in thi s family. 
3.2. 1.4 SNRNP25 
The SNRNP25 gene is located on chromosome 16: 103 829·107669 (UCSC 
Genome Browser, GRCh37/hg19 assembly; Kent et al. , 2002). SNRNP25 has three 
protein coding transcripts. The largest one contains five exons and codes for a 132 amino 
acid protein. This gene encodes a small nuclear ribonucleoprotein (SNRNP) with a 
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molecular weight of 25 kDa. SNRNPs are made up of small nuclear RNAs and are 
involved in cellular processes such as splicing of RNA transcripts to make mRNAs. 
SNRNP25 encodes a protein that is a component of the Ul2-type spliceosome which 
functions in removing introns with a unique splice sequence for recognition (UCSC 
Genome Browser; Kent et al., 2002). Recently, an additional role for SNRNP25 was 
discovered. A study showed that the prevalence ofPF was the key significant difference 
between patients with or without anti-U \1 /U \2 antibodies (Fertig et a\., 2009). The 
results of this study concluded that presence ofanti-Ull /U12 antibodies is a novel 
biomarker for PF (Fertig et al., 2009). Following this, it is postulated that a genetic 
change in one of the genes coding for the proteins of the U12-type spliceosome could 
alter the structure of the spliceosome and thus cause the presence of these specific 
antibodies in PF patients. Therefore, SNRNP25 was selected as a candidate gene. 
All five exons of SNRNP25 were fully sequenced in the seven selected individuals 
from R0942. There were three substitution variants found in this gene (Table 3.2). One 
variant (c.-66C>G) was located in the S'UTR; the second variant found (c.70-15C>T) 
was located in intron 1; the last variant found (c. *132T>G) was located in the 3 'UTR. All 
three variants were previously reported in the literalUre, were of unknov.m predicted 
impact, did not segregate with FPF in R0942 (Figure 3. 7) and had a greater minor allele 
frequency than 0.01 in dbSNP. Due to these observations, all three variants found in 
SNRNP25 were excluded as potentially pathogenic genetic variants. 
3.2. 1.5 ILI7C 
IL/7C is loca1ed on chromosome 16: 88705001 -88706882 (UCSC Genome 
Browser, GRCh371hgl9 assembly; Kent et al., 2002). This gene has one protein-coding 
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transcript which contains three exons and codes for a 197 amino acid protein. ILl 7C 
encodes a cytokine that is involved in releasing tumor necrosis factor alpha and other 
interleukins from activated cells (UCSC Genome Browser; Kent et al., 2002). TheIL 17 
family of cytokines has been documented to be involved in many pulmonary 
inflammatory responses (Kawaguchi eta!., 2004). The cytokine pathway leading to 
pulmonary inflammation and ECM remodeling is a major contributor to the pathogenesis 
of lPF. Furthermore, cytokines from the IL17 family can induce the expression of 
MUC5B (a known IPF-causing gene) in bronchial epithelial cells, lending further support 
to its potential involvement in an IPF molecular pathway (Kawaguchi eta!., 2004). From 
these functional considerations, ILl 7C was selected as a candidate gene. 
All three exons of IL17C were fully sequenced in the seven selected individuals 
from R0942. There was only one variant found in this gene (Table 3.2). This variant was 
a substitution (c.444C>T) that resulted in a synonymous change (p.Ser148=). The variant 
was previously reported in the literature, had a minor allele frequency of0.041 (1000 
Genomes Project) and did not segregate with FPF in R0942 (Figure 3.7). Thus, this 
variant was classified as non-pathogenic. 
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Figure 3.7: Segregation analysis of a S' UTR variant and a 3'UTR variant in 
SNRNP25 and an exonic va riant in ILl 7C. Segregation of SNRNP25 variants 
c. -66C>G and c. *132T>G are shown in the first and second lines respectively. 
Segregation of IL !7C variant c.444C> T is shown in the third line. Red 
arrowheads indicate individuals with DNA sequenced. These variants did not 
segregate with the disease in this family. 
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Table 3.2: C haracterist ics of a ll var iants found b y Sanger seq u encin g o n 
chromosom e 16 ROis 
Exon I Var iant I I A . I I I Caucasi I G ene Type ::~o P~ed icted d bSNP an Pop. . Add itio~al h tmpact 10 Freque m format1on 
c ange ncy 
HapMap does not 
intron c.-50- CEU· segregate with 
sacs 1 18T>G substitution Unknown rs27829 o_gg2 FPF 
1 in 3' UTR 
c.•426del deletion Unknown n/a region, does T not segregate 
with FPF 
rs266766 does not 
c.19G>C, 2bp p.Giu7Ar 
n/a 0 n/a segregate with 
c.20A>G substitution 9 rs266766 FPF 1 
HapMap >1% 
c.437 p.Gin146 rs223562 CEU· population 
A>G substitution Ar Missense 4 0.440 fre"quency 
pilot 1 
intron c .682+11 rs223563 CEU: >30 bases into 
4 5C>T substitution Unknown 0 0.750 the intron 
HapMap does not 
TELO c.2021A> rs224812 CEU: segregate with 16 G substitution ,., Gln-->Ar 8 0.372 FPF 2 dbSNP:a 
intron c.2226+3 rs112488 vg het: >30 bases into 
18 8A>G substitution Unknown 82 0.455 the intron 
HapMap 
intron c.2227- rs373672 CEU: >30 bases into 
18 39C>T substitution Unknown 1 0.250 theintron 
c.2415T> p.Aia805 Synonymo rs318022 HapMap >1% 21 substitution CEU: population c 8 0.429 fre"quency 
HapMap 
c .*174C> CEU· >in non-coding 
21 T substitution Unknown rs9454 0.367 region 
1000 
rs256214 Genome >1 % 5' UTR c.-66C>G substitution Unknown 5 sMAF population C=0.463/ frequency 
SNRN 583 
P25 intron c.70- HapMap does not 
1 15C>T substitution unknown CEU: segregate with 0.460 FPF 
c.*132T> rs104500 HapMap >1% 3'UTR G substitution Unknown 1 CEU· population 0 .301 freauencv 
intron c.795+11 rs173734 pilot 1 high 
8 A>G substitution unknown 0 CEU: population 0 .967 freauencv MSLN 1000 does not 
11 c.1204A> substitution p.Asn402 Missense rs734912 Genome segregate with G A•p 55 sMAF FPF 
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0.095 
1000 
Genome \does not 
intron c.1230+1 rs734912 sMAF segregate with 
11 6G>T substitution unknown 58 0.018 FPF 
1000 does not 
IL17C c.444C>T substitution p.Ser148 Synonymo rs110766 Genome segregate with 88 sMAF 
0.041 FPF 
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Figure 3.8: BioGPS human tissue gene expression profiles for SOCSJ and MSLN. 
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Figure 3.9: A) BioGPS human tissue gene expression profile for TEL02. B) STRING TEL02 protein to protein 
interactions 
3.2.2 Results from candidate gene sequencing - Chromosome 6 
3.2.2. 1 EDN I 
The EDNI gene is located on chromosome 6: 12290529-12297427 (UCSC 
Genome Browser, GRCh37/hgl9 assembly; Kent eta!., 2002). This gene has one protein-
coding transcript containing five exons and coding for a 212 amino acid protein. EDN 1 
encodes the endothelin-1 protein which participates in a variety of physiological 
pathways in the human body. Specificall y in the lung, endothelin-1 drives mult iple 
processes that all lead to ECM deposition such as fibroblast activation, proli feration, and 
differentiation into myofibroblasts (Swigris and Brown, 20 I 0). The fibroblast pathway 
that leads to excess ECM deposition is one of the hallmarks of iPF. Patients with I.PF 
have significant ly increased levels of £DN1 protein in comparison to healthy contro ls in a 
number of studies. In a possible-disease model involving EDN 1, injured AECs would 
recruit a variety of pro-fibrotic cytokines such as endothelin-1. In tum, aberrant activation 
and differentiation of fibrob lasts to myofibroblasts, excess ECM and collagen deposits 
and abnormal tissue repair would occur, leading to IPF (Swigris and Brown, 20 I 0). 
Furthermore, EDN 1 is expressed in lung tissue over 30x more than median in all other 
tissues, suggesting its profound ro le in various lung processes (Figure 3.1 3). The 
significant expression of EDN 1 in lung tissue and previous functional evidence 
documenting its role in fibroblast cascades led to the selection of EDN1 as a candidate 
gene for Sanger sequencing. 
All five exons of EDN1 were fully sequenced in the seven selected individuals 
from R0942. There were three variants found in this gene (Table 3.3). One of the variants 
(c. -1 3 ldeiA) was located in the 5'UTR. This deletion was previously reported in the 
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literature and had a minor allele frequency of 0. 718. Therefore this was labeled a non~ 
pathogenic variant. The second variant found in EDl•.U was located in ex on 3 and was a 
substitution (c.318A>G). This was a homozygous change in all seven individuals and the 
variant was previously reported in the literature, causing a synonymous amino acid 
change. Due to these observations, the variant was excluded from being a potential 
pathogenic variant. The final variant was a substitution (c.594G>T) found in exon 5. This 
subst itution was predicted to cause a missense change in the resulting amino acid 
(p.Lyst97Asn). However, thi s variant had a HapMap CEU minor allele frequency of 
0.071 and was only found in one unaffected individual (Figure 3.1 0). Thus, this was 
unlikely to be an FPF~causing variant. 
1) EDNJ c.594G>T 
,- 1 ~ 
T(G T/T T/T 
Figure 3.10: Segregation analysis of an exonic variant found in EDNI. Segregation of 
EDNJ variant c.594G>T is shown in the first line. Red arrowheads indicate individuals 
with DNA sequenced. This variants did not segregate with the di sease in this family. 
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3.2 .2.2 CD83 
CD83 is located on chromosome 5: 14117487-14137148 (UCSC Genome 
Browser, GRCh37/hgl9 assembly; Kent et al., 2002). This gene has one protein-coding 
transcript that contains five exons and codes for a 205 amino acid protein. The CD83 
gene codes for a membrane protein that participates in the regu lation of ant igen 
presentation (UCSC Genome Browser; Kent et al., 2002). CD83 is also expressed by 
dendritic cell s that initiate and control various immune responses in the body (Bantsimba-
Malanda eta!., 201 0). Although there are many dendritic cells that act in the lung, their 
involvement in IPF has not been documented. A recent study was the first to demonstrate 
that dendritic ce ll s that express CD83 accumulate in the lung during bleomycin-induced 
fibrosis of the lung (Bantsimba-Malanda eta!. , 2010). Since these cell s are involved in a 
proinflammatory pathway leading to fibrosis , CD83 was selected as a candidate gene. 
All five exons of CD83 were fully sequenced in the seven selected individuals 
from R0942. There were five variants found in this gene (Table 3.3). One variant (c.38-
43C>G) was located in intron I and was labeled non-pathogenic due to its location (43bp 
before the start of ex on 2) and a minor allele frequency of 0.266 in control populations. 
Three variants were located in the non-cod ing region of ex on 5. These were previously 
reported substitution variants that were also labeled non-pathogenic since they did not 
segregate with FPF (Figure 3. 11 ), had a > I% population frequency and had no known 
functional impact reported by the literature. The last variant found was a substitution 
(c.207G>A) located in exon 3. This was a synonymous variant that had a minor allele 
frequency of0.265 (Table 3.3). This variant was also classified as non-pathogenic. 
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Figure 3.1 1: Segregation ana lysis of three \'a r iants in exon 5 of CD83. Segregation of 
CD83 variants c. *842C>T, c. *961A>C and c.* 154TI>C are shown in the first, second 
and third lines respectively. Red arrowheads indicate individuals with DNA sequenced. 
These variants did not segregate with the disease in this family. 
3.2.2.3 DTNBPI 
The DTNBP 1 gene is located on chromosome 6: 15523032-1 5663289 (UCSC 
Genome Browser, GRCh37/hg19 assembly; Kent et al., 2002). The longest protein-
coding transcript for this gene contains ten exons and codes for a 351 amino acid protein. 
DTNBP 1 codes for dystrobrcvin binding protein I which is expressed ubiquitously and 
has functional roles in organelle biogenesis and trafficking (Kent et al., 2002). There is 
evidence showing that a nonsense mutation in DTNBPI causes Hermansky·Pudlak 
syndrome (HPS) type 7 (Li et a!., 2003). HPS is a genetically heterogeneous disorder 
characterized by oculocutaneous albinism, prolonged bleeding and sometimes pulmonary 
fibrosis (Li et al., 2003). There are seven subtypes of HPS, each with slight ly different 
phenotypical manifestations. In three of the HPS subtypes including I-IPS type 7, dyspnea 
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or severe pulmonary fibrosis is also observed (Pierson et al., 2006). Since a nonsense 
mutation in DTNBPJ causes HPS type 7, it is plausible that a different genetic mutation 
could result in PF without the other disease manifestations. From these observations, 
DTNBPJ was selected as a candidate gene. 
All ten exons of DTNBPJ were fully sequenced in the seven selected individuals 
from R0942. There were two variants found in this gene (Table 3.3). One of the variants 
(c.-17A>G) was a 5' UTR substitution variant and the other (c.* 105A>G) was located in 
the non-coding region of ex on 1 0. These variants had minor allele frequencies of0.138 
and 0. 127 respectively and did not segregate with FPF (Table 3.3; Figure 3.12). These 
variants were thus classified as non-pathogenic. 
1) DTNBPl c.-17A>G 
2) DTNBPl c.*lOSA>G 
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Figure 3.12: Segregation analysis of both variants found in DTNBPJ. Segregation of 
DTNBP 1 variants c.-1 7 A>G and c.* I 05A>G are shown in the first and second lines 
respectively. Red arrowheads indicate individuals with DNA sequenced. These variants 
did not segregate with the disease in this family. 
68 
3.2.2.4 VEGFA 
VEGFA is located on chromosome 6: 43737946-43754223 (UCSC Genome 
Browser, GRCh371hg19 assembly; Kent et al. , 2002). The longest protein-coding 
transcript for VEGF A contains eight exons and codes for a 412 amino acid protein. 
VEGFA codes for vascular endothelial growth factor a. This is part of a protein complex 
that targets endothelial cells and precipitates a wide variety of physiological effects such 
as increasing angiogenesis/ endothelial cell growth, promoting cellular migration and 
regulating apoptosis. VEGFA primarily promotes angiogenesis (blood vessel gro\Nth). An 
imbalance in angiogenic factors such as VEGFA and transforming-growth factor B 
(TGF/f) that leads to abnormal vascular growth has been demonstrated with IPF 
(Antoniou et al., 20 10). Increased vascularization is also displayed around fibroblastic 
lOci and in areas of fibrosis in the lung (Cosgrove et al., 2004). Moreover, expression of 
VEGFA is !Ox higher in lung tissue than median value in all other tissues (Figure 3.13). 
These factors led to VEGFA being selected as a positional and functional candidate gene. 
All eight exons of VEGFA were fully sequenced in the seven selected individuals 
from R0942. There was one substitution variant (c.534C>T) found in the coding region of 
ex on I. The C> T substitution resulted in a synonymous amino acid (serine). This variant 
was previously reported in the literature and had a 1-lapMap CEU minor allele frequency 
of0.195 (Table 3.3). Therefore, the variant was classified as non-pathogenic. 
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Table 3.3: Characteristics of a ll variants fou nd by Sanger sequencing on 
chromosome 6 ROis 
Gene E v . t T .d Predic ted dbSNP p Add1t1ona l I I I Amino I . I I Caucasian I .. 
xon anan y pe c~~~~;.~e impac t 10 Freq~~~cy info rmation 
[c.-
5' UTR 131deiA] deletion unknown rs104786 PDR90: in 5' UTR 
+[c.- 94 0.718 reg1on 
131deJA 
EDN1 (c.318A> substitut synonymou HapMap >1% G]+[c.31 s:Giu--> rs5369 population 
8A>G ion Glu CEU: 0.770 fre"quenc 
c.594G> substitut p.Lys197 HapMap does not 
missense rs5370 segregate with T ion Asn CEU: 0.071 FPF 
c.38- substitut rs223536 Pilot 1 CEU >1 % intron 1 unknown population 43C>G ion 8 0.175 freauenc 
c .207G> substitut synonymou rs774320 HapMap does not 
A s: Arg--> 6 CEU: 0.265 segregate with Ac FPF 
c:842C substitut rs105064 HapMap >1% CD83 unknown popu lation 
>T ion 8 CEU: 0.150 freauenc 
c.*961A substitut rs105065 HapMap >1% 
unknown population 
>C ion 0 CEU: 0.460 freauenc 
c:1547T substitut Pilot 1 CEU: does not 
>C unknown rs9230 0.242 segregate with FPF 
[C· >1 % 
5' UTR 17A>G]+ substitut unknown rs1 15583 Pilot 1 CEU: population 
DTNB [c. - 24 0.192 frequency 17A>G P1 does not 
10 c:105A substitut unknown rs104763 HapMap segregate with 
>G 1 CEU: 0.271 FPF 
VEGF c.534C> substitut synonymou HapMap >1% 
s: Ser--> rs25648 population A T Sec CEU: 0.195 fre"quency 
70 
EDNJ 218995_s_at VEGFA 
210512 !I at 
- 500 1 
Figure 3.13: BioGPS human tissue gene expression profiles for EDNJ and VEGFA . 
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3.3 MUCSB rs35705950 genol)•ping 
3.3.1 Case vs. control analyses 
A case-control analysis was carried out using 110 affected individuals and 277 
healthy controls from the Newfoundland population. From the probands, 30/110 had 
additional family members with PF. The anal ysis was performed twice using SPSSv20.0 
so ftware with Dr. Guangj u Zhai' s guidance (Memorial Uni versity). This analysis was 
perfo rmed once with all 110 cases while controlling for famil ial samples via clustering 
and once by using the 80 unrelated pro bands without including additional affected famil y 
members. The clinical vari ab les/results fo r both analyses are summarized in Table 3.4. 
There was an association between rs35 705950 genotypes and IPF (Figure 
3. 14). The minor allele T was present in 36.4% of affected individuals and 12.6% of 
healthy control s. The genotype frequencies for controls were consistent with Hardy-
Weinberg equilibrium (..f = .05, P = .82) but were significantl y different for all cases (X2 
= 5.22, P = .02) . The odds rati o fo r individuals affected with IPF who were heterozygous 
for the vari ant minor all ele was 5.4 (95% confidence interval, 3.3 to 9.6, P < .00 1). The 
odds ratio for individuals affec ted with IPF who were homozygous for the variant minor 
allele was 12.2 (95% confidence interval, 3.3 to 44.7, P < .00 1). Furthermore, there was 
no signifi cant difference between probands and all cases (P > .05). 
3.3.2 Familial segregation of MUC5B promoter SNP rs357059SO 
Since there were 30 additional famil y members included in one part of the case vs 
control analyses, a segregation anal ysis was performed on alll 2 families that had been 
characteri zed with FPF. From this analysis, rs35705950 was shown to segregate in two 
famili es: Rll 36 and R0942 (Figure 3. 15). 
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Figure 3.14: Excel bar graph comparing differences between genotype frequencies. 
76.2% of controls had the GIG genotype in comparison to 35% ofprobands and 35.4% of 
all cases. Only 23.8% of controls had at least one T allele in comparison to 65% of 
probands and 64.6% of all cases. 
Family R11 36 exhibited segregation of the MUC58 variant T allele with PF. The 
proband, diagnosed with PF at 60 years of age, is homozygous for the variant T allele. 
There are four other affected individuals in this family. Three of these individuals are 
heterozygous for the variant T allele (diagnosed at ages 53, 61 and 92) and one is 
homozygous for the variant T allele (diagnosed at age 64). There arc 14 other individuals 
in this fami ly who are heterozygous for the variant T allele and two others who are 
homozygous for the variant T allele. These 14 individuals are unaffected. In panicular, 
eight unaffected individuals are between 34-48 years old which is before the typical age 
of onset (- 62 years) for FPF in our cohort. All homozygous wild-type individuals were 
unaffected at last follow up. 
Family R0942 also exhibited segregation of the variant T allele. In this family, all 
seven affected individuals were heterozygous for the variant T allele. Out of the 10 
unaffected individuals in this family, 6 are wild-type and 4 carry one copy of the variant 
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T allele. The four unaffected individuals with the variant T allele are 33, 51 , 52 and 78 
years of age. As in family R 1136, no one in family R0942 with the homozygous wild-
type G allele had PF. 
To detennine if segregation of the risk allele occurred by chance in family R0942, 
Simpli fied rapid segregation analysis (S ISA) was conducted (Meller et a!., 20 11 ). This 
analysis is done by calculat ing the number of informative meiosis in a family, assuming 
that the variant in question (in this case, the rs35705950 MUC5B promoter SNP) is only 
introduced once into the pedigree (Moller et al. , 201 1). After obtaining this information, 
the probability for cosegregat ion of the phenotype with the genet ic variant can be 
calculated. From performing this analysis, the probability by chance that co-segregation 
of the variant T allele with pulmonary fibros is occurred in fami ly R0942 was 1.56%. This 
confirms it is unlikely that segregation of the MUC5B rs35705950 variant T allele with 
FPF occurred by chance in fami ly R0942. A manuscript with these findings have been 
submitted on March 2013 to a peer-rev iewed journal , Thorax , fo r publication (Appendix 
I). 
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Table 3.4: Clinical variables and findings from rs35705950 MUCSB promoter SNP 
Clinical variables 
Age (year)* 
Gender 
Smoking status•• 
Smoking duration 
(years) 
Pulmonary function 
tests: mean % of 
predicted value••• 
FVC 
FEV1 
TLC 
DLCO 
Diagnosis by lung 
biopsy 
Allele frequency: 
Wild type allele (G) 
frequency 
Minor allele (T) 
frequency 
Genotype: 
GIG 
GIT 
TIT 
Odds Ratio (95% Cl) 
GfT vs. GIG 
TIT vs. GIG 
Chi-squared, P value 
for Hardy-Weinberg 
equilibrium 
genotyping case vs. control study. 
All cases (n=110) 
62.1 ± 12.3 
M = 67 (60.9%) 
F = 43 (39.1 %) 
smoker= 17 (15.5%) 
ex-smoker= 73 
(66.3%) 
occasional= 3 (2.7%) 
never= 17 15.5%) 
25.0 ± 16.5 
84.1% ± 18.8% 
83.0% ± 15.9% 
81.1% ± 16.6% 
59.4% ± 17.5% 
45 (40.9%) 
63.60% 
36.40% 
39 (35.4%) 
62 (56.4%) 
9(8.2%) 
5.4 (3.0 • 9.6), p < .001 
12.2 (3.3 - 44.7), p < 
.001 
X'= 5.22, P = .02 
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Cases: probands 
only (n=SO) 
63.1 ± 9.6 
M = 51 (63.8%) 
F = 29 (36.2%) 
smoker= 6 (7.5%) 
ex-smoker = 62 
(77.5%) 
occasional = 0 (0.0%) 
never= 12 (15.0%) 
25.0 ± 16.0 
83.2% ± 18.1% 
82.1% ± 15.8% 
81 .4%~ ± 15.8% 
56.6% ± 14.8% 
35 (43.8%) 
62.50% 
37.50% 
28 (35.0%) 
44 (55.0%) 
8 (10.0%) 
5.3 (3.1 - 9.2), p < .001 
15.2 (4 3 - 52.6), p < 
.001 
x' = 2.40, p = .12 
Controls 
(n=277) 
61.2 ± 9.4 
M- 158 
(58.5%) 
F = 112 
(41 .5%) 
smoker = 33 
(12.2%) 
ex-smoker= 
128 (47.4%) 
occasional = 
2 (0.01%) 
never= 107 
(39.6%) 
26.1 ± 15.6 
N/A 
N/A 
N/A 
N/A 
N/A 
87.40% 
12.60% 
211 (76.2%) 
62 (22.4%) 
4(1.4%) 
N/A 
N/A 
x' = .05, p = 
.82 
Control population age, gender. smoking status and duration is based on n:270 since questionnaires were not 
returned by 7 participants. Control population allele frequency, genotypes and odds ratio based on n:277 
"For cases. age of diagnosis is used. For controls. age of sample collection is used . 
.. For smoking status: Ex-smoker (all cases): smoking duration is 28.9 ± 13.8 years with 71 .2% having smoked 
over 20 years. Ex-smoker (probands only): smoking duration is 28.7 ± 13.1 years with 71.0% having smoked 
over 20 years. Ex-smoker(controls): smoking duration is 22.8 ± 14.8 years with 53.1% having smoked over 20 
years_ 5 total occasional smokers: only smoke socially with 1/5 having smoked over 20 years 
•••abnonnal if FVC, FEV1 , TLC or OLCO: <80% predicted 
FVC: forced vttal capacity, FEV1 : forced expiratory volume exhaled in the 1st second, TLC: total lung 
capacity, OLCO: diffusing capacity of the lung for carbon monoxide 
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RIJ36 
GIT 
Figure 3.15: Segregation analysis of MUCSB promoter SNP rs35705950 in two FPF 
families: Rl136 and R0942. 
Genotypes for all individuals with DNA in R0942 and R 11 36 are wrinen on the pedigree 
below the individual ' s symbol. Individual with no labels did not have DNA available for 
genotyping. The vari ant allele Tis highlighted in red . In Family Rl\ 36, the two partially 
shaded individuals represent individuals that are possibly affected but have not been 
confinned clinicall y. 
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4. Discussion 
4.1 Summary of the candidate gene analysis 
Previous research carried out by Ms. Laura Edwards was done to determine the 
genetic loci linked with PF by using a genome-wide scan with microsatellite markers 
(2006). Fine-mapping was also done using a SNP genome-wide scan to narrow down the 
ROI linked with FPF in s ix Newfoundland families (Kamel, 20 10). From the ROis found 
on chromosome 6p and 16p, eleven genes were sequenced by Kamel (20 10). Sequencing 
of candidate genes from these two RO!s was unsuccessful in finding a variant causing 
FPF in six Newfoundland families. 
The purpose of the candidate gene analysis in th is thesis was to ident ify a 
relatively highl y penetrant genetic variant that causes FPF in Family R0942. From the 
total of nine candidate genes that were analyzed in thi s thesis, 28 genetic variants were 
found as shown in Table 3.2 and Table 3.3. Using a combination of filtering criteria for 
each genetic variant found, a11 28 of these variants were excluded as FPF-causing in 
Famil y R0942. The variants were categorized based upon whether they segregated with 
the d isease in family R0942; the Caucasian population frequency for the variant ; previous 
literature reporting the variant and its effects; an bioinformatic analyses on the effects of 
the variant. All 28 variants found did not segregate with FPF in family R0942 and were 
prev iously reported in the dbSN P database. Of these, 26 SN Ps were reported to have 
minor allele frequencies greater than I% in a Caucasian population sample. All variants 
found to have a minor all ele frequency between 1-5% were re-examined. There was only 
one variant in thi s range (MSLN c. l230+ 16G>T, MAF 1000 Genomes: 1.8%). This 
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variant was excluded as being FPF-causing since it did not segregate with FPF in family 
R0942. Finally, the two SNPs that did not have a minor allele frequency reported in the 
literature were not shown to segregate with the disease in Family R0942 and thus also 
excluded. 
Out of all 28 genetic variants found, five were predicted to cause changes in 
amino acid. These five variants caused a missense change. These variants were filtered 
again using bioinformatics analysis, population frequency data and literature reviews. 
During this step, Panther, PolyPhen and SIFT analysis was conducted to see the 
pathogenicity of the variant. Furthermore, population frequency data was gathered from 
1000 Genomes and/or HapMap when available. Finally, a PubMed literature search was 
conducted to see if additional information on the variant has been published recently. 
After these additional filtration strategies, these variants were also excluded as FPF-
causing in this family. 
Overall, there were no variants found via candidate gene analysis that were 
deemed FPF-causing. This is not altogether unexpected since there are over 300 genes in 
the ROts on chromosome 16 and 6 that were not selected for sequencing in this study 
based on functional/expression data (UCSC Genome Browser, build GRCh37/hg l9; Kent 
et al., 2002). It is plausible that the pathogenic variant is contained in one of these 
unselected genes or in another gene in a region not highlighted by linkage analysis (see 
Limitations, section 4.3). 
79 
4.2 The role of the MUC5B promoter SNP in IPF 
The purpose of the MUC5B rs35705950 SNP genotyping analysis was to test the 
significance of a recently discovered MUC5B promoter variant and its association with 
risk of developing IPF. From the results of the MUC5B promoter SNP genotyping case 
vs. control study, it is evident that the minor allele, T, ofrs35705950 is associated with 
lPF. This association is seen when both ' probands only' and 'all cases' are compared to 
controls (Table 3.4). An additive genotypic effect for the variant T allele with risk of 
developing PF is also demonstrated by both case versus control analyses. Furthermore, 
the minor allele segregated with PF in two large affected families. Recent research 
provides evidence for significantly higher expression of MUC5B in patients with IPF 
compared to controls, MUC5B protein presentation in lung tissue of IPF patients, 
increased MUC5B expression for unaffected subjects carrying the minor allele compared 
to unaffected subjects carrying the wild·type (Seibold eta\., 2011). Smoking, which is 
well-known to be associated with numerous !LOs, appeared to have little effect on the 
association between all subjects and the minor allele ofrs35705950. Coupled with 
previous research, our findings demonstrate the risk of IPF development with the 
rs35705950 promoter polymorphism is considerable. 
Since the minor allele frequency of rs35705950 is 0.051 (I 000 Genomes project, 
dbSNP), it is not a rare variant in the normal population. It appears that an increased 
expression or MUC5B in the lung, due to the variant allele, increases the risk for IPF 
development. Furthermore, our results have demonstrated that the risk is an additive 
genotypic effect (i.e. if someone possesses two copies of the variant T allele, this 
individual has an increased risk of developing IPF compared to someone possessing one 
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copy of the variant T allele). Thus, in both fami lial and sporadic patients, the MUC5B 
promoter polymorphism confers risk to all individuals who carry at least one copy of the 
minor T allele. When combined with environmental factors such as smoking, 
occupational hazards, textile dust, and asbestos, it is likely that these individuals will 
develop IPF in comparison to someone without the rs35705950 minor T allele. 
Mucins are a protein family that has a primary ability to fonn gel surfaces. Mucins 
are highly glycosylated and are present mainly on the surface of epithelial cells (Devine 
and McKenzie, 1992). Mucins have a variety of documented functions in both normal 
cells and tumour cells (Table 4.1 ). The exact mechanism by which the MUC5B promoter 
polymorphism promotes the development of IPF is not fully understood but a few 
theories have been postulated. 
The main theory is based on IPF development as a result of numerous injuries to 
the lung and aberrant wound repair processes. From this, it is plausible that significantly 
increased amounts of MUCSB due to the variant allele can impair the defense 
mechanisms of the mucosal host (Seibold et al., 2011). Impaired defense of the mucosal 
host would cause excessive injury to the lung since clearance of various particles is 
reduced, ultimately leading to IPF. Two other prevalent theories involve 1) excess 
MUC5B in respiratory bronchioles interfering with alveolar repair and 2) disruption 
and/or introduction of transcription-factor binding sites in the A1UC5B promoter region 
due to the presence of the variant T allele leading to ectopic production of MUC58 
protein in a variety of cells in the lung, causing injury to the brochoalveolar unit (Seibold 
et al., 20 11). 
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Despite the association of the MUC5B promoter polymorphism with PF in the NL 
cohort, it is possible that the SNP is not associated with the disease. For instance, only 2 
out of 12 families with familial pulmonary fibrosis demonstrated segregation of the 
variant T allele with the disease. It is possible that there are alternative genetic causes for 
FPF in the I 0 families that did not show segregation of MUC5B with FPF. Since known 
genetic causes of FPF (variants in TERT TERC. ABCAJ, SFTPC. SFTPCA2) have 
already been tested in these families, there could be a novel genetic variation that is 
causing FPF in these fami lies. It is also possible that the MUC5B rs35705950 SNP is not 
the sole cause of PF in the familial form and instead serves as a modifier allele. As a 
modifier allele, the presence of the variant T allele will increase the risk of an individual 
developing PF but this outcome is not absolute and will differ depending on other genetic 
variants and environmental factors. 
Also, in the two families (R 1136 and R0942) that exhibited segregation of the 
MUC5B variant T allele with PF, there are 14 and 4 individuals respectively that carry the 
variant T allele and are unaffected at last follow up (Figure 3.15). Although this is 
consistent with PF being a late·onset diease with reduced penetrance, it is also possible 
that the MUC5B rs35705950 variant T allele does not have as large of an effect on the 
disease as originally demonstrated by Seibold et al (2011). 
Taking these alternative explanations into consideration and despite the signjficant 
association of the rs35705950 MUC5B promoter polymorphism with IPF and the 
increased risk associated with it, further research must be done to elucidate the exact 
mechanism of action exerted by this variant allele (see section 4.4). These findings can 
play a role in identifying individuals who may be at risk to develop PF. Preventative 
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education could be provided for mutation-positive individuals in hope to lower the 
chances of developing PF. With the results of this project, preventative measures such as 
education could be provided at an early age for individuals who carry the MUC58 
promoter SNP. Changes in lifestyle (i.e. smoking habits, occupational health and hazards) 
may lower the risk of the mutation-positive individual developing lPF. 
4.3 Limitations of this study 
There were a number of limitations in this study. One of the biggest limitations 
stems from the sequencing methodology used in this study. The seven individuals 
screened in Family R0942 were investigated only for exonic genetic variants. Functional 
exons only account for 2% of the mammalian genome (Makalowski, 2000). Therefore, 
since the majority of the genome is non-exonic, large expanses of sequence was not 
analyzed and disease-causing variations in these regions of the genome could have been 
missed. 
Besides point mutations and small insertions/deletions in non-exonic parts of the 
genome, there are a number of other genetic variations that cannot be identified by 
methods used in this study. For instance, large insertions and/or deletions cannot be 
identified via Sanger sequencing in a disease that has an autosomal dominant mode of 
inheritance. Comparative genomic hybridization (CGH) is a method that could be utilized 
to find any regions that may have been deleted or duplicated. Hence if the FPF phenotype 
is displayed due to a potential copy number variation in DNA, CGH would be an 
effective method to determine this. Futhennore, whole genome sequencing (WGS) would 
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be another effective method to find point mutations, insertions/deletions of all sizes and 
copy number variations since the data can be analyzed by read depth. 
Genetic variations in various promoter or repressor sequences are also not 
detected by methods used in this study. Most promoter or repressor sequences are located 
in the 5'UTR, 3' UTR and/or intronic regions. Since the sequence coverage in this study 
encompasses the exons and <25 base pairs of intron-exon boundaries, promoter or 
repressor sequences are not covered. There could be genetic variants in these regions that 
may have consequences on gene expression, transcription and/or regulation. To identify 
potential variants in these regions, sequencing of the promoter/repressor regions coupled 
with quantitative gene expression analyses must be carried out . Finally, large genetic 
changes such as translocations and inversions caiUlot be detected by methods used in this 
study. 
Another limitation in this study is the lack of functional testing for all genetic 
variants found. If a variant was found in a candidate gene, criteria for filtering the variant 
depended on bioinformatics tools such as PolyPhen and SIFT; information from 
databases such as Ensembl , dbSNP and UCSC Genome Browser; and previous functional 
testing/expression analyses documented in the literature. In-house functional tests that 
would aid in determining the consequence of a genetic variant in comparison to wild-
type, such as gene expression analyses and protein/enzymatic activity assays, were not 
performed in this study. Also, for synonymous variants, splice predictor tools were not 
utilized. 
The use of a candidate gene approach is another limitation in this study. To date 
there are over 15000 genes in the human body. Of these genes, hundreds of these have 
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functi ons/roles that are st ill unknown. Once a region(s) of interest is determined, a 
candidate gene approach is limited to selecting genes with known functionality. All genes 
with unknown functions or hypothetical genes were excluded as candidates. It is possible 
that one of these excluded genes that could harbour a potential FPF -causing vari ant. 
Sequence capture of the ROis would be an ideal solution but thi s was not performed due 
to limited resources. 
Though it is rare, possible phenocopies may be another limitat ion in thi s study. If 
someone in the R0942 family had PF due to a non-genetic cause, thi s individual may not 
have the FPF-causing variant. Since it is assumed that FPF in Family R0942 is due to a 
relati ve ly strong genetic predisposit ion, a phenocopy would lead to erroneous conclusions 
with regards to linkage analysis, fine-mapping and haplotyping. 
Additionally, envirorunental factors such as smoking cigarettes is a confounding 
factor that could account for higher rates of PF, and this was not controlled for in the 
study. Finally, using controls from a colorectal cancer project is a limi tation in the case-
control study presented here since there is no clinical data pertaining to lung disease 
avai lable for these contro ls. 
4.4 future work 
Since there are some limitations in the methods of this study that result in 
potential genetic variants to be missed, whole genome sequencing and CGH should be 
conducted on a few affected individuals. This would help in identifying all SNPs, 
insertions, deletions and copy number variations in the entire genome. If the genetic 
variations found by these methods are properly filtered, the FPF-causing variant could be 
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identified. Furthennore, these results could be tested in other Newfoundland famil ies and 
patients that have PF to detennine if the same genetic cause accounts for PF in multiple 
cases. Once the genetic cause is identified, clinical screening for the pathogenic variant 
can be conducted for at-risk family members. For those that carry the variant, genetic 
counselors could provide preventative education and support. Also, antifibrotic treatments 
can be provided by physicians and the mutation-positive individuals can be placed on a 
lung transplant list earlier to minimize waitlist time and while they are relatively healthy. 
Future studies should also carry out various functional tests to elucidate the exact 
mechanism of action of any pathogenic variants found, such as the MUC5B promoter 
polymorphism. For instance, functional studies such as gene knock-out and/or 
mutagenesis can be conducted to compare MUC58 expression in affected individuals 
who are mutation carriers of one of the other known lPF-genes in comparison to MUC58 
expression in affected individuals who have no known mutations in the known-IPF genes. 
Further studies involving a genetically modified MUC58 mouse model can be performed 
as well. These functional tests are of utmost importance since these tests can also 
illustrate the pathways and complex interactions involved in the pathogenesis of the 
disease. Also, there are many non-synonymous/ missense variants found in humans that 
do not result in the display of any abnonnal phenotype- functional studies would clarify 
the precise role of the variants. Overall, studies that focus on investigating the genetic 
causes of PF hold great potential for finding results that can be transferred to clinics. It is 
hopeful that these results could positively impact the diagnosis, prevention, treatments 
and prognosis of PF. 
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5. Conclusion 
In the candidate gene study, the genetic cause ofFPF in Family R0942 was not 
determined. The candidate gene approach utilizing previous work done (Edwards, 2006; 
Kamel, 2010) failed to detect a FPF-causing variant in a ponion of the RO!s determined 
by l inkage analysis. More candidate gene sequencing and/or next generation sequencing 
techniques should be carried out to discover this pathogenic variant. However, the variant 
allele of a A1UC5B promoter SNP that is associated with developing PF segregated with 
all affected individuals in Family R0942. This M UC5B variant may account for PF in this 
family by playing a role in the development of the disease. Currently, exome sequencing 
is also being perfom1ed on three individuals in Family R0942 (R0942.0002, R0942.0005, 
R0942.1 002; shown in Figure 3.2). The results from the exome sequencing project will 
help determine if there is an additional explanation for FPF in this family. 
In the case vs. control study, a significant association was observed between the 
rs35705950 MUC5B promoter SNP and development of lPF. Since this association was 
originally found in a few Caucasian populations in the USA, our study validates this 
association in the Newfoundland population as well. This significant association observed 
in multiple independent populations suggests that the rs35705950 MUC5B promoter SNP 
plays an important role in the pathogenesis of IPF. Further studies must be carried out to 
understand the precise mechanisms of this promoter SNP. 
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Appendix A: 2-point parametric linkage LOD scores on SOOk SNPs for R0942, 
dominant model 
g 2 
This is a Manhattan plot received by Mr. Fady Kamel. This data and the accompanying 
SNP genome-wide ana lysis for R0942 were re-visited by me in order to confirm and fine-
map the ROis. 
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Appendix 8: Candidate gene tab les for ROis on chromosome 6p and 16p 
Candidate 
Gene Posit ion Function ExE!:ression ? 
HULC chr6:8597 441-8599080 highly up-regulated in liver cancer (non-protein coding RNA): a novel high: liver very genewithstrikingup-regulationinhepatoceltu larcarcinoma unlikely 
chr6:10504902- transcript ion factorAP-2alpha(activatingenhancerbindingprotein2 high: retina, sequenced TFAP2A 10520593 alpha): defects in this gene are a cause of branchiooculofaciat placenta (Kamel) syndrome(BOFS) 
chr6:10629554-
gtucosaminyt {N-acetyl) transferase 2, !-branching enzyme (I blood 
GCNT2 group)--> encodes enzyme responsible for formation of blood group I ubiquitous unlikely 10737587 antigen, Mutations:have been associated with aduH i blood group 
henot 
chr6:10803174-
PAK1 interacting protein 1; Mutation analysis shows PIP1 interacts 
PAK11P1 specifically with the N-terminal regulatory domain of PAK1, which high: prostate un likely 
:;; 10817956 contains NCK-binding motif, a dimerization domain , an inhib~ory 
switch domain and a kinase inhibitor segment 
TMEM14C chr6:10831134- Transmembrane protein 14C; putative mitochondrial transporter 
'" 
unlikely 10839348 
TMEM148 chrB: 10855981- Transmembrane protein 146, unknown ,,, unlikely 10865200 
male germ celt-associated kinase: product of this gene is a Almost 
MAK chr6:10870942- serine/threonine protein kinase relatedtokinases involved in cell cycle exclusively in very 10939096 regulation testis, primarily unlikely in ermcells 
chr6:10981442- glial cells missing homolog 2 (Drosophila): thought to act as a binary 
high: skeletal 
GCM2 switch between neuronalandglialcelldetermination, Mutations in th is muscle, liver, very 10990084 geneareassociatedwithhypoparathyroklism heart .. . low: unlikely 
"' 
SYCP2L chrB: 10995050- synaptonemal complex protein 2-like: loci associated with age at unknown unlikely 11 082527 menarche and age at natural menopause (study in Nature Genetics) 
ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 2: when 
ELOVL2 chr6:11 088979- overexpressed in preadipocyte celt lines: increased TAG synth, high: feta l liver. very 11152610 enhanced bulidup of lipid droplets, induced expression of liver, heart unlikely 
diacyl£l1:tcerolacyltransferase-2etc 
hypotheticalproteinLOC221 710, functionunknown unknown unlikely 
chr6:11210708- most HERVs (endogenous RVs) are nonfunctional, the HERV·W and ERVFRDE1 11220057 
HERV·FRD envelope (env) proteins can induce cell-cell fusion when high: placenla unlikely 
e~ressed in cells ~ssessing a~~r~riate rece~tors 
high: in kidney, 
chr6:11291517- neural precursor cell expressed. developmentally down-regulated 9: 
lur'IQ and 
NEDD9 may be an important linking element between extracellular signaling placenta ... lung possible 11340901 highest and regulation of the cytoskeletoo, linked in melanomas ... 
expression, 
>>10xM 
specific 
chr6:11646497- Transmembrane protein 1708, the TMEM170B gene is conserved in functions and TMEM170B 11691743 chimpanzee. dog. mouse. rat, chicken. and zebrafish. expression unlikely pattern unknown 
!BioGPS) 
chr6:12120710- the proteins bind specific DNA sequences, including kappa-S motif in 
high: cardiac 
possible HIVEP1 the promoters/enhancer regions of several genes and viruses myocytes, liver, 12273218 heart ... lung: but unlikely (including HIV} ..... has some effects in pulmonary hypertension 
median 
j EDN1 chr6:12398515- This peptide is a potent vasoconstrictor and is produced by vascular High: lung sequenced 
"' 
12405413 endothelial cells. Has been implicated in wrt IPF ... 
chr6:12825819- phosphatase and actin regulator 1 . recombinant rat Phactrt high: placenta, PHACTR1 ofb ... lung: unlikely 13395507 inhibited PPt enzymatic activ~y in a concentration-dependent manner median 
chr6:13413163- a role in regulating cell growth and differentiation, Activation of an high: heart ... TBC107 13436766 oncogenic TBCt 07 (TBCt domain family, member 7) protein in low: kidney, possible pulmonary carcinogenesis liver, placenta 
chr6:13471798- high: whole very GFOD1 glucose-fructose oxidoreductase domain containing 1 brain ... . lung: 13595766 
- t.5xmedian unlikely 
SIRT5 belongs to the sirtuin family of NAO(+)-dependent deacetylases widely chr6:13682771- expressed in possible SIRT5 13713949 and mono-AOP-ribosyltransferases. Sirtuins control a variety of cellular fetal and adult but unlikely processes, such as aging, metabolism, and gene silencing tissues 
chr6:13723538-
high: 
NOL7 NOL7-transfected cells had decreased angiogenesis in a mouse model adrenal/thyroid unlikely 13729106 (mainrole=angiogenesis) gland. heart. 
muscle 
chr6:13729709-
the protein that binds RAN. a small GTP binding prtn (part of RAS 
RANBP9 superfamily) key for translocation of RNNpr's through the nuclear pore high: testes very 13819775 complex .... also interacts with other prtns(met proto-oncogene. unlikely 
homeodomain interacting protein kinase 2, androgen R.. 
CCDC90A chr6: 13898999- coiled-coil domain containir'IQ 90A, m~ochondrial precursor? high: unlikely 
13922768 lymphoblasts, 
pineal, CD34 
cells 
RNF182 chr$14032656- ring finger protein 182: involved in protein ubiquitinylalion; protein, zinc ubiquitously unlikely 14088219 ion, metalionbinding, ligaseactiv~y expressed 
high: immune 
chr6:14225844- involved in cell-cell adhesion and signal transduction, immune system, lymph CD83 14245127 response, regulation of interleukin-4,10, and 2 __ ."A role for dendritic nodes. spleen. sequenced cells in bleomycin-induced pulmonary f1brosis in mice?" and tonsils 
lung: median 
high: dorsatroot 
chrl>: 15354506- jumonji , AT rich interactive domain 2: overexpression of JMJ appeared ganglia neurons, JARID2 15630232 to inhibit cell growth, whereas Jmj-deficient mice had cell growth cerebral unlikely enhancement cortex . lung: 
median 
chr$:15631785- dystrobrevinbinding protein 1:proteinsareassociatedw~h ubiquitously DTNBP1 15771268 Hermansky-Pudlak syndrome and schilophrena. have widespread expressed. high sequenced functions in body- in whole brain 
i5: 
LOC40124 chrt3:28935381· hypothetical LOC401242, non-coding RNA · 
"'' 
very 
2 28939433 unlikely 
chrt3:28978758-
The TRIM motif includes three zinc-binding domains, a RING, a B-box 
TRIM27 type 112, and a coiled-coil region .. localizes to nuclear matrix. It higher in CD unlikely 28999747 interacts with the enhancer of polycomb protein and represses gene cells (BioGPS) 
transcription.ltisalsothoughttobeinvolvedi 
ZNF311 chr$:29070573- zinc finger protein 311 (ZNF311 ), mRNA. 
"'' 
unlikely 29081016 
LOC10012 chrt3:2911 1979- hypothetical protein LOC100129636 (LOC100129636). mRNA 
"'' 
unlikely 9636 29152496 
chrt3:2911 9969- olfactory receptor, family 2, subfamilyW, member 1: The olfactory high: ganglion very OR2W1 29120931 receptor proteins are members of a large family of G-protein-eoupled cells unlikely receptors (GPCR) arising from single coding-exon genes 
OR2B3 chr$:29161964-29163069 
OR2J3 chrt3:2918764 7-
Olfactory receptors interact with odorant molecules in the nose, to 
29188582 initiate a neuronal response that triggers the perception of a smell. The 
"'' 
unlikely olfactory receptor proteins are members of a large family of G-protein-
OR2J2 chr$:29249290- coupled receptors (GPCR) 29250330 
OR14J1 chr$:29382446-
293834 11 
OR5V1 chr6:29430986-29432033 
OR12D3 chr6:29449179-29451047 
OR12D2 chr6:29472395-29473427 
OR11A1 chr6 :29501260-29503488 
OR10C1 chr6:29515772-29516710 
OR2H1 chr6:29534209-29540078 
MA$1L chr6:29562522-29563658 
"' LOC10050 
"' 
chr6:29605162-
7362 29609324 
UBD chr6:29631368-29635681 
SNORD32 chr6:29658008-
8 29658084 
OR2H2 chr6:29663662-29664724 
GABBR1 chr6:29677984-29708941 
MOG chr6:29732737-29748128 
ZFP57 chr6:29748148-29752910 
HLA-F chr6:29799096-29802282 
MAS1 oncogene-like: The authors concluded that MRGs may regulate 
nociceptorfunctionandlordevelopment, includingthesensationor 
modulation of pain 
hypothetical LOC100507362 (LOC100507362), transcript variant 1, 
non-coding RNA 
ubiquitinO:encodingaproteinsimilartodiubiquitin. The1 .1-kb 
transcript was detected only in B-celllines transformed by Epstein-Barr 
virus 
small nucleolar RNA, C/0 box 328 
olfactory receptor, family 2, subfamily H, member 2 
GABA(B) receptor 1 gene is mapped to chromosome 6p21.3 within the 
HLA class I region close to the HLA-F gene. Susceptibimy loci for 
multiple sclerosis, epilepsy, andschizophreniahavealsobeen 
mapped in this region. 
myelin oligodendrocyte glycoprotein: a membrane protein expressed 
on the oligodendrocyte cell surface and the outermost surface of 
myelin sheaths. Due to this localization, it is a primary target antigen 
involved in immune-mediated demyelination. 
zinc finger protein 57 homolog (mouse): Studies in mouse suggest that 
thisproteinmayfunctionasatranscriptionalrepressor. Mutationsin 
thisgenehavebeenassociatedwithtransientneonataldiabetes 
mellitus type 1 
major h~tocompatibi lity complex, class I, F: Unlike most other HLA 
heavychains,thismoleculeislocalizedintheendoplasmicreticulum 
and Golgi apparatus, with a small amount present at the cell surface in 
some cell types. It contains a divergent peptide-binding groove, and is 
high: specific 
unlikely sensory neurons 
"'' 
unlikely 
high: B 
lymphoblasts unlikely 
"'' 
unlikely 
high: ganglion 
unlikely cells 
~~h~ht~~~~~: unlikely 
high· 
hypothalamus, 
unlikely sprnalcord, 
brain 
"'' 
unlikely 
highest: whole 
blood, high: lung unlikely 
thought to bind a restricted subset of peptides for immune 
presentation. Thisgeneexhibits fewvariants 
LOC28583 chr6:29802357- hypothetical LOC285830, non-coding RNA high: ovary, unlikely 0 29624605 lymph node 
IFITM4P chr6:29826563- interferon induced transmembrane protein 4 pseudogene, non-coding oJ• unlikely 29626904 RNA 
HCG4 chr6:29666767- HLA complex group 4 (HCG4), non-coding RNA ubiquitous unlikely 29666629 
chr6:29902735-
high: lung. 
HLA-G major histocompatibility complex, class I, G: belongs to the HLA class I blood, fetal unlikely 29906676 heavy chain paralogues derived 
lacentalcells 
HCP5P10 chr6:29947651- HLA complex P5 pseudogene 10 (HCP5P1 0). non-coding RNA oJ• unlikely 29949539 
chr6:29963362- major histocompatibility complex. class I, H, non-coding RNA HLA-H 29966635 represents a transcribed pseudogene, possibly derived from HLA-A oJ• unlikely Thisgenedisplaysextensivevariation. 
:s HCG2P7 chr6:29974787- HLA complex group 2 pseudogene 7 (HCG2P7). non-coding RNA high: skin, unlikely 29976410 ganglion cells 
HCG4P6 chr6:30000348- HLA complex group 4 pseudogene 6 (HCG4P6), non-coding RNA ubiquitous unlikely 30001407 
major histocompatibility complex, class I, A : Class I molecules: central 
chr6:30016266- role in immune system by presenting peptides derived from the ER HLA-A 30021640 
lumen. Polymorphisms within exon 213 are responsible for peptide ubiquitous unlikely 
binding specific~y of each class 1 molecule. Typing for these 
potymorphisms is done for bone marrow/ kidney transplantation 
HCG9 chr6:30050671- HLA complex group 9 (non-protein coding): ils function has not been high: liver, heart unlikely 300541 56 determined 
ZNRD1- chr6:30076767- ZNRD1 antisense RNA 1 (non-protein coding), non-coding RNA high: pineal unlikely A51 30136940 
HLA..J chr6:30081727- major histocompatibility complex, class I. J: transcribed pseudogene. highest: whole unlikely 30065712 possibly derived from HLA-A blood, high: lung 
ZNRD1 chr6:30137015- zinc ribbon domain containing 1: encodes a protein with similarity to oJ• unlikely 30140665 the Saccharomyces cerevisiae Rpa12p subunit of RNA polymerase I 
chr6:301 42911- protein phosphatase 1, regulatory subunit 11: specific inhibitor of high: blood, PPP1R11 30146067 
protein phosphatase-1 (PP1) with a differential sensitiv~y toward the brain, lung, unlikely 
metal-independent and metal-dependent forms of PP1 placenta 
RNF39 chr6:30146022- ringfingerprotein39: Studiesof a similarratproteinsuggestthatthis high: superior unlikely 
30151607 gene encodes a protein that plays a rote in an early phase of synaptic cervical 
plasticity ganglion, 
trachea 
tripartite motif containing 31 : member of the tripartite motif (TRIM) 
chr6:30178653- family_ The TRIM motif includes three zinc-binding domains, a RING, a high: skeletal TRIM31 30188846 B-box type 1 and a B-box type 2. and a coiled-coil region_ The protein muscle, heart unlikely localizes to both the cytoplasm and the nucleus. Its function has not 
been identified. 
TRIM40 chr6:30212489- tripartitemotifcontaining40 
"" 
unlikely 30224491 
chr6:30227703- tripartite motif containing 10: localizes to cytoplasmic bodies. Studies high: early TRIM10 in mice suggest that this protein plays a role in terminal differentiation unlikely 30236690 ofe hroidcells erythroid cells 
TRIM15 chr6:30238962- tripartite motif containing 15: localizes to the cytoplasm 
"'' 
unlikely 30248452 
chr6:30260211- tripartite motif containing 26: localizes to cytoplasmic bodies. Function high: B TRIM 26 unknown, but RING domain suggests that the protein may have DNA- unlikely 30289132 bindi activit . lymphoblasts 
HLA-L chr6 30335318- major histocompatibility complex, class I, L, pseudogene; non-coding 
"'' 
unlikely ~ 30342707 RNA 
HCG18 chr6:30363153- HLA complex group 18; non-coding RNA oJ• unlikely 30402906 
TRIM39 chr6:30402987- tripartite motif containing 39. function of this protein has not been oJ• unlikely 30419485 identified. 
chr6:30420885- ribonuclease PIMRP 21kDa subunit: a protein subunit of nuclear High: heart. b RPP21 30422614 ribonuclease P, which processes the 5-prime leader sequence of lymphoblasts. T unlikely recursortRNAs 
"''" 
HLA-E chr6:30565162- major histocompatibility complex, class I, E: belongs to the HLA class I high: whole unlikely 30569961 heavy chain paralogues. blood, lung 
GNL1 chr6:30617134- guanine nucleotide binding protein-like 1: shows a high degree of high: pineal unlikely 30633350 similarilywithitsmousecounterpart 
PRR3 chr6:30632465- proline rich 3: function not well known in humans high: B unlikely 30640452 lymphoblasts 
chr6:30647149- Al P-binding cassette. sub-family F (GCN20). member 1: protein found high: B ABCF1 30667288 in tumor necrosis factor-alpha-stimulated synoviocytes (cells of lymphoblasts possible alveolar-capillary membrane) 
Gene Position Function Expression Candidate ? 
LOC10028 
8778 chr16:4043-7324 WAS protein family homolog 1 pseudogene (LOC100288778), non- of• unlikely coding RNA 
POLR3K chr16:36979-43632 high: 
polymerase (RNA) Ill (DNA directed) polypeptide K: the polymerase lymphoblasts, 
responsible for synthesizing transfer and small ribosomal RNAs in CO cells ... unlikely 
eukaryotes Lung: median 
ex ression 
~RNP25 chr16:43829-47669 small nuclear ribonucleoprotein 25kDa (U111Ut2)-> study: Anti-
U11/U12 RNP antibodies are present in the sera of approximately 3% high: heart, liver, 
sequenced of patients with SSe and are a mar1{er for lung fibrosis. which is often brain 
severe. 
RHBDF1 chr16:48058--62629 high: OFB.Iung. poss but integral to membrane, serine-type endopeptidase activity, prostate. 
lacenta unlikely 
"' 
MPG chr1 6:67018-75843 N-methylpurine-DNA gtycosylase: emoves a diverse group of 
"' damaged bases from DNA, including cytotoxic and mutagenic 
high: thyroid, 
unlikely 
alkylation adducts of purines prostate. lung 
NPRL3 chr16:75804-128672 nitrogen permease regulator-like 3: Galactose-binding domain, cellular high: C0711 
unlikely component early erythroid 
HBZ chr16: 142854-144504 he zeta-globin polypeptide is synthesized in the yolk sac of the early 
HBM chr16: 155973-156767 embryo, while alpha-globin is produced throughout fetal and adu~ life. Hblevels 
HBA2 chr16: 162846-163709 The zeta-globin gene is a member of the human alpha-globin gene decline possible cluster that incllldes f1ve functional genes and two pseudogenes. The sometimes in 
HBA1 chr16: 166679-167520 order of genes is: 5' - zeta - pseudozeta - mu - pseudoalpha-1 - alpha- IPF 
HBQ1 chr16:170333-171178 2 -alpha-1 - thetat -3' 
LUC7L chr16:178971-219450 LUC7-Iike (S. cerevisiae); may represent a mammalian 
heterochromatic gene, encoding a putative RNA-binding protein similar ruo unlikely to the yeast Luc7p subunit of the Ut snRNP splicing complex that is 
norma11:1 r~uired for 5-~rime s~lice site selection 
ITFG3 chr16:224802-256120 integrin alpha FG-GAP repeat containing 3 (ITFG3). mRNA; integral to high:thyroid, 
membrane. FG-GAP repeats are found in N terminus of integrin alpha prostate. 
unlikely chains, a regionthatisimportantfor ligandbinding. AputativeCa2-+ retina ... lung· 
binding motif is found in some of the re~ats -3xM 
RGS11 chr16:258311-265915 act as GTPase-activating proteins {GAPs) on the alpha subunits of 
signal-transducing G proteins. RGS proteins can serve as negative higher in pineal 
unlikely regulators of G protein-mediated signaling pathways by speeding the gland 
inactivation of GTP-bound G-al~ha subunits. 
ARHGDIG chr16:270607 -273004 Rho GOP dissociation inhibitor {GOt) gamma (ARHGOIG): The GOP- high: brain very 
dissociation inhibitors (GOts) play a primary role in modulating the region unlikely 
activation of GTPases by inhibiting the exchange of GOP for GTP 
PDIA2 chr16:273119-277210 protein disulfide isomerase family A, member 2: are endoplasmic 
reticulum(ER)residentproteinsthatcatalyzeproteinfoldingandthiol- higher in unlikely 
disulfide interchange reactions pancreas 
AXIN1 chr16:277441-342677 encodes a cytoplasmic protein which contains a regulation of G-protein 
signaling (RGS) domain and a dishevelled and axin (DIX) domain. possible Mutations in this gene have been associated with hepatocellular of• 
carcinoma, hepatoblastomas, ovarian endometriod adenocarcinomas, but unlikely 
and medullablastomas ... reduced exp in human lung carcinomas 
MRPL28 chr16:357385-360570 mitochondrial ribosomal protein L28: Mammalian mitochondrial 
ribosomal proteins are encoded by nuclear genes and help in parotein ubiquitous unlikely 
synthesis within the mitochondria 
TMEMBA chr16:360777-371951 transmembrane protein 8A high: placenta .. . unlikely lung: 4xM 
NME4 chr16:387193-390755 non-metastatic cells 4, protein expressed in (NME4), nuc gene high: prostate, 
encoding mitochon. protein: ubiquitous enzymes that catalyze transfer heart, liver, 
small intesline, unlikely of gamma-phosphates. via a phosphohistidine intennediate. between 
and skeletal g nucleoside and dioxynucleoside tri- and diphosphates muscle tissues 
DECR2 chr16:391859-402488 2,4-dienoyl CoA reductase 2, peroxisomal (DECR2) high: liver unlikely 
RAB11FIP RAB11 family interacting protein 3 (class II): ave regulatory roles in the 
3 chr16:415669-512482 ~~~~~~P~r~~~:g~t:~~s~:t~:~~t;~~~~~~r~~:~t~:n~er~~~:ie Rab high: kidney unlikely 
GTPases 
SOLH chr16:517857 -544637 small optic lobes homolog (Drosophila): protein containing zinc-finger-
like repeats and a calpain-like protease domain. The encoded protein 
"'' 
very 
may function as a transcription factor. RNA-binding protein. or in unlikely 
(J:rotein::fl'rolein interactions duri!:!!:J visual s~stem develo~ent 
MIR3176 chr16:533278-533367 microRNA 3176: microRNAs (miRNAs) are short (20-24 nt) non-coding 
RNAs that are involved in post-transcriptional regulation of gene 
ru• unlikely expression in muHicellular organisms by affecting both the stability and 
translation of mRNAs 
NHLRC4 chr16:557033-559496 NHL repeat containing 4: oJ• unlikely 
PIGQ chr16:560005-57 4109 phosphatidylinositolglycananchorbiosynthesis, classQ: Thisgene is high: C071/ involved in the first step in glycosy1phosphatidylinositol (GPI)-anchor 
early erythroid unllikely bios nthesis 
RAB40C chr16:579670-619274 
member RAS oncogene family (RAB40C)· higher: brain unlikely neurons 
WFIKKN1 chr16:621013-624117 WAP. follistatirul<.azal, immunoglobulin, kunitz and netrin domain high: pancreas, poss but 
containing 1: These domains have been implicated frequently in kidney, liver, unlikely 
inhibition of various types of proteases ... found in squamous cell lung placenta. and 
carcmoma 
'"" 
C16orf13 chr16:624430-626348 
chromosome 16 open reading frame 13 (C16orf13), transcript variant 
of• n/a 7 mRNA 
WDR90 chr16:639364-<l57630 WO repeat domain 90 of• unlike!~ 
RHOT2 chr16:658134-664172 ras homolog gene family , member T2 (RHOT2), nuclear gene high: retina. encoding m~ochondrial protein ... role in mitchon. Distribution and pineal , CD cells unlikely trans rt 
RHBDL1 chr16:666076-<l66266 rhomboid , veinlet-like 1 (Drosophila) ... implicated in the modulation of high: brain , 
unlikely epidermal growth factor receptor. kidney, heart 
STUB1 chr16:670116-672769 high: striated 
ubiquitin ligaseJcochaperone that participates in protein quality control muscle( heart, 
by targeting abroad rangeofchaperoneproteinsubstratesfor skeletal unlikely 
degradation muscle) .... L ittle 
inlun 
JMJD6 chr16:671668-67 4440 jumonji domain containing 8: Transcription factor jumonjilaspartyl beta- high: smooth 
and cardiac unlikely hydroxylase 
muscle 
WDR24 chr16:67 4703-680401 WD repeat domain 24: G-protein beta W0-40 repeat high: thyroid unlike !~ 
s FBXL16 chr16:682501-695826 
F-box and leucine-rich repeat protein 16: they interact with high: amygdala very ubiqu~ination targets through other protein interaction domains unlikely 
METRN chr16:70517 4-707 481 Meteorin regulates glial cell differentiation and promotes the formation high: whole very 
of axonal networKs during neurogenesis brain unlikely 
family with sequence similarity 173, member A: hypothetical protein high: thyroid, lung , liver, heart. n/a 
FAM173A chr16:711159-712591 LOC65990 brain 
CCDC76 chr16:712583-7164 7 4 coiled-coil domaincontaining78 high: colon, Sl unlike!~ 
HAGHL chr16:716959-719716 
hydroxyacylglutathionehydrolase-like: hydrolaseactiv~y. metal ion 
of• unlikely binding 
NARFL chr16:719770-730998 nuclear prelamin A recognition factor-like : shares similarity with several 
bacterial iron-only hydrogenases, including conservation of a high: liver, heart, 
unlikely distinctive active site iron sulfur cluster, termed the H cluster ... skeletal muscle 
Involved in rese£nse to h>:e£xia, o2 homeostasis etc 
i MSLN chr16:750766-758866 precursorproteinthatiscleavedinto2 products, megakaryocyte 
- potentiatinglactorandmesothelin. Megakaryocyte potentiation factor 
functions as a cytokine that can stimulate colony formation in bone 
marrow megakaryocytes. Mesothelian: an anchored cell-surface 
protein, may function as a cell adhesion protein. Overexpressed in 
high: lung sequenced 
epithelial mesotheliomas, ovarian cancers, some squamous cell 
carcinomas 
MSLNL chr16:759429-772927 mesothelin-like: little known. but may be involved in cell adhesion, 
"' 
unlikely 
vacoularfusionproteinMON1 
MIR662 chr16:760184-760278 microRNA 662 
"' 
nla 
RPUSD1 chr1 6:77 4975-778384 RNA pseudouridylate synthase domain containing 1: involved in high: Burkitts 
pseudouridinesynthesis lymphoma, B unlikely I m hoblasts 
CHTF18 chr16:778623-7BB075 chromosome transmission fidelity factor 18 homolog {S. cerevisiae) 
are components of an alternative replication factor C (RFC) complex high· unlikely 
that loads PCNA onto DNA during S phase of the cell cycle lymphoblasts 
GNG13 chr16:788042-790734 guaninenucleotidebindingprotein:functionassignaltransducersfor 
the 7-transmembrane-helix G protein-coupled receptors. GNG13 is a high: thalamus. 
un likely gammasubunitthatisexpressedintaste, retinal,andneuronaltissues cerebellum 
andf!la):sake;,:roleintastetransduction 
PRR25 chr16:795444-803862 proline rich 25: "A small proline-rich protein, spr1 : specific marker for 
"" 
unlikely squamous lung carcinoma" 
LMF1 chr16 843635-960985 involved in the maturation and transport of lipoprotein lipase through high: adipose 
the secretory pathway. Mutations in this gene are associated with tissue, skeletal unlikely muscle, heart, 
combined lipase defiCiency 
and liver. 
0 sox8 chr16:971809-9769BO involved in the regulation of embryonic development and in 
N determination of the cell fate. The protein may act as a transcriptional high: brain 
activator after forming a complex with other proteins. may be involved 
inbraindevelopmentandfunction. Haploinsufficiencyforthis protein regions, most unlikely 
may contribute to the mental retardation found in haemoglobin H- tissues 
related mental retardation (ART-16 syndrome) 
SSTRS somatostatin RS: this receptor is mediated by G proteins which inhibit high: brain, 
adenylylcyclase, anddifferentregionsofthis receptor molecule are 
endocrine and unlikely required for the activation of different signaling pathways. A mutation in 
this gene results in somatostatin anal~ resistance nervous system 
C1QTNF8 chr16: 1078227-1086245 Ctq and tumor necrosis factor related protein 8 ru• nla 
CACNA1H chr16:1143242-1211773 calcium channel, voltage-dependent, T type, alpha 1H subunit: 
encodes aT-type member of the alpha-1 subunit family, a protein in high: adrenal very the vottagtH!ependent calcium channel complex. Calcium channels 
mediate the influx of calcium ions into the cell upon membrane cortex, brian unlikely 
polarization 
TPSG1 chr16:12 11653-1215255 Tryptases comprise a family of trypsin-like serine proteases, the 
TPSB2 chr16:12 18337-1220186 peptidase family St . Tryptases are enzymatically active only as high: most 
TPSAB1 chr16: 1230679-1232556 
heparin-stabilizedtetramers, and they are resistant to all known human tissues, possible endogenous proteinase inhibitors.Tryptases have been implicated as not in skeletal 
TPSD1 chr16: 124627 4-1248495 
mediators in the pathogenesis of asthma and other anergic and muscllspteen 
inflammat9!Y_ disorders 
UBE21 chr16:1299181-1315391 ubiquitin-conjugating enzyme E21 (UBC9 homolog, yeast): modification 
of proteins with ubiqu~in is an important cellular mechanism for high: most unlikely 
targeting abnormal or short-lived proteins for degradation tissues 
BAIAP3 chr16: 1323607-1339443 BAll-associated protein 3 (BAIAP3): This p53-target gene encodes a 
brain-specificangiogenesisinhibitor. ltsexpressionpatternand high: pituitary. very 
similaritytootherproteinssuggestthatitmaybeinvotvedinsynaptic hypothalamus unl ikely 
functions 
GNPTG chr16: 1341901-1353353 Nacetylglucosamine-1 -phosphaletransferase:catalyzesthefirststep high: thyroid. insynthesisofamannose6-phosphatelysosomalrecognition 
amygdala, unl ikely marker.Mutations in the gene encoding the gamma subunit have been 
associated with mucoli idosis IIIC pineal, lung 
UNKL chr16: 1353207-1404 706 unkempt homolog (Orosophila)-l ike (UNKL): RING finger protein inmost tissues unl ikely unkempt-likeisoform 1 
CCDC154 chr16: 1424390-1434491 coiled-coil domain containing 154: involved with Tropomyosin 
"'' 
unl ikel}:' 
CLCN7 chr16: 1434936-1465086 chloride channel?: Defects inthis genearethecauseofosteopetrosis 
autosomal recessive type 4 .. 0steopetrosis is a rare genetfc disease high: adrenal 
characterized by abnormally dense bone, due to defective resorption cortex/gland, unlikely 
of immature bone. OPTA2 is the most common form of osteopetrosis, retina, PFC 
occurring in adolescence or adulthood 
PTX4 chr16: 1475941 -1478469 pentraxin 4, long : Some PTXs are part of the humoral arm of innate high: in small intestine, testis. immunity and behave as functional ancestors of antibodies by 
and bone possible mediating agglutination, complement activation, and opsonization ... 
marrow . low 
0 affect macrophage activation brain w 
TEL02 chr16 1483353-1500461 telomere maintenance 2: encodes a protein that functions as an S-
phase checkpoint protein in the cell cycle. Theproteinmayalsoplaya 
"'' 
sequenced 
role in DNA repair 
IFT140 chr1 6: 1500429-16021 10 intraflagellar transport 140 homolog (Chlamydomonas); WD40 repeat, high: thyroid unlikely Quinoprotein amine dehydrogenase, beta chain-like 
TMEM204 chr16: 1524232-1545244 transmembrane protein 204: C160RF30 plays a role in cell adhesion highest: lung possible and cellular permeabi lity at adherens junctions 
CRAMP1L chr16: 1604642-1667910 Crm, cramped-like (Drosophila): DNA-binding, 
"'' 
unlikel}:' 
HN1L chr16: 1668279-169207 4 liver. kidney 
hematological and neurological expressed 1-like: which are proposed prostate, testis 
unlikely to be involved in embryo development and uterus at 
vain levels 
MAPK81P3 chr16:1696222-1760319 sharessimilaritywiththeproducto!Drosphsydgene, requiredfor 
interactn of kinesin I with axonal cargo. Studies of the similar gene in 
mousesuggestedthatthisproteinmayregulateproteinkinasesofthe high: brain, 
unlikely JNK sJgnaling pathway, thusfunctionasascaffold protein in neuronal endothelial cells 
cells. Celeganscounterpartofthisgeneregulatessynapticvesicle 
transort 
microRNA 
"'' "'' 3177 chr16:1724987-1725068 
NME3 chr16:1760322-1761711 non-metastatic cells 3, protein expressed in (NME3}: role for the NME3 high : prostate, unlikely 
gene in normal hematopoiesis and raised the possibility that ~s pineal gland, 
overexpressioncontributestodiffefentiationarrest, a feature of blastic heart ... lung: 
transformation in chronic m:zo:e~enous leukemia 4<M 
MRPS34 chr16: 1761697-1763141 m~ochondrial ribosomal protein 534 (MRPS34), nuclear gene high: burl<itts lymphoma, B unlikely encoding mitochondrial protein I m hoblasts 
EME2 chr16: 1763230-1766240 ME2 forms a heterodimer with MUS81 that functions as an XPF-type 
'"' 
unlikely flap/fork endonuclease in DNA repair (OMIM) 
SPSB3 chr16: 1766714-1772582 
spiAiryanodine receptor domain and SOCS box containing 3 high: CD4/CD8 possible Tcells but unlikely 
NUBP2 chr16:1772934-1779193 highest: heart, 
subthalamic 
NUBP2 is a member of the NUBPIMRP gene subfamily of ATP-binding nucleus, 
unlikely proteins: endothelial 
cells .. also high 
inlu 
IGFALS chr16:1780415-1783735 insulin-like growth factor binding protein, acid labile subunit (IGFALS): 
serumproteinthatbinds insulin-likegrowthfactors, increasing their 
half-life and vascular localization. Productionofthisproteinis high: liver very 
~ stimulated by growth hormone. Defects in this gene are a cause of unlikely acid-labile subunit deftcienc:y, which maifests itself in a delayed and 
slow ubert . 
HAGH chr16: 1799105-1817196 hydroxyacylglutathione hydrolase: athiolesteraseand is responsible high: liver, earty very for the hydrolysis of S-lactoyl..glutathione to reduced glutathione and 
0-lactate. erthyroid unlikely 
FAHD1 chr16:1817226-1830204 fumarylacetoacetate hydrolase domain containing 1 (FAHD1), nuclear 
'"' 
unlikely gene encoding mitochondrial protein· 
C16orf73 chr16: 1823985-1862180 hypothetical protein LOC254528 isoform 1 
'"' 
n/a 
NCRNA002 
non-protein coding RNA 254 
"'' 
n/a 54 chr16: 1666267-167 4233 
HS3ST6 chr16: 1901466-1908232 heparan sulfate (glucosamine) 3-0-sulfotransferase 6: binds to HSV-1 high: mucosal {herpes simplex virus type 1 ), the resulting pr serves as a entry R for unlikely 
HSV-1 membranes 
SEPX1 chr16: 1928235-1933295 selenoprotein X, 1: This protein belongs to the methionine sulfoxide high: liver, 
reductase B (MsrB) family, and it is expressed in a variety of adult and leukocytes. unlikely 
fetal tissues, contains a selenocysteine (Sec) residue at its active site tow: lung, brain 
RPL3L chr16:1934561-1944660 ribosomal protein l3-like: The protein belongs to the LJP family of 
ribosomal proteins.A novel ribosomal protein l3-like gene (RPLJL) high: skeletal unlikely maps to the autosomal dominant polycystic kidney disease gene muscle, heart 
ion 
NDUFB10 chr16: 1949516-1951977 NAOH dehydrogenase (ubiquinone) 1 beta subcomplex. 10: part of the high: heart unlikely first enzyme complex in the electron transport chain of mitochondria. 
RPS2 chr16:1952063-1954628 ribosomal protein 52: This gene encodes a ribosomal protein that is a high: CD cells unlikely 
component of the 405 subunit. The protein belongs to the S5P family 
of ribosomal proteins. It is located in the cytoplasm .... Role in 
controllinglet-7aexeressioninhumanerostatecance 
SNORA10 chr16: 1952336-1952468 small nucleolar RNA. HIACA box 10 
"" 
n/a SNORA64 chr16: 1952975-1953108 small nucleolar RNA, HIACA box 64 
SNHG9 chr16: 1954998-1955506 small nucleolar RNA host gene 9 (non-protein coding) 
"'' 
unlikelr: 
SNORA78 chr16: 1955186-1955312 small nucleolar RNA, HIACA box 78 
"'' 
n/a 
RNF151 chr1 6: 1956876-1958977 ring finger protein 151 : RNF151 , a testis-specific RING finger protein, high: testis very interacts with dysbindin ... may play a role in acrosome formation unlikely 
TBLJ chr16: 1962065-1968752 transducin (beta)-like 3: sequence similarity with members of the 
~E:iS~t==~~ri~~=~:~~~~i ~2~~~[~~:~~~f~~~6ly ~:;:;:agftr:~:· possible 
~~~~~~~~~~~~!,~~~~s:}!:n!~~~~~~~~o~~u~::;;~~~~~: ~mphoblasrs ' but unlikely 
This gene has multiete l!!!i):aden~lation sites. 
NOX01 chr16:1969042-19711 85 possible 
NADPH oxidase organizer 1: catalyl:e the transfer of electrons from High: colon. 
(NOX01 
:7. NAOPH to molecular oxygen to generate reactive oxygen species liver. kidneys and rung , (ROS) and 
fibrosis 
GFER chr16:1974151 -1977751 growth factor, augmenter of liver regeneration: hepatotrophic factor 
designated augmenter of liver regeoeration (ALR) is thought to be one high: kidneys, 
unlikely factor responsible for the extraordinary regenerative capacity of brain 
mammalian liver. .. Mutation "' autos recessive m:t:oeath~ 
SYNGRJ chr16: 1979947-1984277 synaptogyrin 3: encodes an integral membrane protein. The exact 
lunctionofthisproteinisunclear, butstudiesofasimilarmurine brain and unlikely proteinsuggestthatitisasynapticvesicleproteinthatalsointeracts placenta only 
with the do amine trans rter 
ZNF598 chr16: 1987769-1999764 zinc finger protein 598: 
"'' 
unlikerx: 
NPW chr16:2009522-201 0757 high: brain. 
neuropeptide W: 23- and 30-amino acid neuropeptides that lymphoblastic leukemia, fetal billdlactivate two G-protein coupled Rs in the CNS. The neuropeptides kidney, unlikely 
enhance cortisol secretion from adrenal cells via adenylate 
colo rectal 
cyclase/PKAsignalingcascade. 
adenocarcinoma 
, trachea 
SLC9A3R2 chr16:2016889-2029028 solute carrier family 9 (sodium/hydrogen exchanger), member 3 high: adrenal 
regulator 2: is a sodium/hydrogen exchanger in brush border 
cortex, liver, unlikely membrane of the proximal tubule, Sl and colon- plays a major role in 
transeeithelial sodium absor:Qtion skeletal muscle, 
NTHL1 chr16:2029817-2037868 nth endonuclease Ill-like 1 (E. coli): the encoded protein has DNA ~ah~-~-i~~~g : over possible glycosylase activity on DNA substrates containing oxidized pyrimidine 
residues and has apurinic/apyrimidinic lyase activity .. . linked to COPD, 3><M 
lu cancer 
TSC2 chr16:2037991-2076714 tuberous sclerosis 2: Mutations in this gene lead to tuberous sclerosis 
complex. Its gene product is believed to be a tumor suppressor and is 
able to stimulate specifiC GTPases. The protein associates with high: thyroid, unlikely hamartin in a cytosolic complex, possibly acting as a chaperone for heart, pineal 
hamartin .... mutations also causal in Pulmonary 
L m ha ioleiom atosls 
PKD1 chr16:2076712-2125900 polycystic kidney disease 1 (autosomal dominant): mutations in this high: gene cause autosomal dominant polycystic kidney disease type 1, 
renaVepithelial unlikely characterized by the growth of fluid-filled cysts that replace normal 
cells 
renal tissue and result in end-SlaB! renal failure 
MIR1225 chr16:2080197 -2080286 microRNA 1225: belongs to subfamily of miRNAs called mirtrons, that 
arise from short hairpin introns. Mirtrons differ from in that they use 
"'' 
unlikely 
SJ?:Iicingratherthancleav~b;r:Drosha 
MIR3180-5 chr16:2125979-2126131 microRNA 3180-5 
"'' 
un likel~ 
RAB26 chr16:2136652-2144142 member RAS oncogene family: regulatOfS of vesicular high: adult/fetal fusion/trafficking. This G-prtn family regulates intercellular vesicle brain unlikely trafficking, incll.ldi~ exoc~osis, endoc~osis, rec:r:cting 
SNORD60 chr16:2145025-21451 07 small nucleolar RNA, C/D box 60 
"'' 
nla 
0 
"' 
TRAF7 chr16:2145600-2166131 high:colorectal 
TNF receptor-associated factor 7: ignal transducers for members of adenocarcinoma unlikely the TNF receptor superfamily , fetal brain, B 
hoblasts 
CASKIN1 chr16:2167165-2166466 CASK interacting protein t : coat tl"le cytoplasmic tails of neurexins and high: brain, lung, 
unlikely othercellsurfaceproteins liver 
MLST8 chr16:2195179-2199419 MTOR associated protein, LST8 homolog (S. cerevislae): regulates high: prostate, 
unlikely cell growth in response to nutrients and growth factors liver 
C16orf79 chr16:2199255-2201 070 
"'' "'' 
n/a 
PGP chr16:2201604-2204823 phosphoglycolate phosphatase: may have an important regulatory high: skeletal. 
unlikely influence on oxygen transport in man cardiac tissues 
E4F1 chr16:2213568-22257 44 E4F transcription factor 1: The zinc finger protein is one cell 
transcription factors whose DNA-binding activities are regulated high: CD4. CDS 
unlikely through adenovirus Et A . plays an important role in the cellular life-or- Tcells 
death decision controlled b;r:J?:53. 
DNASE1L2 chr16:2226469-2228713 deoxyribonuclease 1-like 2: strong endonuclease activity in the high: brain, presence of both Ca(2+) and Mg(2+). Inhibited by increasing salt unlikely 
concentration pituitary 
DCI chr16:222987 4-2241603 dodecenoyi-CoA isomerase (DC\), nuclear gene encoding very 
mitochondrial protein: a key mitochoodrial enzyme involved in beta- high: liver, heart 
oxidation of unsaturated FA's unlikely 
RNPS1 chr16:22431 01-2257859 RNA binding protein S 1, serine-rich domain: protein binds to the high: prostate unlikely mRNA and remains bound after nuclear export, acting as a 
nucleocytoplasmicshuttlingprotein ___ stronglyactivatesplicingof 
constitutivel:1 and altematively S(l:liced (l:re-mRNAs 
MIR3677 chr16:2260715-226077 4 
"" '"' 
n/a MIR940 chr16:22617 49-2261842 
ABCA3 chr16:2265880-23307 48 ATP-binding cassette, sub-family A (ABC1), member 3 ABC proteins 
transportvariousmoleculesacrossextra-andintracellular high: lung sequenced membranes ... have been linked with IPF "Usual interstitial pneumonia {Fady) 
in an adolescent with ABCAJ mutations" and other papers. 
ABCA17P chr16:2330924-2416701 ATP-binding cassette, sub-family A (ABC1), member 17, pseudogene: testis-specific unlikely shares a common 5' end with ABCAJ 
CCNF chr16:2419396-2448860 cyclin F: important regulators of cell cycle transitions through thei r 
ability to bind andactivatecyclin-dependentproteinkinases ... theF- high: early un likely 
box proteins function in phosphorylation-dependent ubiquitination. erthyroid 
C16orf59 chr1 6:2450116-2454965 
"'' 
n/a 
NTN3 chr16:2461501-2464147 netrin 3: netrins are a family of chemotropic factors that guide axons to high very 
their targets cilary/dorsalroot un likely an lions 
0 TBC1D24 chr1 6:24651 48-2495735 high: brain, ~ followed by 
TBC1 domain family , member 24: suggesting it is involved in cell testis, skeletal unlikely signaling : ismutatedinfamilialinfantilemyoclonicepilepsy muscle, heart, 
kidney, lung, 
and liver 
ATPSVOC chr16:2503728-251 0225 ATPase. H+ transporting, lysosomalt6kDa, VO subunit c: a 
mu~isubunitenzyme thatmediatesacidificationofeukaryotic high: whole intracellular organelles. which isnecessaryforproteinsorting, unl ikely? 
zymogen activation, receptor-mediated endocytosis, synaptic vesicle brain , lung 
proton gradient generation 
AMDHD2 ch r1 6:251 0364-2519733 amidohydrolase domain containing 2: product is putative N- highest in 
un likely acetylglucosamine-6-phosphate dendritic cells 
CEMP1 ch r16:2520037 -2521410 high: periodontal 
cementum protein 1: could be involved in regulating the ligament/ un likely cementogenesis process during root development. cementum-
formin cells 
MIR3178 ch r16:2521924-2522007 
"'' PDPK1 ch r16:2527971-2593190 3-phosphoinositide dependent protein kinase-! : activates PKB, high: prostate, lsoforms of protein kinase B are overexpressed in some ovarian. CD34/CD33 un likely pancreatic, and breast cancer cells, and PKB has been shown to 
cells (l:rotectcellsfromaE!2etosis 
LOC65227 hypothetical LOC652276 (LOC652276), non-coding RNA 6 ch r16:2593386-2620496 
FLJ42627 chr16:2628984-2636131 hypothetical LOC645644 (FU42627), non-coding RNA 
KCTD5 chr16 2672496-2699032 potassium channel tetramerisation domain containing 5: interacts with high: bronchial 
the large regulatory proteins Rep78, Rep68 of adena-associated virus- epithelial cells, unlikely 
2 AAV-2 . 
'"" PRSS27 chr16:2702424-2710553 protease, serine27: Pancreasinis apancreatictrypticserinepeptidase high: pancreas, possible 
that cleaves peptides after an arginine residue. lung but unlikely 
LOC10012 hypothetical LOCI 00128788 8788 chr16:2727078-27 42602 
SRRM2 chr16:2742331-2761414 serine/arginine repetitive matrix 2: a potential blood biomarker expressed in all 
unlikely revealinghighatternativesplicing in Par1<inson'sdisease. tissues 
TCEB2 chr16:2761416-2767298 transcription elongation factor B (SUI). polypeptide 2 (elongin B): 
encodes the protein elongin B, which is a s~bun~ ~- the transcription h" h: liver heart ;~:~I~L~~~~~ ~::s~~) t~~~~~;~~:~s~~~;~t;:~~f.i~h; ~~~ction of :~:~!~~~Its , possible :~o~~~:i~~~--b~: ':;1~~=-~-~~":uCC~~~~~h!~~=:~~=~tes t:Stis, pineal ' 
pulmonary hypertension and fibrosis in mice (paper). 
PRSS33 chr16: 277 3955-2 776 709 protease, serine, 33 of• n/a 
:;;: PRSS41 chr16:2788487 -2795134 protease,serine, 4 1 
"" 
n/a 
PRSS21 chr16:2807165-2811719 testisin :encodes a cell-surface anchored serine protease, a member 
ofthetrypsinfamilyofserineproteases. ltmaybe invoiYedin high: testicular unlikely 
progression of testicular tumors of germ cell origin rei• 
ZG16B chr16:282017 4-2822286 zymogen granllle protein 16 homolog B (rat): 
high: salivary 
unlikely gland trachea 
PRSS30P chr16:2829575-2832753 protease, serine, 30 homolog (mouse), pselldogene, non-coding RNA of• n/a 
PRSS22 chr16:2842729-2848172 This gene encodes a member of the trypsin family of serine proteases. high• 
The enzyme is e:>:pressed in the airways in a developmentally esophagus, unlikely trachea ... . lung· 
regulated manner low 
FLYWCH2 chr16:2873197 -2889384 FL YWCH family member 2 
high: colorecta1 
unlikely adenocarcinoma 
FLYWCH1 chr16:2901981-2930159 FL YWCH-type zinc finger-containing protein 1 
high:C04T 
unlikely cells. thalamus 
KREMEN2 chr16:2954218-2958382 kringle containing transmembrane protein 2: The encoded protein 
forms a ternary membrane complex with DKK1 and W NT receptor 
lipoprotein receptor-related protein 6 (LRP6), inducing rapid 
endocytosis and removal of LRP6 from the plasma membrane .. high in liver possible 
Inhibition of WnVbeta-catenin!CREB binding protein (CBP) signaling 
reverses pulmonary fibrosis ... Dickkopf proteins influence lung 
epithelial cell proliferation in idiopathic pulmonary fibrosis (paper) 
PAOR4 chr16:2959343-2963486 progestin and adipoQ receptor family member IV: hormones b ind to high: retina unlikely 
these Rs, involved in a variety of metabolic processes 
PKMYT1 chr16:2962793-2970541 protein kinase, membrane associated tyrosine/threonine 1: This kinase 
prelerentiallyphosphorylatesand inactivatescelldivisioncycle2 high: early protein (CDC2), and thus negatively regulates cell cycle G21M 
erythroid unlikely transition. This kinase is associated with the membrane throughout the 
cell cycle 
LOC28387 hypotheticallOC283875 
"" 
nla 5 chr16:2979056-298451 1 
CLDN9 chr1 63002458-3004507 Claudins are integral membrane proteins and components of tight 
~ chr16:3004714-3008189 junction strands. This protein is one of the entry cofactors for hepat~is high: heart. C virus. Mouse studies showed that this gene is needed for the 
skeletal muscle unlikely preservation of sensory cells in the hearing organ and the gene 
deficiency is associated with deafness 
TNFRSF12 high: heart, 
A chr16:301 0314-3012384 tumor necrosis factor recep~or _supe~amily,_ member 12A: stim_ulation of :id:~ia~r:'1~hi~l . 
cell growth and an_g1ogenes1S, ~~~uct!on_ol mfl~mmatory cyt~mes, and 1 p .. pOSSible 
under some expenmental condiltons, sttmulatton of apoptosts... i~::Sm1ediate 
e ression 
C> HCFC1R1 chr1 6:3012627 -3014288 host cell factorC1 regulator 1 (XP01 dependent): the HCFC1 protein 
"' 
is involved in control of the cell cycle and transcriptional regulation high: whole unlikely 
duringherpessimplexvirusinfection brain, heart, lung 
THOCG chr1 6:3014033-3017757 THO complex 6 homolog (Drosophila): THO complex: nuclear complex 
that is required for transcription elongation through genes containing high: CO cells unlikely 
tandeml re ated DNA s 's. 
CCDC648 chr16:3017869-3025543 
coiled-coil domain containing 648: molecular function- Rab GTPase 
"'' 
nla binding 
MMP25 chr16:3036683-3050725 matrix metallopeptidase 25: involved in breakdown of ECM in normal possible physiological processes (embryonic development. reproduction, tissue high: leukocytes. 
remodeling), also in disease processes (arthr~is and metastasis). lung, and spleen but unlikely 
IL32 chr16:3055314-3059669 fl32 (a cytokine)stimulates monocytic cells to produce various high: CD4/8 T proinflammatory cytokines and chemokines through the NF-kappa-8 
cells, 8 possible and p38 MAPK inflammatory signal pathway ... may be involved in 
inflammato!}:lautoimmune diseases ... associated with COPD. lymphoblasts 
ZSCAN10 chr16:3078896-3082862 zinc finger and SCAN domain containing 10: 
"'' 
nla 
MGC3771 chr16:3100462-3105600 hypothetical LOC81854 (MGC3771), transcript variant!. non-coding high: cardiac 
RNA myocytes, unlikely 
skeletal muscle 
ZNF205 chr16:3102564-3110519 Kruppel-type zinc finger protein that contains a KRAB A box N-terminal high: cardiac 
myocytes, some unlike ly to8zincfingermotifs. brainr ions 
ZNF213 chr1 6:3125058-3132806 C2H2 zinc finger proteins such as ZNF213: have bipart~e structures in high: testis, 
which one domain binds DNA/RNA and the other modulates target unlike ly 
aeneexoression ovary 
OR1F1 chr16:3194248-3195186 Olfactory receptors interact with odorant molecules in the nose. to high: heart. liver. 
OR1F2P chr16•3205563-3206547 initiate a neuronal response that triggers the perception of a smell. The ganglion cells . 
unlikely olfactory receptor proteins are members of a large family of G-protein- some brain 
coupled receptors (GPCR) arising from single coding-exon genes. regions 
ZNF200 chr16:3212326-3225187 zinc finger protein 200: novel binding partner of histone H3 high: testis unlikely methyltransferaseG9a. 
MEFV chr16: 3232029-3246628 encodes a protein: pyrin or marenostrin: is an important modulator of high: ganglion 
innate immunity. Mutations in this gene are associated with cells , peripheral unlikely 
Mediterranean fever, a hereditary periodic fever syndrome blood , 
FLJ39639 chr16•3253769-3257567 hypothetical protein FLJ39639 
"'' 
n/a 
ZNF263 chr16:3273488-3281460 zincfingerprotein263 high: retina unlikel:i 
TIGD7 chr16: 3288809-3295440 tigger transposable element derived 7: tigger subfamily of pogo 
superfamily of DNA-mediated transposons in humans. These proteins· high:cilary 
related to DNA transposons found in fungi/nematodes, and more ganglion, 
unlikely distantly to the Tc1/mariner transposases ... also very similar to the atrioventricular 
major mammalian centromere protein B. eKSct function of this gene is 
""'" not known 
;; ZNF75A chr16•3295434-3308577 zincfingerprotein75a ubiquitous exp unlikel:i 
OR2C1 chr16: 3345890-3346925 high: heart, liver, 
olfactory receptor , family 2, subfamily C, member 1: function above in ganglion cells , 
unlikely 
"OR1F1 " some brain 
re1ons 
MTRNR2L4 chr16•3361 054-3362284 MT-RNR2-Iike 4: function not well known. in extracellular region 
"" 
unlikel:i 
ZNF434 chr16:3372086-3391 026 zincfingerprotein434 
ZNF174 chr16:3391191-3395044 zinc finger protein 174- isofonnb 
"" 
unlikely 
ZNF597 chr16:34261 11-3433491 zincfingerprotein597 
NAT15 chr16:3447993-34 76964 N-acetyltranslerase 15 (GCNS-related, putative) (NAT15), transcript high: lung , liver, possible 
variant 3: SNPs have been associated with lung cancer. heart but unlikely 
C1 6orf90 chr16:3483485-3485422 chromosome 16 open reading frame 90: predicted 
"'' 
unlikel:i 
CLUAP1 chr16 •3490964-3526586 clusterinassociatedprotein 1: expressionisfrequenllyupregulatedin high: pineal unlikely cotoncancer, provisionalstatus 
NLRC3 chr16:3529037 -3567393 NLR family , CARD domain containing 3 
"'' 
unlikely 
SLX4 chr16:3571184-3601586 SLX4 structure-specific endonuclease subunit homolog (S. cerevisiae) 
encodes a structure-specific endonuclease subunit. The encoded 
protein conta ins a central BTB domain and it forms a multiprotein high: brain. lung. 
complex. is required for repair of specific types of DNA lesions and is thyroid unlikely 
critical for cellular responses to replication fo~ failure. The encoded 
protein acts as a docking platform for the assembly of multiple, 
mutated in FANCONI ANEMIA 
DNASE1 chr16:3642941-3648097 deoxyribonuclease 1: encodes a member of ONase family . This protein high: small unlikely 
TRAP1 chr16:3648039-3707599 
CREBBP chr1 6:3715057-3670122 
ADCY9 chr16:3952651-41 06187 
SRL chr16:4179376-4232082 
TFAP4 chr16:4247166-4263002 
is stored in zymogen granules of the nuclear envelope/functions by 
cleaving DNA. Mutations in gene: associated with systemic lupus 
erythematosus (SLE), an autoimmune disease. A recombinant form of 
this protein is used to treat the one of the symptoms of cystic fibrosis 
by hydrolyzing the extracellular DNA in sputum and reducing its 
viscosity 
TNF receptor-associated protein 1: HSP90 proteins are highly 
conservedmolecutarchaperones thathavekeyroles in signal 
transduction, protein folding, protein degradation, and morphologic 
evolution 
CREB binding protein, transcript variant 2: involved in transcriptional 
coactivation of many different TFs. First isolated as a nuclear protein 
that binds to cAMP-response element binding protein (CREB), this 
gene is now known to play critical roles in embryonic development, 
growth control, and homeostasis by coupling chromatin remodeling to 
transcription factor recognition. 
adenylate cyclase 9:catalyses the formation of cyclic AMP from AlP 
type 9 is a widely distributed adenytyl cyclase, and it is stimulated b~ 
beta-adrenergic receptor activation but is insensitive to forskolin, 
calcium, and somatostatin 
sarcalumenin: this gene encodes a 160-kD glycoprotein protein 
involvedincalciumsignaling. 
transcriptionlactorAP-4 (activatingenhancerbindingprotein4): 
TFAP4 activates both viral and cellular genes by binding to the 
symmetrical DNA sequence CAGCTG: target of MYC, blocks p21 
expression (overexpression is a prognostic indicator for gastric 
carcinoma) 
iQbiS2 ....:) chr16:4322226-4329599 GLIS family zinc finger 2: function as activators and/or repressors of 
gene transcription: plays an essential role in the maintenance of renal 
tissue architecture through prevention of apoptosis and fibrosis. 
COR07-
PAM16 
PAM16 
COR07 
l\fASN 
DNAJA3 
chr16:4330253-4406963 
chr16:4330253-4341374 
chr16:4344544-4406963 
chr16:4361650-4373530 
chr16:4415659-4446776 
the conjoined read-through of 2 genes (listed below) 
presequence translocase-associated motor 16 homolog {5. cerevisiae) 
{PAM16). nuclear gene encoding mitochondrial protein 
coronin 7: plays a role in Golgi complex morphology and function 
vasorin:directly binds to transforming growth factor (TGF)-beta and 
attenuates TGF-beta signaling: potential therapeutic target for vascular 
fibroproliferativedisordersbymodulatingarterialresponse 
OnaJ (Hsp40) homolog, subfamily A, member 3: belongs to the 
evolutionarily conserved DNAJIHSP40 family of proteins: 
intestine. 
pancreas 
high: local~esto 
mitochondria 
ubiquitousexp 
high: colon ... 
moderate: lung, 
kidneys, spleen, 
testis, ova!i: 
high: muscle 
celts 
high: colorectal 
carcinoma celts 
high: kidney .... 
low: heart, lung, 
placenta 
high: brain, 
thymus, kidney 
high: vascular 
smooth muscle 
celts 
high: heart, liver, 
skeletal muscle 
HMOX2 chr16:4466342-4500349 heme oxygenase (decycling) 2: part of the heme degradative pathway: mgn: 1esus, 
unlikely 
unlikely 
unlikely 
unlikely 
unlikely 
sequenced 
(Fady) 
unlikely 
sequenced 
(Fady) 
unlikely 
unlikelv 
cleaves heme to form biliverdin. which is subsequently converted to whole brain, 
bilirubin bybiliverdin reductase, andcarbonmonoxide, a putative brochial 
neurotransmitter epithelial cells. 
lon . liver. heart 
C16orf5 chr16:4500678-4528817 high: brain ... 
chromosome 16 open reading frame 5: ascertained in a patient with Little to no very 
epilepsy and mental retardation expressiOn 1n unlikely 
'"" family with sequence similarity 100, member A: hypothetical protein high: thyroid, unlikely FAM100A chr16:4598885-4604928 LOC124402 e:lacenta 
MGRN1 chr16:4614827 -4680976 mahogunin, ring finger t : is a C3HC4 RING-containing protein with E3 
ubiquitin ligaseactivityinvilro. Mahogunin istheproteinmutantin high: brain, lung, 
unlikely 
'mahoganoid.' a coat-color mutation of mice in which pigmentation is liver 
verysimilartothatof'mahogany.' 
NUDT16L1 chr16:4683695-4685861 
nudix (nucleoside diphosphate linked moiety X)-type motif 16-like 1 
high: heart, 
prostate, thyroid, unlikely 
liver 
chromosome 16 open reading frame 71: hypothetical protein high: testis very C16orf71 chr16:4724290-4739398 LOC146562 unlike!~ 
;:; ZNFSOO chr16:47 40816-4 757167 zinc finger protein 500 "'' 
unlike!~ 
SEPT.12 chr16:4767673-4778400 septin 12, trans. var_ 2: conserved GTP-binding proteins that function 
as dynamic. regulatable scaffolds for recruitment of other 
proteins/involved in membrane dynamics, vesicle trafficking, apoptosis, 
and cytoskeleton remodeling, as well as infection, neurodegeneration, 
high: testis unlikely 
and neoplasia. 
GLYR1 chr16:47932054837304 gtyoxylate reductase 1 homolog (Arabidopsis): localizes to the nucleus high: CD cells unlikely ina varietyof cell lines 
UBN1 chr16:4837913-4872364 
obinuclein 1, transvar2: innucleus. interactswith somecellularlviral 
TF• ubiquitoosexp unlikely 
PPL chr16:4872509-4927137 periplakin: a component of desmosomes and of the epidermal cornified 
envelope in keratinocytes: its C-terminus interacts with intermediate high: epidermis, sequenced filaments. "IdentifiCation of Periplakin as a New Target for 
stomach, cornea (Fady) Autoreactivity in Idiopathic Pulmonary Fibrosis" Am J Respir Cril Care 
Med. 
SEC14L5 SEC14-Iike 5 (S. cerevisiae) 
high: OFB, 
unlikely chr16:4948319-5009157 e:ineal 
NAGPA chr16:5014846-5023943 N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase: This gene encodes the enzyme that catalyzes high: brain, 
unlikely the second step in the formation of the mannose 6-phosphate myeloid cells 
rec£!1nit ion marker on l~sosomal hY!!rolases. 
chromosome 16 open reading frame 89: hypothetical protein high: thyroid, possible 
C16orf89 chr16: 5034124-50561 12 LOC146556 ,,,. but unlike!~ 
ALG1 chr16:5061811-5077381 asparagine-linked gtycosylation 1, beta-1 ,4-mannosyltransferase 
"" 
unlikely 
homolog (S. cerevisiae): enzyme encoded by this gene catalyzes the 
firstmannosylationstepinthebiosynthesisoflipid-linked 
oligosaccharides. This gene is mutated in congenital disorder of 
gl:,:cos;t:lationt;t:~lk 
FAM86A chr16:507 4302-5087790 
family with sequence similarity 86, member A: hypothetical protein high: pituitary, 
unlikely LOC196483 isoform t liver 
RBFOX1 chr16:6009133-7703341 RNA binding protein, fox-1 homolog (C. elegans) 1: Ataxin-2 binding 
protein 1 has an RNP motif that is highly conserved among RNA- high: whole binding proteins. This protein bindstotheC-terminusofataxin-2and brain unlikely 
maycontributetotherestrictedpathologyofspinocerebellarataxia 
type 2 
TMEM114 chr16:8559503-8562227 transmembraneprotein114 
high: eye, brain, 
unlikely testis 
METTL22 ch r1 6:8623028-8647580 methyltransferase like 22: hypothetical protein LOC79091 
"'' 
unlikel~ 
ABAT chr16:872207 4-8785933 4-aminobutyrate aminotransferase: responsible for catabolism of 
gamma-aminobutyric acid (GABA, a Nn, into succinic high: brain, 
semialdehyde.BAT deftciency phenotype includes psychomotor pituitary. liver unlikely 
retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and 
EEG abnormalities. 
TMEM186 ch r1 6:8796538-8799006 transmembrane protein 186 
high: B 
unlikely 
c;; 1:tm~hoblasts 
PMM2 chr16:8799171-8850695 phosphomannomutase 2: catalyzes the isomerization of man nose 6-P high: CD cells. B 
to mannose 1-P. Mutations in PMM2: cause defects in glycoprotein lymphoblasts, very 
biosynthesis,whichmanifestsascarbohydrate-deficientglycoprotein small intestine, unlikely 
s ndromet I smooth muscle 
CARHSP1 ch r16:8854303-8870364 calcium regulated heat stable protein 1, 24kDa: is required for effective high: testis 
tumor necrosis factor alpha mRNA stabilization Moderate: liver, unlikely lun , lacenta 
chr16:8893452- ubiquitin specific peptidase 7 (herpes virus-associated): may function 
USP7 8964842 asatumorsuppressorinvivothroughthestabilizationofp53 ... PML- high: CD7t possible 
HAUSP networll controls PTEN deubiquitinylation and subcellular early erythroid but unlikely 
localization, which is perturbed in human cancers 
C16orf72 ch r16:9093038-9121 056 
chromosome 16 open reading frame 72: hypothetical protein 
"" 
unlikely LOC29035 
MIR548X chr16:9236275-9236304 microRNAs are short (20-24 nt) non-coding RNAs that are involved in 
post-transcriptionalregulationofgeneexpressioninmutticellular 
"'' 
unlikely 
organisms by affecting both the stability and translation of mRNAs ... 
chr16:9754766- glutamate receptor, ionotropic, NMDA: class of ionotropic glutamate-
GRIN2A 10183764 gated ion channels: shown to be involved in long-term potentiation ( high· 
subthalamic unlikely activity-dependentincreaseintheefftciencyofsynaptictransmission 
nucleus thoughttounderliecertainkindsofmemoryandlearning) 
chr16: 10430226- activatingtranscriptionfactor7interactingprotein2: bindstoMBD1 high: testis, T 
unlikely ATF71P2 10484996 whichisinvovledintranscriptional repression and heterochromatin cells 
fonnalion 
chr16: 10529780- high: lung , sequenced EMP2 10582040 ep~helialmembraneprolein2: involvedincellproliferalionandcell-cell ovary. heart. interactions intestine {Fady) 
chr16: 10628862- tektin 5 (provisional status): suggests that TEKT5 plays an important 
TEKTS 10696303 role in flagella fonnation during spenniogenesis/ implicated in spenn 
motility "'' 
unlikely 
chr16:10745199-
NUBP1 10770709 nucleotide binding protein 1 (MinD homolog, E. coli) : plays a vital role high: lung, testis unlikely in cell function 
chr16:10768034- family with sequence similarity 18. member A (predicted status) 
"" 
n/a FAM18A 10820122 
chr16:10878556-
CIITA 10926341 class II. major histocompatibility complex, transactivator: "Expression high: liver, possible 
of major histocompatibility complex class II antigens on lungs in rat 
skeletal muscle but unlikely withbleomycin-inducedpulmonaryfibrosis" 
:;;: l nFXI 
I chr16:10930249- Dexi homolog (mouse): upregulated in emphysematous tissue high: heart, liver. sequenced 10943758 lung (Fad~) 
chr16: 10945846- C-type lectin domain family 16, member A: associated with Type 1 high: kidneys. 
unlikely 11183547 diabetes testis, ovary 
chr16:11255775-
11257540 suppressor of cytokine signaling 1: family members are cytokine- high: Tcells sequenced inducible negative regulators ofcytokine signaling 
chr16:1 1269215- transrtion protein2 (duringhistonetoprotaminereplacement); 
TNP2 11270661 mammalian spenniogenesis, importin alpha-4 required fo r active high: testis very 
transport ofTnp2intonucleiofrattestisgenncells unlikely 
chr16:11274645- protamine family: Prolamines are the major DNA-binding proteins in 
PRM3, 2, 1 11274953 the nucleus of spenn, and package the DNA in a volume less than 5% high: testis unlikely 
ofasomaticcellnucleus 
C160RF75 
RMI2 is a component of the BLM complex, which plays a role in high: lymphoma, 11353118 homologous recombination-dependent DNA repair and is essential for lymphoblasts unlikely 
aka RMI2 genome stability ... involved in Bloom Syndrome 
chr16:11549079- lipopolysaccharide-induced TNF factor: Lipopolysaccharide is a potent 
LITAF 11588823 stimulatorofmonocytesandmacrophages.causingsecretionof highest in possible inflammatory mediators. encodes lipopolysaccharide-induced TNF- lymphoblasts, T 
alpha factor, a DNA-binding protein and can mediate the TNF-alpha 
cells but unlikely 
expression by direct binding to the promoter region of the TNF-alpha 
gene. Thetranscriptionofthisgeneisinducedbytumorsuppresorp53 
andhasbeenimplicated inthep53-inducedapoptoticpathway. 
Mutations in this gene cause Charcot-Marie-Tooth disease type tC 
(CMTI C) and may be involved in the carcinogenesis of extramammary 
Paget's disease (EMPD). Multiple alternatively spliced transcript 
variants have beenfoundforthis gene 
chr16: 11669790-
SNN 11680516 stannin:cytokinesinducedexpressionofstannin in cultured human highest: brain unlikely umbilical vein endothelial cells reg1ons 
chr16 :11680444-
TXNDC11 11744149 thioredoxin domain conta ining I t : cell redox homeostasis, sometimes high: dendritic unlikely part of the membrane ... cells 
chr16 :11751943-
ZCJH7A 11798615 zinc finger CCCH-type containing 7A: functional module in low: lung, testis, very 
macrophage activation, liver, heart unlikely 
chr16:11821193- breast cancer anti-estrogen resistance 4. non-coding RNA 
"" 
very 
BCAR4 11830190 unlikel 
chr16:11835556-
RSL1D1 11852943 ribosomal L 1 domain containing 1: RNA binding-structural constHuent low: lung, colon, very u; of ribosome Sl unlikely 
chr16: 11869486- Gt to S phase transHion 1, transcript variant 2, mRNA: hypothesized 
GSPT1 11917326 that Gsptt , in a binary complex with eRFI , functions as a polypeptide high: bronchial unlikely 
chain release factor epithelial cells 
chr16: 11966465- tumor necrosis factor receptor superfamily, member 17: R expressed 
TNFRSF17 11969426 in mature B lymphocytes, and may be important forB cell development high 
and autoimmune response may transduce signals for cell survival lymphoblasts, unlikely 
and proliferation dendritic cells 
chr16:11978103-
RUNDC2A 12054642 RUN domain containing 2A: 
"'' 
unlikely 
chr16: 12053556-
sorting nexin 29: are a large group of proteins that are localized in the SNX29 12575647 cytoplasm and have the potential for membrane association either 
through lipid-binding PX domain or through protein-protein interactions 
with membrane-associated protein complexes. Some members of this 
ubiquHous unlikely 
family have been shown to facilitate protein sorting 
chr16:12661157- high: CD33 
CPPED1 12805245 calcineurin-likephosphoesterasedomaincontainingt : hydrolase myeloid, CDt4 
monocytes, unlikely activity, metalionbinding 
cardiac 
myocytes 
chr16: 12902978- high: brain 
SHISA9 13241774 shisa homolog 9: modulates short-term pl astic~y at specific excitatory {dentate gyrus unlikely synapses granule cells) 
chr16: 13921515- possible: 
ERCC4 13953706 excision repair cross-complementing rodent repair deficiency. have been 
complementation group 4: involved in the 5' incision made during ubiquitous linked to 
nucleotide excision repair . .. . Defects inthisgeneareacauseof 
xeroderma pigmentosum6 lung 
cancer ... 
chr16:14072697-
MKL2 14268131 MYOCARDIN-LIKE 2: RNA interference of MKL 1 or MKL2 reduced 
serum and RhoA activation in Hela cells, and the combination of ubiquitous unlikely 
MKL1 and MKL2 RNA interference completely abolished induction 
o; 
Candidate 
Gene Position Function I Ex~:!:ression ? 
LOC73227 chr16:84922957- Homo sapiens sWnilar to hCG1645603 (LOC732275), non-coding RNA 
"" 
unlikely 5 64936786 
LOC40055 chr16:85065632- hypothetical LOC400550 (LOC400550), transcript variant 1, non-
"" 
unlikely 0 85099967 coding RNA 
chr1 6:85101634-
FOXF1 85105571 fork head family of transcription factors , found in promotors of SPB high:lung (adult possible Paper: shows weak expression of the gene in IPF and fetal), Sl 
chr16 :85 121283-
MTHFSD 851 46342 methenyltetrahydrofolate synthetase domain containing: a folate high:prturtary, unlikely metabolizing enzyme testis, 
chr16:85146427- hypotheticalprotein, functionunknown 
"" 
unlikely FLJ30679 85148406 
chr16:85158358- possible FOXC2 85160038 fork head box C2 (MFH-1, mesenchyme forkhead 1): rt may play a role high: liver, heart, in the development of mesenchymal tissues cardiac cells but unlikely 
::; 
chr16:85169616-
FOXL1 85172805 forkheadboxl1 (FOXL1) high: liver unlikely 
LOC10050 chr16:85893906- hypothetical LOC100506581 (LOC100506581): 
"'' 
unlikely 6581 85908527 
chr16:85920443- f-box protein 31 (FBX031): suggested to function as a tumor 
FBX031 85974895 suppressor by generating SCF-FBX031 complexes that target high: testis, 
unlikely substrates crrtical for the nonnal execution of the cell cycle (i.e endothelial cells 
ubiquitination and degradation) 
MAP1LC3 chr16:85983302-
B 85995881 microtubule-associated protein 11ightchain3beta: asubunitol high: heart. 
neuronal microtubule-associated MAP1A and MAP1B proteins, which brain, skeletal unlikely 
are involved in microtubule assembly and important for neurogenesis muscle 
chr16:85997353-
zinc finger, CCHC domain containing 14 high: testis, 51, unlikely ZCCHC14 86082961 fetal brain 
chr16:86194000- junctophilin 3: Junctional complexes blw the plasma membrane and 
JPH3 86289262 endoplasmiclsarcoplasmic reticulum are a common feature of all high whole 
excitablecelltypeslmediatecrosstalkblwcellsurfaceand brain, cardiac unlikely 
intracellular ion channels cells 
chr16:86298919- kelchdomaincontaining4 high: CO cells unlikely KLHDC4 86357099 
chr16:86421130- high: bronchial 
SLC7A5 86460601 
solute carrier family 7 (cationic amino acid transporter, y+ system). eprthetiatcetts. unlikely 
member 5: involved in tung cancer eartyerthyroid , 
ineat 
chr16:86479126- carbonic anhydrase VA. mrtochondriat: large family of zinc 
CA5A 86527613 metattoenzymes that catalyze the reversible hydration of carbon high: liver unl ikely 
dioxide. tt may play an important role in ureagenesis and 
gluconeogenesis 
chr1 6:86561 125- BTG3 associated nuclear protein: protein binds to matrix attachment 
BANP 86668425 regions. The protein forms a complex wrth p53 and negatively high: heart, unlikely 
regutatesp53transcriptionlfunctionsasatumorsuppressor/cettcycle spleen, thymus 
regulator 
chr16:8702 1380-
ZNF469 87034666 encodes a zinc-finger protein: Mutations in this gene cause brittle comeasyndrome- raregeneticconnectivetissuedisorder ubiquitous unl ikely 
characterized by tax joints, scoliosis and fragile sclera of the eye 
chr16:87047515- aka FOG (friend ofGATA1 )- GATA1 involved in erythroid 
high: 
00 ZFPM1 87129075 different iation 
hematopoietic unlikely 
tissues 
chr1 6:87 164290-
ZC3H18 87225873 
zinc finger CCCH-type containing 18: shown to be involved in an in 
"" 
unlikely 
vrtro model of trypanosome differentiation 
chr1 6:87232502- interleukin 17C: a Tcett-derivedcytokinethatsharesthesequence 
IL17C 87234383 similarity wrth tL17. This cytokine was reported to stimulate the release high: activiated possible 
oftumornecrosisfactoratphaandinterleukin1 beta from a monocytic Tcetts 
cett tine 
chr1 6:87237198- cytochrome t>-245, alpha polypeptide: Mutations in this gene are 
CYBA 87244958 associated with autosomal recessive chronic granulomatous disease 
(CGD), that is characterized by the failure of activated phagocytes to high: blood, lung unlikely 
generate superoxide, which is important for the microbicidal activity of 
these cells. 
ch r1 6:87245849-
MVD 87256996 mevatonate (diphospho) decarboxylase: catalyzes the conversion of high: adipocytes, mevalonate pyrophosphate into isopentenyl pyrophosphate in one of adrenal cortex unlikely 
theear1ystepsincholesterolbiosynthesis. 
chr1 6:87257282- hypothetical LOC197187 (MGC23284), transcript variant 2, non-coding 
"'' 
unlikely 
MGC23284 87281095 RNA 
SNAI3 chr16:87271591- snail homolog 3 (Drosophila): which plays roles in mesodermal skin melanoma. unlikely 
87280383 formation during embryogenesis pooled lung/ 
spleen. lung 
epidermoid 
carcinoma, 
chr16:87290404-
ring finger protein 166 
"'' 
unlikely RNF166 87300330 
chr16:87300392- cytosolic thiouridylase subunit 2 homolog (S. pombe): Wobble uridine 
CTU2 87309287 tRNA thiolase Ctu1-Ctu2 is required to maintain genome integrity inS 
"'' 
unlikely 
pombe 
chr16:87309247- family w~h sequence similarity 38. member A: FAM38A encodes 
FAM38A 87378873 PIEZOI . a protein that induces mechanically activated (MA) currents in high: pineal, 
unlikely various cell types; essential components of distinct mechanically lung. T cells 
activated cation channels. 
chr1 6:87397687- chromatin licensing and DNA replication factor 1: involved in the high 
CDT1 87403167 formation of the pre-replication complex that is necessary lor DNA lymphoblast unlikely 
replication cells. CD cells 
chr16:67 403378-
adenine phosphoribosyltransferase: enzyme catalyzes formation of 
<; APRT 87405843 AMP and _inorganic pyrophosphate from adenine ~nd 5- h" h: liver ih':~~O::i'~:C::~~~:=PP~~~~:;~u~~~:;~~~ ~!~c~~~~~ut~~of p~state, lung unlikely 
enzyme causes 2,8-dihydroxyadenine urot~hiasis 
chr16:87 407643- galactosamine (N-acetyl)-6-sulfate sulfatase: a lysosomal GALNS 87450875 exohydrolase required for the degradation of the glycosaminoglycans, 
keratan sulfate, and chondro~in 6-sulfate. Mutations can lead to high: prostate, unlikely 
deficiencies of this enzyme, which lead to Morquio A syndrome, a pineal 
lysosomal storage disorder. 
chr16:87451007- traff1Ckingproteinparticlecomplex2·1ike: high: heart. liver, unlikely TRAPPC2L 87455021 testis 
chr16:87457249-
PABPN1L 87460569 poly(A) binding protein, nuclear !·like (cytoplasmic): important role in high: oocytes unlikely fertility involving the oocyte potential for embfYO development 
chr16:87468764-
core-binding factor, runt domain, alpha subunit 2; translocated to, 3: CBFA2T3 87535109 interacts with DNA-bound transcription factors and recruit a range of high: dendritic 
corepressorstofacilitatetranscriptional repression. The cells. C034 unlikely 
t(16;21)(q24:q22) translocation is one of the less common kaJYOtypic cells, thymus 
abnormal~ies in acute myeloid leukemia. 
chr16:87687755- acyi-CoA synthetase family member 3 {ACSF3), nuclear gene 
"'' 
unlikely ACSF3 87748498 encoding m~ochondrial protein: Acyi.CoA is involved in the metabolism 
of fatty acids 
chr16:87753129-
chromosome 16 open reading frame 61 : non-coding RNA ,,, unlikely C16orf81 87757584 
chr16:87765664- cadherin15, type1 , M-cadherin (myotubule): Theproteinisthoughtto 
CDH15 87789401 high: be essential for the control of morphogenetic processes, specif~eally 
cerebellum, unlikely myogenesis, and may provide a trigger for terminal muscle cell 
skeletal muscle differentiation 
chr16:87811612-
ZNF778 87823466 zinc finger protein 778: member of the krueppel C2H2-type zinc-finger 
protein family, is a candidate gene for autism and variable cognitive high : liver, heart unlikely 
impairment in the 16q24.3 microdeletion syndrome 
chr16:87861536- high: skeletal 
ANKRD11 88084470 ankyrin repeat domain 11 : interacts with p160 nuclear receptor muscle, myeloid unlikely coactivators af'ld inhibits ligaf'ld-dependent transcriptional activation leukemia cells 
chr16:88102306- spasticparaplegia7(pureandcomplicatedautosomalrecessive) 
SPG7 88151675 (SPG7), nuclear gene encoding mitochondrial protein: Mutations 
unlikely ~ associated with this gene cause autosomal recessive spastic high: thyroid paraplegia? 
chr16:88154632-
RPL1 3 88157349 ribosomal protein L 13: encodes a ribosomal protein that is a high: epithelial 
component of the 60S subunit. e)(Jlressed at significantly higher levels 
relo unlikely in benign breast lesions than in breast carcinomas 
chr16:88155339-
small nucleolar RNA, C/D box 68 
"'' 
unlikely SNORD68 88155410 
chr16:88169677- copine VII : member of the copine family, which is composed of 
CPNE7 88191155 calcium-dependent membrane-binding proteins. contains two N- high: skeletal 
unlikely terminal C2 domains and one von Willebrand factor A domain. The muscle 
protein may be involved in membrane trafficking 
chr16:88207217-
DPEP1 88232340 dipeptidase 1 (renal): a kidney membrane enzyme implicated in renal high: kidney, unlikely metabolism of glutathione and its conjugates pancreas 
chr16:88238345- high: thyroid, 
CHMP1A 88251630 chromatin modifying protein 1A: involved in mullivesicular body sorting blood , heart, unlikely ofproteinstotheinteriorsoflysosomes 
'""" chr16:88251711-
chromosome 16 open reading frame 55: LOC124045 high: testis unlikely C16orf55 88265176 
CDK10 chr16:88280577- cyclin-dependent kinase 10: known to be essential for cell cycle high: thyroid, unlikely 
88290273 progression. This kinase has been shown to play a role in cellular liver, heart, PFC 
proliferation and its function is limited to cell cycle G2-M phase 
chr16:88290266-
spermatogenesis associated 2-like 
"' 
unlikely SPATA2L 88295622 
chr16 :88301042-
chromosome 16 open reading frame 7 high: retina, unlikely C16orf7 88314895 myeloid cells 
chr16:88314894- high; kidney, zincfingerprotein27 liver, lung. unlikely 
ZNF276 88334833 sleen 
chr16:68331460-
FANCA 88410566 Fanconi anemia, complementation group A : Fanconi anemia is a high: genetically heterogeneous recessive disorder characterized by lymphoblast unlikely cytogenetic instabilrty, hypersensitivity to DNA crosslinking agents, cells increased chromosomal breakage, and defective DNA repair. 
chr16:88422408- most tissues, 
SPIRE2 88465228 spire homolog 2 (Drosophila) little/none in unlikely heart and ;::; skeletal muscle 
chr16:88467495-
TCF25 88505293 transcription factor 25 (basic helix-loop-helix): member of basic helix- high: whole unlikely loop-helix family of TFs that are important in embryonic development brain, CD cells 
chr16:88511788- melanocortin 1 receptor: encodes the receptor protein for melanocyte-
MC1R 88514886 stimulating hormone (MSH). Loss-of-function mutations are associated 
ubiquitous, skin unlikely with increased pheomelanin production, which leads to lighter skin and 
hair color. 
chr16:88515918- tubulin, beta 3: primarily expressed in neurons and may be involved in 
TUBB3 88530006 neurogenesis and axon guidance and maintenance. Mutations in this high: fetal and 
unlikely genearethecauseofcongenitalfibrosisoftheextraocularmuscles adult brain 
type3. 
chr16:88542684- high: bronchial 
DEFB 88561968 differentially expressed in FDCP 8 homolog (mouse) epithelial cells, 
smooth muscle 
unlikely 
chr16:88563684-
CENPBD1 88566741 CENPB DNA-binding domains containing 1: high: brain unlikely 
chr16:88566489- AFG3 ATPase family gene 3-like 1 (S. cerevisiae), pseudogene 
'"' 
unlikely AFG3L1P 88590529 (AFG3L 1 P), transcript variant 2, non-coding RNA: The yeast Afg3 and 
chr16:88598780-
DBNDD1 88613438 
chr16:88616509-
GAS8 88638880 
chr16:88622817-
C16orf3 88623810 
LOC10013 chr16:88636811-
0015 88641692 
chr16:88650475-
~ PRDM7 88669839 
Real mitochondrial chaperoneslproteases function both in 
posttranslational assembly and in the turnover of mistranslated or 
misfoldedpolypeptides 
dysbindin (dystrobrevin binding protein 1) domain containing 1 
growth arrest-specifiC 8: gene is sometimes deleted in breast and 
prostrate cancer, is a putativetumorsuppressorgene. 
chromosome 16 open reading frame 3, hypothlicl. Pr. LOC750 
common in breasUprostate cancer, suggests the presence of a tumor 
suppressor gene. 
5-hydroxyisourate hydrolase pseudogene (LOC100130015), transcript 
variant! , non-coding RNA 
PR domain containing 7: a transcription factor of the PR-domain 
protein family, contains aPR-domain and multiple zinc finger motifs. 
Transcription factors of this family: usually involved in cell 
differentiation, tumorigenesis 
high: liver, PFC possible but unlikely 
high: heart. 
skeletal muscle, unlikely 
tung 
"' 
unlikely 
-
"' 
unlikely 
"' 
unlikely 
Appendix C: forward and Reverse Primer Sequences for All Genes Sequenced in 
Family R0942 
Sequences in capitalleners are located in exonic regions. Sequences in lower case letters are 
located in intronic and/or UTR regions. 
-
Gene Forward primer ==:> I Reverse Primer .._ I 
primer name I sequence primer name I sequence 
aacggggaaaaatagaagca 
EON1_ex1_F attgtctggggctggaataa EON1_ex1_R a 
EON1_ex2_F caggctgtgtgcttcatctg EON1_ex2_R ggcacttggatggtgttagaa 
EDN1_ex3_F gcccagtggaataggtgtgt EON1_ex3_R aacaggaaggcagtaccatga 
EON1_ex4_F agcctcctgaactccttcct EON1 ex4 R taagaagggctggaggaaca 
EDN1 EDN1 ex5a EON1- exsa CAGAAACTCCACCCC 
i' - caggttttgtttgtgccaga R - TGTGT 
EDN1 ex5b 
-
TCCTCTGCTGGITCCT EON1 ex5b 
-
AGTATGGGGGATGGA 
i' GACT R GGAAG 
TGGCAGAAGT A TnCC 
EDN1 ex5c F CACAT EDN1 ex5c R ttaatcacattaacccactc 
SOCS1_ex1 
-
SOCS1 ex1 
-
F gcggaaagagaaaccaaaagt R- ccggagaaaggctgtgct 
SOCS1 ex2a SOCS1 ex2a AGGCCATCITCACGC 
F- tgtgtccactgaggctgaac 
-
R TAAGG 
SOCS1 SOC51_ex2b CCCCTTCTGTAGGATG SOCS1_ex2b AGGGGAAGGAGCTCA F GTAGC R GGTAG 
socS1 ex2c AGAGCITCGACTGCCT socs1 ex2c AGGTAGGAGGTGCGA 
F-
-
cnc R - GITCA 
SOCS1 ex2d GCAGACCCCITCTCAC SOCS1 ex2d 
F- CTCT R cagcaggtcagccttaggac 
TEL02_ex1_F atgggagaaactaaggcgaga TEL02_ex1_R caacagcttacggggaacac 
TEL02_ex2_F agcgaactctgggtggaaac TEL02_ex2_R aggctcttggtccagtcctt 
TEL02 ex3 F tggacttcacgctggttatg TEL02 ex3 R gacggcatcaaccagagact 
TEL02 ex4- TEL02 ex4-
s_F agttttgctgtcggttggag s_R acaccctgtggcacctacat 
TEL02_ex6_F agaggctcgtggctaggaat TEL02_ex6_R ctcactcagagccgtcacag 
TEL02 ex7- TEL02 ex7-8-
TEL02 8-9 -F agtcctggcatggctcttg 9_:-R 
gagctcagggctgagaacct 
TEL02.=-ex10- TEL02_ex10-
11 F tggcctgaggtggaatctta 11_R agagaagaagcacggagcag 
TEL02=ex12- TEL02 ex12-
13_F ctgctccgtgcttcttctct 13_:-R agccatatgtcaccctcagtg 
TEL02 ex14- TEL02 ex14-
15-F gtagctccctcaatgccatc 15_=-R acaaggagacccaggttttg 
TEL02 -ex16 
-
TEL02_ex16 
-F" ctgtgagctacggggaagtg R ctgggtctcctacagccaaa 
TEL02 ex1 7 
-
TEL02 ex17 
-
-
F" gctgctttgtgggatcctct R gt1cacacccaaacccactc 
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TEL02 ex18- TEL02 ex18-
19::F ccggaaatgtctgctcctac 19::R ctgcctggcacacttcctat 
TEL02 ex20 TEL02 ex20 
-F - aggcagacacaggggtcttat R" aggagctgcaacacacacac 
TAGCGGACTGGCTGC 
TEL02 ex21a TEL02_ex21a 
i' acagtgctgcctgcacagag 
-
R ACT AT 
TEL02 ex21b GCTGCTICTGCAGAGA TEL02 ex21b 
i' CTCAA R actccccacacatcatatcc 
CD83_ex1_2_ CD83 ex1 2 
F caccctctcggaatctggtt -R -- ggagatggttcctgctgtct 
CD83_ex3_F ttccgaagatgtagccttgg CD83_ex3_R tccactttcagccacagatg 
C083_ex4_F ctgatggtgggaagaggaga CD83_ex4_R cctcaaaaagtccagggttc 
AATGTCCAGGAGGTI 
CD83 CD83_ex5a_F 
gagacgccagtgaaatggtt CD83_ex5a_R GACCA 
TGAAGATGGCATCCTG 
AGACCCTGCTGGGGA 
CD83_ex5b_F TGAA CD83_ex5b_R ATAGT 
TGGATAGCACCCTCT 
GCTGTACCAGCCCAG 
CD83_ex5c_F ATGTI CD83_ex5c_R CATCC 
TGTIGCATGGGCT AA T 
CD83 ex5d F GAAG CD83 exSd R gcagaagcatctctgggaag 
DTNBP1_ex1 DTNBP1_ex1 
-
_F aggagctactggccctctc R tctcacatgacttccctcca 
DTNBP1_ex2 DTNBP1_ex2_ 
-
F gcctggacgacagagtgag R gcactcaacaaatctaaggttca 
DTNBP1_ex3 OTNBP1_ex3_ 
-
F aaagcatgtgaccagatttca R aatttccaatcactgcattaaga 
DTNBP1_ex4 DTNBP1_ex4_ 
-
F agcaccacaggatattccac R gggagtttcataatcaacgact 
DTNBP OTNBP1_ex5 DTNBP1_ex5 
-
1 F 
-
attggaggtttcctgcactg R ccagaatttcatgtgttcctga 
DTNBP1_ex6 DTNBPLex6_ 
F 
-
ttatggtttaatgttggccagt R cagccgggacttctaaagag 
DTNBP1_ex7 DTNBP1_ex7 
-
F 
-
ccactgtgggcatttaaagta R ctgcaccttcctaacacacc 
DTNBP1_ex8 DTNBP1_ex8 
-
F 
-
gcgagcagctgtttataccc R acagaacggaacttctgagga 
DTNBP1_ex9 DTNBP1_ex9_ 
~ 
_F aatgccaatggaagttcacc R agatggttctcacgtctcacc 
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DTNBP1_ex1 DTNBP1_ex10 
O_F gttggcggcaattctgatt _R tgcacgtcccttcactctaa 
GGCCCGAGCT AGCAC 
VEGFA ex1a VEGFA ex1a 
F- ggcaaagtgagtgacctgct R TICT 
- -
CCAACTICTGGGCTGT 
VEGFA ex1b VEGFA ex1b 
F- TCTC R cctgcacctaagacgacaga 
-
-VEGFA_ex2 
-
VEGFA ex2 
-
F aagacttggagaagccagagg R- aattaggccatccacccatc 
VEGFA_ex3_ VEGFA_ex3 
-
VEGFA F 
tggaaggacttgcctgattc R ccacctgttcccaaagtgtt 
VEGFA_ex4 
-
VEGFA_ex4 
-
F ggttgtcccatctgggtatg R atgcttaaccctggcacaga 
VEGFA_ex5_ VEGFA ex5 
-
F tcatcaccatcttaacccttcc R- cccaacagaggtagccaaga 
VEGFA_ex6_ CTGTGTGGCTTTGCTTTGGT VEGFA ex6 
-
TCTACCCGTIGGTGCCAATI 
F c R- A 
VEGFA_ex7_ CTAGCCAGTGCTGCCTCTTT VEGFA_ex7 
-
TGTGA TGCCCCTCTCTGACT 
F c R T 
VEGFA_exB_ VEGFA exB 
-
F ctcctcacttggccctaacc R- tctgtcgatggtgatggtgt 
SNRNP25_ex SNRNP25_ex 
1_F cacttgtcattggtcactgc 1 R agtctcccaccagcacctt 
SNRNP25_ex SNRNP25_ex 
2_F cggcttgttctttgttgttg 2 R caggctgaccagcactgtta 
SNRNP25_ex SNRNP25_ex 
3 F gcacagaggtgttggttcct 3_R agagctgtttccaggtggtg 
SNRNP SNRNP25_ex SNRNP25_ex 
25 4_F caggtcccataggactgcat 4_R ccttggaggagggtgttatct 
CCCAGGTTACTGTGG 
SNRNP25_ex SNRNP25_ex 
CTTTC 5a_F tgttgtttcttcgtggtcctc 5a_R 
TIGGCCTGAGACTGAC 
SNRNP25_ex 
CTCT 
SNRNP25_ex 
5b F 5b R agggaaccctaaaggctgag 
MSLN_ex1_F gacaggaggagccagtccag MSLN_ex1_R acaggcactccagggagaag 
MSLN_ex2_F gtacatgggcctgagccact MSLN_ex2_R accgtggatacgtgacagaga 
MSLN_ex3_F gggaactcctgctccagaga MSLN_ex3_R aggtggagcagaggaggaag 
MSLN_ex4_F atctgactgggctcaggact MSLN_ex4_R gagctgcctgtgaattcctc 
ATCTGGGctgtgaagagag 
MSLN 
MSLN_ex5_F tccacttccacagattctcg MSLN_ex5_R g 
MSLN_ex6_F caggccacagcagagatgt MSLN_ex6_R ctcagcgcttttggaactg 
CTGCACCCGTTICTIC 
MSLN_ex7_F TCC MSLN ex7 R gtgtcctcacgctgctgata 
MSLN exB- MSLN exS-
-
g_F ctggcctcttccctctctg g_"R cactggcaaacagggattct 
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IL17C 
MSLN ex10 MSLN ex10 
GT AGAGctgcaggccaaga 
i' - tcatctcacaggaggtgtgg R - g 
MSLN ex11 
-
MSLN ex11 
-i' ctgctgtgtccaagccatc R ctccaccaccagcataacct 
MSLN ex12- MSLN ex12-
13~F gtcatgtggcatgagattgg 13~R ccgagtggagtctgtgcttc 
MSLN ex14 MSLN ex14 
i' - ctgtaaggcaagtgggcttc R - caccagggcttctccactt 
CAGGACGGTGAGMC 
MSLN ex15 
-
MSLN ex15 
-i' ggcagtttggacacaggaga R AGGTC 
CCTGGTCCTAGACCTC 
MSLN_ex16 
- AGCA 
MSLN_ex16 
-F R agcagggtcaggaagacctc 
IL 17C_Ex1 _F ttcccgaggaggaagtggt ll 17C_Ex1 _R cctcccctacccccagact 
IL 17C_Ex2_F agcctctctgggcttcagtt IL 17C_Ex2_R tgacaggtgagaaccaccaa 
IL 17C_Ex3a_ IL 17C_Ex3a_ TGTIGGGGGAGGCAT 
F ctgcctcaggtcctatcctg R ATAM 
IL 17C_Ex3b 
-
GGGCCCCT AGACTGG IL 17C_Ex3b_ 
F ACAC R gctgcgtagacctttctgga 
Primer sequences for validating MUC5B rs35705950 genotypes: 
MUC5B F 
MUC5B_R 
ggccagaatgagggacagt 
brtttgctcagcgtgtttgaa 
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Appendix D: Thermocycler programs used 
''Touchdown" Thennocycler Program 
--
~u _.liM 
\ \ 
_.{, 
'\...,...- 1\ 
\ 
-
~14x• r-- \ 
\ 
.... 3 X ... 
\ 
),. 
Time(min:sec) 
127 
"Standard" Thennocycler Program 
--
f---ti_H 
\ 
0 ~ 
..___,, 
\ v \ 
lr"u \ 
1- 'I"' 35x ,..._ \ 
\ 
\ 
0 
... 
0 
Time (min:sec) 
For 'Standard" programs, the 55"C temperature was changed for some cond itions and named accordingly. 
For example, if 55"C was changed to 57"C, the condition was named ''Standard57". 
"AP Standard" Thennocycler Program 
--
f---tl." 
\ 
" \ v \ 
.... \ 
;-'I"' 35x • ,..._ \ 
\ 
\ 
\, . 
Time(min:sec) 
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"Gal12new" Thennocycler Program 
--
h· 
'\ 
1\ 
" 
'\ .......- \ 
\ 1-I"' 25x • ~ \ 
\ 
\ 
), , 
Time (min:sec) 
"Abiseq" Thennocycler Program 
~ 
"\ 
'.,.,--r-\ 
35x 1\ 
\ . 
Tlme(mln:sec) 
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"Exosap" Thermocycler Program 
/\ 
/ \ 
/ \ 
/ 
I(" \ 
\ 
\ 
\, . 
Time (min:sec) 
"Denature" Thermocycler Program 
~ 
"' "' 
"' "' 
"' 
"' 
"' "' ),. 
Tme (min: see) 
130 
Appendix E: Setting up plate information for genotyping using SDS version 2.4 
software 
o Once the SDS version 2.4 software is opened, input the DNA numbers for the 
plate into both curves: a Standard Curve (AQ- Allelic Quantification) and an 
Allelic Discrimination Curve (AD). Save bOlh files. 
o Open up SDS 2.4 and open up the AD file that was created. Click on the 
" Instrument" tab and click "Connect to Instrument" so the machine and computer 
can connect. Once connected, click the "Open/Close" button. The door will slowly 
open and a tray will come out. Place the prepared 0.1 ml MicroAmp Fast Optical 
96 reaction well PCR plate on the tray with the correct orientation. Click the 
"Open/Close" button again and wait for the plate to go into the machine. 
o PRE-READ in AD: Within the AD file that is open, highlight all of the samples 
and click the "Pre-Read" button. Wait for the Pre-Read to take place. Save and 
close the AD file. 
o AQ RUN: Open up the AQ file and highlight all samples in the file. Set up the 
thermocycler conditions to the desired condition. Choose "Fast" or "Standard" 
and choose the correct thcrmocycler condition under the "Thermal Cycler" tab 
(conditions vary based on the PCR master mix used). Save the file and click the 
"Start Run" button. This run will take approximately 90 minutes. Once the AQ 
Run is completed, save the AQ file again. 
o POST-READ in AD: Open the AD file and do a "Post-Read." This will allow for 
analysis of the results. Save the file after the Post-Read. 
o ANALYSIS: In the AD file, press the green ·'play" button in the icons at the top 
of the program to begin the analysis. Save the analysis and transfer the files to a 
computer. Analyze by saving a copy of the AD plot as an image fi le and exporting 
the data as a .txt fi le. Open the .txt file in Microsoft Excel to analyze it in table 
form. 
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Append ix F: Steps for Ethanol p recipitation of cycle sequencing reactions 
1. Add 5!J-1 of 125mM EDTA to each reaction well. 
2. Add 65!J-I of 100% EtOI-I to each well, cover, vortex. 
3. Allow to precipitate 2 hours to overnight in the dark at room temperature. 
4. Centrifuge plate fOr 30 minutes at 3000 x g. 
5. Remove plate and invert plate gently to decant EtOH. 
6. Keep plate inverted and place on folded paper towel on plate carrier and spin up to 
200rpm and stop. 
7. Add 150~1 of70% EtOH wash. 
8. Centrifuge plate for 15 minutes at 3000 x g. 
9. Remove plate and invert plate gently to decant EtOH . 
1 0. Keep plate inverted and place on folded paper towel on plate carrier and spin up to 
200rpm and stop (same as step 6). 
II. Allow the plate to dry completely (uncapped) for - 30 minutes in the dark. 
12. Add 15-lS!J-I of deionised formam ide (Hi-Di fonnamide) to each reaction well. 
13 . Vortex to resuspend and centrifuge up to 600rpm for a few seconds. 
14. Run 'denature' program on thermocycler and quick-chill before loading on sequencer. 
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Appendix G: All genes fully sequenced in the regions of interest on chromosome 6 
and 16. 
Previously sequenced* in at Sequenced in 5 affected and 2 
least 2 affected patients from 6 unaffected individuals in 
FPF families Famil R0942 
Chromosome 6 16 6 16 
DEXI SOCSI TFAP2a EMP2 EDNI TEL02 Genes TFAP2fJ VASN CD83 SNRN/'25 
sequenced WRNIPI GLIS2 DTNBPI MSLN SERPINBI TID/ VEGFA IL I7C PPL 
*For more detail on previously sequenced candidate genes, review Kamel, 2010. 
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Appendix 1: Manuscript submitted to Thorax for publication on March 2013. 
THORAX 
An loternauonal journal of Re!oplratory Medicine 
Association between a Promoter SNP in MUCSB and 
Idiopathic Pulmonary Fibrosis in the Newfoundland 
population 
>oum01l: Thorolx 
Manuscript 10: Orilft 
Artide Type: Researth Letter 
Date Submitted by the Author: n/a 
Complei:e List of Authors: Pn-zada, Ashar; Memonal Urnvers1ty of Newfound land, OIS<: tDhM of 
Genetics 
Mahoney, l<nsta; Memonal Uruvers•I Y of Newfoundland, OISC:IPI•ne of 
Genetics 
Zt\a1, Guanmu; Memonal Un1\.<ers1ty of Newfoundland, o,u,phne of Genet iCS 
Noble, B.arbara : Eastern Health, 
Femomdez, Br!dqet ; Memonal UmverSII V of Newfool\dlalld, D•sc•plule of 
Genetics 
Woods, M•ch.ael; Memomol Unwet's.ty of Newfoundl-and, D•sc•plone of 
Genetics 
KeywOI"ds: ldt~Jpath•cou lmonaryfibros•s 
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ABSTRACT 
B•l'kz:round: Recently. a promoter variant (r<:.3S705950) up<>tream of MUCSB has been 
'>hewn to be associated with IPF in US populatiom. 
M t>tbods: The S~"P n 35705950 wa'> genotyped by a TaqM an SNP Genotyping n'>say. A 
case--control au.1lysis wac.. carried out using 110 affected individualo;: and 277 healthy 
control.r; from the Newfoundland population. 
Resulb: ThCTe i-5 significant a'>o:.ociation between rc,35705950 genotype'> and IPF. Tite 
odds ratio'> for all individuals affected with IPF who were heterozygom and homozygous 
for the variant a1lele of th is promoter polymorphi<:.m . respectively were 5.4 (95% Cl 3.3 
to 9.6. P < .001) and 12 .2 (95% CI 3.3 to 44.7. P < .001). Furthemtore. a large family 
displayed segregation of the variant allele with the phenotype. 
Conclusions: The minor T allele of rs35705950 io; '5ignificruu ly a\\ocinted with PF in thi\ 
Newfotmdland cohort and may contribuie to n \ mall proportion of FPF fnmilie\ with 
tmknown genetic etiology. 
Recently. Seibold et al.1 identified a variant (rs35705950) located in a promoter region 3 
kb up~trerun of a major gel-fonning mucin gene. M UC5B. that i'> 1\\\ocinted w ith both 
\poradic and familial IPF in US population\. Our sn1dy validate\ the 1\\sociation of 
rs3 5705950 with both sporadic ru1d familial fonm of iPF in the 1\ewfoundland 
population and we al\o show o;:egrcgntion of the variant in A large FPF pedi~ee. 
One-hw1drcd and ten affected individuals wa-e recmited through te'>pirology clinic'> in 
the only tertiary care hos.pital in Newf01mdlnnd. Canada. All proband<> were sequenced to 
exclude possible IPF-causing genetic variation\ in TERT. TERC. SFTPC and SFTPAi 
Si.'tty-eight of the PF patiento;: were sporadic and 42 were familial. with at lea\t one 
affected f~t or '>econd-degree relative. All affected individuals had high re\olurion 
computed tomograms of the chest and met the ATS/ERS criteria for dingtlosi'> of IPF1. 
Healthy individuals. previously recn1itcd for a colorectal cancer srudy by random-digit-
dialing, served a\ a control cohort4 . To genotype rs3S705950. a TaqMan SNP Oenotyping 
assay using a 7900HT Real-time PCR aunlyzer (Applied Bio'>ystems. CA. USA) \ \'8'> 
implemented. A case-control nnalysis wao;: cmried om using 110 affected individuals and 
277 healthy controls. The rutnl~i'> wn<;, pcrfonued twice to detenuine odd'> ratios rutd 95% 
confidence in tervals in the two ~up-, - once with aJI I IO ca<;,e~. while controllin,p: for 
fanlilial \ampk~ via chtsterin!l: and once by using. only tlte SO \Uu-clated familinl and 
\ parodic probands (SPSS vlO.O.O. IBM Software). 
The clinical vruinbles w d I'C:SUl!~ for both anal}"'ies arc: '!ilUtunruized in Table: 1. There: wa\ 
n si!lnificaot Msocintion bctw cc..tl n-35705950 !l~lotype\ nud lPF. The: odd.<;.mtio for 
individuals affected with IPF who were beterozygon\ fo1' tbe minor allele wa~ 5.4 (95% 
confidence in terval. 3.3to 9.6. P < .001). The odd'!i mtio for individual\ affected with IPF 
who were bomozy~ous for the minor nllele wa\ l.l . .l (95% cotrtideuc-e intc:rval, 3.3 to 
44.7. P < .OOl). lu tercsti.llg.ly. the u.n.relnted probiUld t\llal)"\i\ \bowed the C>dd' mtio for 
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affected proband'!> homozygou'!> for the variant T allele wa'!> slightly higher than in the 
'!>rune analy<.;is for all case'!> (OR = 15.2: 95% Cl. 4.3 to 51.6. P < .001). 
Our cohort included affected probands and relatives from 12 PF familie'i. Segregation 
analY$i'> wa<; pcrfonued on the 12 familie... Family R0942 exhibited segregation of the 
variant T allele (Figure 1). In this family. all seven affected individual<> were 
heterozygous for the variant T allele. To detem1ine if segregation of the risk allele 
occurred by chance. SISA (simplified rapid seg~gation analysis) was conducted'. From 
this analy'>is. the probability that co-'!>egre11:ation of the variant T allele with PF occurred 
by chance was 1.56% in this family. 
Our result'> ti.uther support a significant association between the minor T allele of 
r.35705950 and PF. Intere'!>tingly. the minor T allele segregated. with reduced penetrnnce. 
in an autosomal dominant ntanner in PF families. These findings. further support that the 
minor T allele of rs35705950 is a<;socinted with developing PF in .s.poradic patients. It is 
also the first 5n1dy to '.ihow that thi'i allele may act a'!> a ~latively highly penetrant allele in 
some families. 
Tablf" I: Clinical ,·aria bit'S aod noding'.i ror all casts., probands and controls. 
Clinical varlab._s 
Age (year)' 
Gender 
Smoking status" 
Smoking durotion (years) 
Pulmonary funct~n tests: 
me3n % of predicted V3lue••• 
FVC 
FEV1 
All cases 
(n• 110) 
62.1 ± 12.3 
M-67(60 9%) 
F = 43 (39.1%) 
smoker 17 (15.5%) 
ex-smoker= 73 (66.3%) 
OCC3sion.."l1 = 3 (2.7%) 
never= 17( 15.5%) 
25.0 :t 16,5 
84.1% :1: 18.8'tf! 
83.0% :t 1 5.~ 
Cases: probands only 
(na80) 
63. 1± 9.6 
M ~ 51 (63.8%) 
F~ 29 (362%) 
smoker 6 (7.5%) 
ell:-smoker = 62 (77.5%) 
occasional = 0 (0.0%) 
never = 12 (15,0%) 
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25.0 :t 16.0 
83.~ :1:1 8 .1% 
82, 1% .:t 15.8% 
Controls 
(n•277) 
61 .2 ± 9.4 
M- 158 (58.5%) 
F = 112 (4 1.5%) 
smoker= 33 (12.2%) 
ell:-smoker = 128 (47.4%) 
occasional = 2 (0.01%) 
r.ever = 107 (39.6~) 
26. 1 .:t 15.6 
N/A 
NIA 
TLC 81.1% ± 16.6% 81.4% ± 15.8% N/A 
DLCO 59.4% ± 17 5% 56 6% ± 14 8% N/A 
D~agnosrs by lung biOpsy 45 (40.9%) 35 (43.8~) N/A 
Allele frequency: 
Wild type <lllele (G) frequency 6360% 6250 ... 87 40% 
Mmor allele (T) frequency 36 40% 37 so·~ 12 60% 
Genotype· 
GIG 39 (35 4 "1.) 28(350 ... ) 211 (762%) 
G/T 62 (56.4%) 44 (55 0%) 62 (22 4%) 
TIT 9 (8.2%) 8 ( 10.0%) 4 (1.4%) 
Odds RatiO (95% C l ) 
GfT vs GIG 5 4 (3 0 + 9 .6). p • . 001 53 (31 -9.2). P < 001 N/A 
TfT vs. GIG 12 .2 (3.3 - 44.7 ). p "' 001 15.2 (4.3- 52.6). p. 001 N/A 
Chi-SQuared, P v<~lue !()( .\~"' 5 .:!.:!. p "' 0.:! .\~ "'.:! 40. P : 1.:! _\.:"' OS P ::: S.:! Hardy-Wemberg eqwl1bnum 
Controlpap.lblion . QM!)@f, ~II'IQSUM3I'ICIG\ntKll'l iSb3S84 01'\n=270U"lU QU~iOM31feSWti@I'IOi telllme<l t.;, 7 p:lfbCJp:ln!S Control 
PQP.IWlOn 3l~le frequency QMot'IPU .lfld OQcH; r.::lllO ~onn,.~71 
.. FOI'smot.l'lgS13tu\ El·'"I~H(3Ut.»tsl ttnol!.lhQCJ.Jr3!10fl" 189! 138yeJfS WIIfl 71 ~n.lii'll'l!l S &aOV&f20Y*3fS. E~· &f 
{PI'Ob3I'I(ISOI'IIy). !UOOt.II"'Qdut:lbOOIS287:r. 1) 1 ye31'iWIItl 7 1 Q'Mon3Vli'IQSITla..toovtflOy~ Ex-t l&f(COOII'Oil) in'IOII~Ciuf3ti0n •t : !28 
:r. t .t a ~3!'1 Wltl1 Sl.I'M. h3vmg sm<».ea ov« 20 ve.:n s to13l occ3Kin.ll sm<».ert. Of'tr smou toel3ty )11 tn 1/5 n3q smouo o~·tr 21l )"63ts. 
'""3bnOI'm3l cfFVC, FEV1, TLCorDLCO" ~ pt'e(lltle<l 
FVC ~ lotted v~31 C.103tlty FE\11: lorCIKi htiii'O.tory VOiul'l'rt ''Mit\l l'l ltlft lSI Second TLC :o lot:ll to$19 t -'PK it/ OlCO ~ d1f!ll«lg CJC).l(~y of 
1M 1UnO tor C311Xln ITIOI'IOndft 
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